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Inhibiting Protein-Protein Interactions using Rationally-
designed Repeat Proteins 
 
Sarah Kay Madden 
Abstract 
 
The inhibition of protein-protein interactions (PPIs) presents a major challenge to drug 
discovery. The properties of consensus-designed tetratricopeptide repeat proteins (CTPRs) 
make them very amenable to be rationally-designed into potential new PPI inhibitors. This 
study sets out to investigate whether this could be achieved through the grafting of binding 
peptides into the inter-repeat loops. The work focused on two PPIs: the interaction between 
Kelch-like ECH-associated protein 1 (Keap1) and Nuclear factor erythroid-2-related factor 
(Nrf2) as well as the interaction between c-Myc and Myc-associated factor X (Max).  
 
In Chapter 3, computationally-designed peptides were grafted into the inter-repeat loops of 
CTPRs as well as into another consensus-designed repeat protein, namely Designed Anrkyrin 
Repeat Proteins but no binding of these proteins to their target was observed. In Chapter 4, a 
number of Keap1-binding peptides were successfully grafted into the inter-repeat loop of  a 
two-repeat CTPR2 protein, with the tightest binding functionalised CTPR having low 
nanomolar affinity for Keap1. In Chapter 5, new strategies were explored in order to further the 
understanding of how best to graft functional peptides into the inter-repeat loop of CTPRs, with 
the introduction of polyglycine residues either side of the grafted peptide being shown to lead 
to a greater than two-fold improvement in the binding affinity. In Chapter 6, it was shown that 
the functionalised CTPRs could be successfully delivered into HCT 116 by encapsulation 
within fusogenic liposomes. In Chapter 7, a peptide segment of a c-Myc inhibitor was grafted 
into a CTPR scaffold, and also engineered as a chemically stapled peptide. Preliminary pull-
down experiments suggested that the stapled peptide bound to c-Myc in HeLa cell lysate.    
 
This thesis demonstrates the amenability of the CTPRs to rational design with binding affinities 
in the low nanomolar range being obtained through peptide grafting into the inter-repeat loop. 
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1 Introduction  
1.1.1 Protein-Protein Interactions 
The human protein-protein interactome is believed to have between 130 000 and 650 000 
unique interactions.11-13 Protein-protein interactions (PPIs) are central to all stages of 
development and homeostasis but also play important roles in the progression of many 
diseases.14, 15  This pathological involvement can occur either through the loss of a specific PPI 
or through the formation of a protein complex at the incorrect time and/or location. This thesis 
focuses in particular on the Keap1-Nrf2 interaction along with the c-Myc-Max interaction both 
of which are deregulated in many human cancers.16, 17 
 
1.1.1.1 Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) and Kelch-like 
ECH-associated Protein 1 (Keap1) 
1.1.1.1.1 The role of the Keap1-Nrf2 system 
The Keap-Nrf2 system helps to protect cellular proteins and DNA from the effects of oxidative 
and electrophilic damage. Under normal conditions, the cellular concentration of Nrf2 is kept 
low through ubiquitination by the Keap1-Cul3 E3 ligase complex and the subsequent 
degradation by the proteasome.17 Under oxidative and electrophilic stress, this degradation 
process is disrupted allowing Nrf2 levels to increase. This increase promotes the activity of 
Nrf2, which is a transcription factor that targets genes coding for a wide range of cytoprotective 
enzymes with antioxidant response elements (ARE) elements in the regulatory regions.2, 18 
Figure 1: A schematic showing the regulation of Nrf2 levels via the Keap1-Nrf2 system using 
the ‘hinge and latch’ model, with the Nrf2 ETGE motif ‘hinge’ having a 200-fold higher affinity 
for Keap1 than the Nrf2 DLG ‘latch’.2, 3 Under Basal Conditions, the polylysine sequence, 
denoted by KKKKKK, is ubiquitinated by the Keap1-Cullin3 E3 ligase complex. This induces 
degradation of Nrf2 by the 26S proteasome. Under stress conditions, covalent modifications of 
the Keap1 cysteine residues induce structural changes in Keap1. This disrupts binding between 
Keap1 and the DLG motif of Nrf2. Nrf2 is therefore not degraded, which upregulates a range 




The C-terminal β-propeller Kelch domain of Keap1 binds to Nrf2.19 Keap1 in turn binds to 
Cullin3, forming the Cullin-RING (really interesting new gene) E3 ligase complex. This 
complex ubiquitinates Nrf2, targeting it for degradation by the proteasome (Figure 1).20 This 
activity can be disrupted, and Keap1 acts as a sensor of oxidative and electrophilic stress. The 
ability of covalent modification by electrophiles or oxidation of Keap1 at cysteine residues to 
inhibit its activity as an E3 ubiquitin ligase is known as the cysteine code.21 The cysteine 
residues of Keap1 have been shown to be amenable to modification by a range of electrophilic 
species, such as diethyl maleate and tert-butylhydroquinione.22, 23  Cys273 and Cys288 have 
been shown to be to be important in the regulation of Nrf2 under both basal and stress 
conditions, whereas Cys151 is more important under cellular stress.24-28 
 
1.1.1.1.2 Protein structure  
Figure 2: A schematic showing the domain structure of Keap1 and Nrf2 and their functional 
roles.29-31 Cys273 and Cys288 are major sites of modification, which sit in the Central 
Intervening Region (IVR). Another is Cys151, which sits in the bric-a-brac, tramtrack, and 
broad complex (BTB) region.   
Nrf2 is an intrinsically disordered protein from the cap‘n’collar (CNC) subfamily of basic 
leucine zipper (bZIP) transcription factors, a family of proteins with high homology in both in 
both the bZIP and CNC domains.32, 33 The CNC domain is a conserved region located at the N-
terminus of the DNA binding region.  
 
 Nrf2 contains seven regions known as Nrf2-ECH homology (Neh) domains, with Neh1 
containing the bZIP domain necessary for heterodimerisation with members of the small Maf 
(musculaponeurotic fibrosarcoma oncogene homologue) family (Figure 2).34 Neh2 contains the 
two degrons DLG and ETGE necessary for binding to the Kelch domains of Keap1.33 These 
are hypothesised to bind Keap1 via a ‘hinge and latch’ mechanism with the high affinity ETGE 
motif acting as the hinge, and the DLG motif (with a 200-fold lower affinity) acting as the latch 





Keap1 is from the BTB (bric-a-brac, tramtrack, and broad complex)-Kelch family of proteins.35 
The BTB domain is responsible for Keap1 homodimerisation as well as binding to Cul3, with 
additional binding to Cul3 occuring through the 3-box motif.36, 37 The C-terminal Kelch domain 
has six Kelch repeats that fold into a six-bladed beta-propellar structure and is responsible for 
substrate capture and for binding to both the DLG and ETGE motifs of Nrf2.3, 7, 19, 38, 39  
 
1.1.1.1.3 The Keap1-Nrf2 interaction interface 
 
Figure 3: A schematic representation of the crystal structure of the Kelch domain of Keap1 
(Blue) in complex with Nrf2 peptide (Green). A: The Nrf2 peptide binds on the top face of the 
Kelch domain, with the blades of the of the β-propellar labelled. B) The interactions between 
Nrf2 peptide and the Kelch domain, with the key interacting residues labelled. Figure derived 
from PDB ID 2FLU.7  
 
Nrf2 binds Keap1 in a β-turn conformation at a shallow pocket formed by the loops that connect 
the β-strands of the Kelch domain.7 A crystal structure of the Kelch domain of human Keap1 
in complex with a 16-residue Nrf2 peptide encompassing the ETGE motif was solved by Lo et 
al. (Figure 3). The crystal structures revealed all six blades of the β-propellar to be involved in 
the binding of Nrf2.19 E79 and E82 are the only Nrf2 residues with side chains that directly bind 
the Kelch domain, with E79 forming hydrogen bonds with Arg415, Arg483 and Ser508 of the 
Kelch domain. The carboxylate of Nrf2 E82 also forms hydrogen bonds with Ser363, Asn382 
and Arg380 of the Kelch domain. Four carbonyl groups and one amide group from the Nrf2 
peptide backbone also interact with the Kelch domain. A crystal structure of the DLG motif of 
Nrf2 in complex with Keap1 revealed it to bind in a similar mode to the ETGE motif in a  β-





1.1.1.1.4 Targeting the Keap1-Nrf2 interaction for therapeutic benefit 
A deficiency in Nrf2 is associated with an increased risk of oxidative damage and inflammatory 
injury, which in turn is related to diseases such as cancer, Alzheimer’s disease, Parkinson’s 
disease, chronic obstructive pulmonary disease, multiple sclerosis, diabetes, osteoarthritis, 
rheumatoid arthritis and asthma.40-42 Targeting the Keap1-Nrf2 interaction has been previously 
thought to be a good therapeutic strategy in the treatment of these disorders. 
  
In cancer there are a number of gain of function mutations that activate Nrf2 through disrupting 
binding to Keap1, and occur in the squamous cell carcinomas of the oesophagus, skin, lung and 
larynx.43, 44 Loss of function mutations in human Keap1 have also been found in lung, 
gallbladder, ovary, breast, liver and stomach leading to Nrf2 activation.45-52   The role of Nrf2 
in upregulating a range of cytoprotective enzymes makes the Keap1-Nrf2 interaction an 
attractive drug target in the chemoprevention of cancer.43, 53-55 However, work has also 
demonstrated how Nrf2 could promote the survival of malignant cells through protecting them 




Figure 4: A schematic showing the different regions of c-Myc protein. The N-terminal region 
is shown in white. 
c-Myc is a transcription factor that plays an important role in regulating cell growth, death, 
differentiation and metabolism.57 c-Myc is composed of an N-terminal transactivation domain 
and a C-terminal basic helix-loop-helix leucine zipper (bHLH-LZ) domain (Figure 4).58  
Monomeric c-Myc is unstructured and is only active once bound to c-Myc-associated factor X 
(Max), forming a coiled-coil structure, with the N-terminus remaining unstructured. The 
leucine zipper is characterised by a (abcdefg)n heptad repeat, with leucine residues occupying 
the ‘d’ position. In the c-Myc-Max dimer, a:d interactions are hydrophobic, with salt bridges 
forming between residues g and e (Figure 5).9  Heterodimerisation initiates binding of residues 
in the basic region of both c-Myc and Max with the E-box sequence (5’-CACGTG-3’) in DNA.9  
The structure of the heterodimer is broadly similar to that of the Max homodimer, which is also 





1.1.1.2.1 Targeting c-Myc for therapeutic benefit in cancer 
The fact that c-Myc is deregulated in many human cancers and the fact that many tumour types 
have been shown to be c-Myc dependent makes c-Myc an attractive drug target.9, 58-62 There 
was initial doubt about whether targeting c-Myc was the correct approach. This was because 
the integral role of c-Myc in cell growth and expansion could mean that this targeting could 
lead to the inhibition of the proliferation of normal tissue.63 Work by Soucek et al. sought to 
provide answers to this debate through use of a genetic mouse model to mimic c-Myc 
inhibition.60 Not only did the work demonstrate that c-Myc inhibition could induce regression 
of both new and well-established lung tumours, but it also indicated that effects to normal 
regenerating tissue were completely and rapidly reversible.   
 
1.1.2 Strategies to inhibit PPIs 
Despite many PPIs being attractive drug targets, inhibiting PPIs presents a major challenge to 
conventional drug discovery. This is due, in part, to their large interaction surfaces, which can 
be between 1500 to 3000 Å2.64-66 Many PPIs also lack small pockets suitable for binding a 
small-molecule and have non-contiguous interaction surfaces.67 Inhibiting protein interactions 
with a high degree of selectivity can present a major challenge due to their often relatively 
featureless interfaces.    
  
Figure 5: A schematic showing the interactions between c-Myc and Max A: Polar interactions 
between the c-MycArg423-c-Myc Arg424- Max Gln91- Max Asn92 tetrad region. c-Myc is 
shown in green. Max is shown in blue. PDB ID 1NKP.9 B: Protein-protein interactions in a 
leucine zipper. Electrostatic interactions are shown via the red arrows. Hydrophobic 




1.1.2.1 Small-molecules to inhibit PPIs 
Using small-molecules to inhibit PPIs offers a useful strategy, as small-molecules can generally 
offer better metabolic stability and cell penetration than peptides. In 1997, Lipinski et al. 
outlined a rule of five that listed five requirements a small-molecule would need to meet in 
order to be considered a viable drug candidate.68 Lipinski's rule states that an orally active drug 
does not have more than one of the following: 
• 5 hydrogen bond donors  
• 10 hydrogen bond acceptors  
• A molecular mass of more than 500 daltons 
• An octanol-water partition coefficient (log P) over 5 
 
However, PPI inhibitors have often had to go beyond these rules in order to achieve good levels 
of  druggability, such as those seen for Phase II clinical trial candidate, Navitoclax, , a BH3 
mimetic that inhibits the anti-apoptotic activity of B-cell lymphoma 2 (BCL-2/XL).69 
Navitoclax violates three of the rules with its molecular mass of 975 Da, Log P of 12 and 11 
hydrogen-bond acceptors.70 
 
The degree of difficulty in drugging a specific PPI interface is dependent on the structural 
complexity of the interaction, with primary interfaces being easiest to target using small-
molecules, followed by secondary interfaces and then tertiary ones.71 The discovery that a few 
residues at an interface were responsible for the majority of the binding energy, so-called “hot 
spots” enabled targeting of these regions using small-molecules.72  Other strategies have 
focused on fragment-based approaches such as using biophysical methods to measure the 
binding of low molecular weight and low complexity small-molecules to these hot spots and 
using these findings to subsequently evolve the molecule in order to achieve better affinity for 
the target.73  Peptidomimetic small-molecule inhibitors have also been used to allow binding of 





1.1.2.1.1 Small-molecules to inhibit c-Myc 
 
Figure 6: Small molecule inhibitors of c-Myc-Max interaction reported by A: Berg et al. and 
B: Yin et al.75, 76   
A range of c-Myc inhibitors have been developed through screening-based approaches rather 
than structure-based methods (Figure 6). This has been done to overcome the fact that c-Myc 
is an intrinsically disordered protein so has very little structural information available and is 
expected to lack conventional small-molecule binding sites. Berg et al. used a CFP/YFP 
fluorescence resonance energy transfer (FRET) assay to screen for small-molecules that were 
able to inhibit c-Myc-Max dimerisation.75 Four small-molecules were identified from the screen 
and three of the compounds were also shown to inhibit binding of c-Myc-Max to DNA. Yin et 
al. subsequently identified several structurally diverse small-molecule inhibitors using a yeast 
two-hybrid approach which were shown to inhibit c-Myc-Max dimerisation using a 
electrophoretic mobility shift assay (EMSA). Three of these small-molecules were 
subsequently tested for their activity in cells.76  A series of other small-molecule inhibitors were 
subsequently identified using similar screening assays.77-81 However, these inhibitors showed 
low potency. Issues with low selectivity were also demonstrated, such as by Hammoudeh et al. 
which identified multiple binding events for their previously reported small-molecule 
inhibitors.57   
 
Small-molecular inhibitors of the c-Myc-Max interaction have also been found to have poor 
biostability and low tumour concentrations.82-84 In order to overcome these limitations, various 




monomer using small-molecules so as to improve binding affinity, conjugation to integrin-
targeted nanoparticles to prevent premature drug escape and metabolism, and covalent linking 
of two different small-molecule inhibitors with adjacent binding sites so as to improve 
potency.85 
 
1.1.2.1.2 Small-molecules to inhibit the Keap1-Nrf2 interaction  
Figure 7: Small-molecule Inhibitors of the Keap1-Nrf2 Interaction.86-89 A: An example of those 
based around a tetrahydroisoquinoline scaffold. B: An example of those based around a 
naphalene sulphonamide scaffold.   
Using small-molecules to inhibit the Keap1-Nrf2 interaction offers a useful strategy since many 
peptides designed to bind Keap1 are negatively charged, so may have poor cell penetration 
properties. A number of small-molecule inhibitors of the Keap1-Nrf2 interaction have been 
identified using high throughput as well as virtual screening methods (Figure 7). A lot of this 
work has focused on using a tetrahydroisoquinoline scaffold, with IC50 values in the low 
micromolar range.18, 87, 88, 90 Structure-activity relationship studies indicated that the aryl ring, 
pthalimide and cyclohexyl carboxylic acid groups were all important for the activity of the 
inhibitor.  
	
The naphalene sulphonamides are another class of small-molecule which have been developed 
as Keap1-Nrf2 inhibitors. Initial studies showed them to have IC50 values in the low micromolar 
range, but further optimisation through substitution of the sulphonamide nitrogen atom with an 
acetic acid group improved the IC50 value to 28.6 nM.86, 89, 90 Both compounds have been shown 





These approaches sit in addition to other inhibitors that modulate the Keap1-Nrf2 interaction 
through methods aside from direct inhibition at the Keap1-Nrf2 interaction interface. A 
common method is through small-molecules that are believed to covalent modify the cysteine 
residues of Keap1 at the thiol group of the cysteine residues. A common class of such 
compounds are CDDO-methyl esters, which are able to modify the thiol groups due to their 
properties as michael acceptors.36, 91-95   
 
1.1.2.2 Peptides to inhibit Protein-Protein Interactions 
Peptides, as segments of larger proteins, are nature’s regulators of PPIs and it therefore makes 
sense to also use them to moderate PPIs for disease control. Their large size relative to small-
molecules means they are often able to span a large proportion of the interaction interface.96 
The use of free peptides for PPI inhibition has its limitations due their low proteolytic stability. 
They also violate Lipinski’s rules and may show a low propensity for cell penetration.68 Various 
strategies have been used to improve the proteolytic stability of these peptides including N-
methylation of the peptide backbone, the use of D-amino acids, the use of other unnatural amino 
acids and the chemical stapling of both natural and unnatural amino acids.97  
Peptide stapling refers to the process where two residue side chains in a given peptide are 
chemically joined together. Peptide stapling can also be used to constrain the peptide in its 
bioactive conformation, helping to improve the binding affinity of the peptide for the target.98, 
99 This strategy has commonly be used to constrain peptides in their bioactive α-helical 
conformation through a range of chemical stapling strategies. This includes hydrocarbon 
stapling, where two α-methyl, α-alkenyl amino acids	residues at the i and i+4 positions can be 
chemically stapled using ruthenium-mediated ring closing metathesis, producing an eight 
carbon tether with a S-configuration at both the i and i+4 positions (Figure 8).4 Peptide stapling 
has also been shown to increase the proteolytic stability of the peptides, with the use of two 




hydrocarbon staples in one peptide being shown to increase the proteolytic stability of longer 
peptides.100 As well as increased proteolytic stability, many stapled peptides have been shown 
to have better cell penetration capabilities than their unstapled counterparts.   
 
1.1.2.2.1 Peptide inhibitors of the Keap1-Nrf2 Interaction  
To date, a series of peptide inhibitors of the Keap1-Nrf2 interaction have been developed.18, 42 
Chen et al. first used an SPR-based assay to determine the minimal Nrf2 peptide that was able 
to bind Keap1, which they found to be LDEETGEFL.101 This was later further explored with a 
fluorescence polarisation assay developed by Hancock et al.102 The study found that Ac-
DEETGEF-OH to show good levels of inhibition but the Ac-LDEETGEFL-OH peptide had a 
10 x lower IC50 (Table 1). The study also used phage display to discover the Ac-DPETGEL-
OH peptide, which showed the highest levels of inhibition. The proline is hypothesised to help 
induce the β-turn conformation present in the intrinsic structure of Nrf2.103    
 
The β-turn conformation of the peptide lends itself well to cyclisation techniques. Lu et al. used 
cyclisation using flanking cysteines to induce cyclisation of the peptide via a disulphide bridge 
(Ac-c[CLDPETGEYLC]-OH) achieving an IC50 of 0.05 μM (Table1).103  Further work used 
macrocycles to target the Keap1-Nrf2 interaction, with a glycine residue used to link both ends 
of the peptide.104 This resulted is a peptide with a KD of 18 nM for Keap1.   
 
In addition, work by Steel et al. was able to deliver Nrf2 peptides into monocytic leukaemia 
(THP-1) cells through conjugation with a TAT peptide.105, 106 In addition, the phage-derived 
peptide, DPETGEL was conjugated to a C18 fatty acid stearic acid at the N-terminus and 
showed good activity in  Hepa1c1c7 cells. Both approaches were found to upregulate Nrf2-
dependent gene products.  
 
Table 1: IC50 values for Keap1-binding peptides determined by a fluorescence polarisation 
competition assay.2, 102, 103  






5.39 ± 0.58 
0.39 ± 0.03 
0.12 ± 0.01 
0.05 ± 0.03 





1.1.2.3 Proteins to inhibit PPIs  
Using proteins to inhibit PPIs is a useful strategy due to their ability to extend over larger surface 
areas. However, approaches focusing on protein design can face problems with protein stability 
and solubility after functionalisation. Most successful approaches have mainly been developed 
by directed evolution (a method used in protein engineering to ensure a protein is evolved in a 
manner mimicking natural selection to achieve the desired functionality), computational design 
and combinations of both these methods.107, 108 Peptide grafting has also been shown to be a 
valuable both as a stand-alone approach, as well as in combination with computational and 
directed evolution methods.109-113 Approaches focusing on grafting into α -helices were shown 
to be most successful. Grafting into protein loops can be especially challenging because it is 
difficult to predict loop conformations as well as predict the entropic cost of binding.114  
However, there has been some evidence that peptide grafting into protein loops can be 
successfully used.115, 116   
Figure 9: Examples of non-immunoglobin scaffolds. A: Affimer B: DARPin C: Anticalin and 
D: Alphabody.117-119 PDB IDs 5OHL, 5EYL, 4MVI and  4  
Most work to date has focused on a small number of non-immunoglobin scaffolds, including 
affimers, DARPins, anticalins and alphabodies (Figure 9).120, 121  Affimers consist of four β-
strands and an α-helix with the loops connecting the β-strands having been shown to be suitable 
for randomisation.122 DARPins are based on the ankyrin repeat with loopDAPRpins having the 
β-turn structure extended to form an elongated loop.123Anticalins have an eight-stranded β-
barrel structure, whereas the alphabodies are a computationally-designed scaffold consisting of 
three α-helices.  A modified version of the alphabody scaffold has been shown to be cell 
permeable.    
  
Although antibodies are easily able to achieve high binding specificity, alternative scaffolds 
offer certain advantages over antibodies such as their smaller size (typically 2-20 KDa vs.150 




temperatures.124 The different topologies of different scaffolds may also influence their epitope 
preferences, further improving the fit of a particular scaffold for the required PPI.125  
 
1.1.2.3.1 Protein inhibitors of c-Myc and the Keap1-Nrf2 interaction  
Residue grafting approaches have already been used to impart affinity of a particular protein 
for Keap1. Guntas et al. created a monobody to target Keap1 with picomolar affinity using a 
computational peptide grafting followed by phage display approach.126 Liu et al. also used a 
computational approach to graft hot spot residues onto geometrically similar regions of an 
antibody Fv scaffold to impart nanomolar affinity for Keap1.127 In 1998, Soucek et al. designed 
Omomyc as a c-Myc dominant negative and c-Myc inhibitor, and it was later shown to induce 
massive tumour regression in several cell types (Figure 10).60-62, 128-130  
 
1.1.2.4 Repeat Proteins 
1.1.2.4.1 Consensus-designed repeat proteins 
Figure 11: A schematic representation of consensus-designed repeat proteins investigated in 
this study. A: A consensus  tetratricopeptide repeat protein (CTPR), B: A Designed Ankyrin 
Repeat Protein (DARPin) and C: A consensus-designed Armadillo repeat protein (ArmRP).  
Tandem repeat proteins are proteins that are made up of repeated units of 20-40 amino acids.131 
A tetratricopeptide repeat (TPR) are a class of repeat protein that are commonly found in nature, 





where they often act as scaffold proteins and have been shown to be important for the 
functioning of chaperone, protein transport, cell-cycle complexes.132, 133 This includes the J-
domain of DNAJ-like proteins which binds to HSP70 and the Anaphase Promoting Complex 
(APC), which contains three TPR-containing proteins that work to induce the selective 
degradation of target proteins at the beginning of anaphase. TPRs consist of 34 amino acid 
forming two helices, Helix A and Helix B, with a short loop in between (Figure 11A).  
 
In consensus-designed proteins, the amino acid sequence has been optimised to maximise 
stability using sequence alignment as well as statistical analysis, in order to determine the ideal 
amino acid at each position.134 Therefore, consensus-designed tandem-repeat proteins are 
exceptionally stable with very high melting temperatures. This stability, and the fact that these 
proteins only have short-range interactions between amino acids that are close in sequence, 
makes for a much simpler architecture than that seen in globular proteins.135 Main et al. were 
able to  optimise the design of the TPR to form a consensus-designed tetratricopeptide repeat 
protein (CTPR).134 Grove et al. further modified the scaffold to include D18Q and E19K 
mutations and Cortajarena et al. later showed the E19K mutation to increase the repeat stability 
through the promotion of charge-charge interactions.136, 137   
 
Ankyrin-repeat proteins are another well-studied class of repeat protein. Each Ankyrin repeat 
consists of a β-turn, followed by two anti-parallel helices, followed by a loop region (Figure 
11B).138  These proteins have also been consensus-designed, producing Designed Ankyrin 
Repeat ProteINs  (DARPins).139  
 
1.1.2.4.2 Consensus-designed repeat proteins to inhibit PPIs  
The high stability of consensus-designed repeat proteins and the fact that these proteins have 
short-range interactions makes for a simple system to engineer.134, 135 Their modular (lego-like) 
architecture means proteins can be built up as required.140 Consensus tandem-repeat proteins 
have exceptionally high stabilities of around 90 oC. Their stability means they can be expressed 
in E.coli in extremely high yields.135 Many artificial binding proteins based on repeat proteins 
have been investigated.141 Among these, DARPins, HEAT repeat proteins, designed-armadillo 
repeat proteins (ArmRP), and consensus-designed tetratricopeptide repeat proteins (CTPRs) 
have proven most popular.142, 143  
 
The use of designed-armadillo repeat proteins (ArmRPs) to create protein binders is particularly 




antiparallel fashion (Figure 11C).144, 145 Varadamsetty et al. were able to design an ArmRPs to 
bind Neurotensin with an affinity of 7 μM using a library-based approach. 
 
TPRs can bind to their binding partners using various binding modes, but the binding of the 
concave groove 2-3 repeats to a short negatively charged peptide remain the most well-
characterised.146-148 This natural-binding mode was manipulated by Cortajarena et al. grafted 
residues from the natural Hsp90-binding TPR domains onto the α-helices of the concave face 
of a TPR3 with micromolar affinity.149, 150 This not surprising since this mode of interaction 
usually achieves similar affinities in nature. The affinity of this designed-interaction was later 
optimised using both rational design and library screening approaches but still remained a 
relatively weak binder.151, 152 A library based approach was also used by Jackrel et al. to develop 
a TPR with up to 10 μM affinity for Dss1.153    
 
Plückthun and colleagues developed loopDARPins by extending the loop of the central repeat 
by 19 residues, without detriment to the stability of the scaffold.123 Ribosome-display was then 
used to induce binding to extracellular signal-related kinase 2 (ERK2) and members of the 
BCL-2 family with nanomolar to picomolar affinity. In addition, Zahnd et al. evolved a 
DARPin with picomolar affinity against human epidermal growth factor receptor 2 (Her2) using 





1.1.2.5 Proteolysis Targeting Chimeras (PROTACs) 
A PROteolysis TArgeting Chimera (PROTAC) is a molecule which targets a protein of interest 
(POI) for degradation.155 This heterobifunctional molecule binds to both the POI and an E3 
ubiquitin ligase. Through binding to the E3 ubiquitin ligase, the PROTAC brings the POI into 
special proximity to the E3 ligase, promoting the poly-ubiquitination of the POI.156 This then 
promotes the subsequent degradation of the POI via the proteasome (Figure 12).  
 
This technology follows previous approaches to reduce the intracellular levels of specific 
proteins. Nucleic acid-based methods to induce protein knock down include antisense 
oligonucleotide RNA interference (RNAi) and CRISPR/Cas9.157-159 However, using these 
approaches in a therapeutic context presents difficulties with achieving sufficient concentration 
Figure 12: The selective degradation of a Protein of Interest (POI) using PROTACs. i) 
PROTACs are heterobifunctional molecules. (ii) The heterobifunctional molecules have a 
moiety designed to bind the POI (blue square) and a moiety designed to bind to the E3 ubiquitin 
ligase (orange triangle).This brings the POI in close proximity to the E3 ligase. iii) The E3 ligase 




at the target site, off-target effects and low metabolic stability.160 Other approaches include the 
use of inducers of protein instability such as the use of heat-shock protein 90 (HSP90) 
inhibitors.161, 162 HSP90 is a molecular chaperone that aids the folding of its client proteins. 
Inhibition of this process can induce ubiquitination of these client proteins, which then undergo 
subsequent degradation by the proteasome. Other approaches include the use of inducers of 
protein instability that require genetic fusion to the target protein such as the use of  destabilising 
domains, ligand-induced degradation, hydrophobic tagging.155, 161  
 
PROTACs are emerging as a novel therapeutic approach for the targeting of diseases that are 
driven by aberrant expression of the protein of interest. PROTACs confer many advantages 
over conventional small-molecules inhibitors. First, they allow targeting of the undruggable 
proteome, which is believed to consist of approx. 85% of the proteome.163  This is possible 
since PROTACs simply require a small-molecule that binds to the POI, whereas a direct 
inhibition approach requires the development of a small-molecule to block a usually large 
protein-protein interface, which presents a major challenge to drug discovery. They are also 
catalytic and so one PROTAC can induce degradation of many target proteins, which allows 
them to demonstrate significantly higher levels of potency than small-molecules at the same 
cellular concentration.157  
 
The initial PROTACs were developed by Sakamoto et al. where peptide moieties were used to 
target the ubiquitin ligase substrate.164 However the peptides were thought to limit cell uptake, 
in part due to their large size (~1.5KDa) as well as poor metabolic properties. Therefore, work 
moved to developing small-molecule PROTACs. Although this has been a successful strategy, 
small-molecule PROTACs are currently limited by the lack of small-molecules that bind E3 
ligases.  
To date, the majority of PROTACs are small molecules, but recent work has also seen the 
development of both protein and peptide-based PROTACs.165, 166 Clift et al. developed the 
Trim-Away approach to target endogenous protein for degradation.165, 167 TRIM21 is a E3 
ubiquitin ligase which binds to the Fc-region of antibodies, targeting the complex for 
degradation through autoubiquitination.168 Trim-Away harnesses the functionality of TRIM21 
and enables the selective degradation of endogenous proteins for which there is an antibody 
readily available. The approach has already been shown to work in a variety of cell types.  
 
In 2018, the first PROTAC harnessing Keap1 was reported by Lu et al.166 This was a 




degradation. The peptide was also conjugated to a polyarginine sequence to improve cellular 
penetration, and showed activity in H-SY5Ycells challenging previous preconceptions that 
peptide-based PROTACs could not be engineered to have good cell-penetration.169  
 
1.1.3 PhD Aims 
The ultimate aim of this thesis was to demonstrate that peptides can be grafted into the loops of 
repeat proteins to impart binding affinity for a particular target. Grafting into protein loops can 
be especially challenging because it is difficult to predict loop conformations as well as predict 
the entropic cost of binding, however the amenability of repeat proteins to protein engineering 
suggested this approach may be viable.114  An initial aim of this thesis was to explore which 
class of repeat protein would be amenable to the grafting of functional peptides into their loops. 
To this end, peptides designed using the cascade method developed by Sormanni et al. were 
grafted into the loops of  DARPins and CTPRs in Chapter 3.108 Although this thesis offered 
some insights into which scaffold may be best suited to peptide grafting into the protein loops, 
it highlighted the fact that it would be best to graft peptides that are known to bind the target 
with high affinity.  
 
This led to the second aim of this work, which was to explore how known binding peptides 
could be grafted into the loop of CTPR proteins. Work focused on grafting Keap1-binding 
peptides into the inter-repeat loops as a model system since these peptides had demonstrably 
good affinity for the target. Upon detecting a positive result, this aim evolved to include 
furthering our understanding of how the CTPRs with grafted Keap1-binding peptides (Keap1 
CTPRs) could be modified to improve protein stability and binding affinity. This part of the 
thesis aimed to answer: How did the binding affinity of the free peptides correlate with the 
binding affinity of the grafted peptides? Could changes to the protein scaffold improve the 
protein stability? These questions were subsequently explored in Chapter 4, with the effect of 
the protein scaffold on protein stability being further explored in Chapter 5.  
 
The CTPRs were amenable to peptide grafting and so could likely accommodate different 
flanking residues. This sparked an interest in whether changes to the binding affinity could be 
impacted by changing the flanking residues (the residues either side of the grafted peptide). 
Could the introduction of flexible residues improve the binding affinity of the grafted peptide 





Having developed CTPRs with high affinity for Keap1, this sparked a questions regarding on 
whether these proteins would be relevant in a therapeutic context. A key  question is how to 
best deliver these proteins into cells. Kube et al. had a developed a method for the delivery of 
proteins into cells using fusogenic liposomes, which was being explored by Dr. Piyush 
Chaturbedy.170 This thesis therefore explored, in collaboration with Dr Piyush Chaturbedy, 
whether the CTPR could be delivered into cells using fusogenic liposomes and if they could 
show functionality within the cell. These questions were explored in Chapter 6. 
 
The work in Chapter 3 explored targeting c-Myc using DARPins with peptides grafted into the 
loops. This investigation and the selected target region for this study sparked an interest in what 
the best approach to target c-Myc would be. At the same time, exploring whether CTPRs could 
bind their targets via their inter-repeat loops also sparked an interest in whether functional 
peptides could be grafted into the helices of the CTPR to impart binding functionality to the 
CTPR scaffold. 
 
Omomyc had been previously developed as c-Myc dominant negative, and shown to induce 
massive tumour regression in a number of cell types, but its poor solubility and intrinsically 
disordered nature would not work well as a potential therapeutic.128 This, and the fact that the 
bioactive conformation of Omomyc is α-helical in the bHLH-LZ region, initiated an interest in 
whether the activity of Omomyc could be encapsulated through peptide grafting into the α-helix 
of the CTPR. The Omomyc peptide was also chemically stapled, as peptide stapling has been 
shown to be a could method in increasingly the proteolytic stability as well as constraining a 
peptide in its bioactive conformation.98-100  
 
In summary, the broad aims of this thesis, which later developed into more specific questions 
shown in blue, were: 
 
• To further the understanding of which repeat protein scaffold would be amenable for 
the grafting of functional peptides into the protein loops: 
- Are CTPRs amenable to the grafting of Keap1-binding peptides into the inter-
repeat loop? 
• To explore which peptides would be good for grafting into the repeat proteins: 
- What is the relationship between the binding affinities of free Keap1-binding 




- How does the length and the sequence of the grafted Keap1-binding peptides 
influence protein stability? 
• To explore how repeat proteins can be optimised to be better therapeutics: 
- Do the flanking residues of the grafted peptide influence protein stability? 
- Can changing the flanking residues of the grafted peptide impact the binding 
affinity of the CTPR for Keap1? 
• To explore whether CTPRs are amenable for use as therapeutics: 
- Are the proteins amenable to mutation to make them resistant to 
ubiquitination? 
- Can the CTPRs be delivered into cells?  
• To investigate whether the functionality of Omomyc could be encapsulated in a new 
molecule better suited for therapeutic purposes: 


























2 Materials and methods 
2.1.1 Materials and stock solutions  
All materials were purchased from Sigma-Aldrich unless otherwise specified. All 
oligonucleotides were purchased from Integrated DNA technologies (IDT).  
 
All buffers were made using Milli-Q water. Specific buffers are described in the relevant 
Methods section.  
 




































50 x TAE 
 
50 mg/mL (sterile filtered, 1000x) 
25 mg/mL (sterile filtered, 1000x) 
50 mg/mL (sterile filtered, 1000x) 
0.5 M in Milli-Q pH 7 
1 M in Milli-Q 
1 M  in Milli-Q (sterile filtered) 
1.5% (w/v) agar, 1% (w/v) tryptone, 0.5% 
(w/v) yeast extract, 1% (w/v) NaCl. 
Autoclaved.  
1.5% (w/v) tryptone, 1% (w/v) yeast 
extract, 0.5% (w/v) NaCl. Autoclaved. 
242 g trizma base, 57.1 mL glacial acetic 
acid, 18.6 g EDTA in a total volume of 1 
L with H2O.  
Protein gel running buffer NuPAGE MES SDS running buffer (20x) 





2.1.2 Molecular Biology 
2.1.2.1 Plasmids 
Table 3: List of Plasmids used in this Thesis for protein expression. * indicates clones that were 
cloned by Albert Perez-Riba/Laura Mitchell (c-Myc DARPin pRSETB, α-synuclein CTPRs 
pRSETB, CTPR2n pRSETB, Keap1 RTPR2) and a plasmid gifted to the lab by Alex Bullock 
(Keap1 pNIC28-BSA4, Nuffield Department of Medicine, University of Oxford). 
 
2.1.2.2 Restriction site digestion 
Gene fragments were codon optimised for expression in the relevant species and avoiding 
internal restriction sites using the GeneArt programme (Thermo Fisher Scientific). All 
Plasmid Name Vector Antibiotic 
resistance 
Protein tag 
c-Myc DARPin* pRSETB Ampicillin N-terminal His-tag 



















































































digestions were carried out at 37 oC for 30 min followed by a 2 min denaturation step at 80 oC. 
All cut plasmid DNA was run on a 1% agarose gel with 1x SYBR safe in TBE buffer at 100V 
for 30 min and gel extracted using a Thermo ScientificTM GeneJET Gel Extraction Kit according 
to the manufacturer’s protocol where it was eluted into 50 μL of sterilised Milli-Q. The cut 
plasmid was dephoshorylated by adding 5.5 μL Antarctic Phosphatase (NEB) to the 50 μL of 
eluted plasmid and incubated for 37 oC for 30 min followed by heating to 80 oC for 2 min as a 
denaturation step.    
 
2.1.2.2.1 Keap1 CTPRs 
The Keap1 CTPRs were cloned through digestion of a gBlock gene fragments (Integrated DNA 
Technologies) encoding for the Keap1 CTPR.  1 μL of  each of BamHI and HindiII FastDigest 
(FD) enzymes was added to 3 μL of 10x FD buffer and  3 μL of 50 ng/μL of G Block, with 
sterilised Milli-Q being added to make up the volume to 30 μL.  5 μg of plasmid DNA 
(pRSETB) was digested using 1 µl of each  BamHI and HindiII FastDigest (FD) enzymes 
restriction enzymes and 2 μL of 10x FD buffer, made up to a total volume of 20 μL with 
sterilised Milli-Q.  
 
2.1.2.2.2 c-Myc CTPRs 
5 μg of pBabe Puro plasmid DNA and the pEX-A2 genes (Eurofins) encoding for the c-Myc 
CTPRs were digested using 1 µl of SalI-HF and 1 µl of EcoRI-HF in 30 μL total volume. The 
digestion was carried out for 1 hr at 37 oC.   
 
2.1.2.3 Polymerase Chain Reactions (PCR) 
2.1.2.3.1 Primer Design  
Primers were used using overlap extension PCR in order to install the W156E mutation into c-
Myc DARPin.  
 
Table 4: Primers used in this thesis.  
 
Primers  5’→3’ Sequence 
c-Myc DARPin W156E-Forward GAACGTGTTGAACTGGTTTTTGAACGT 




2.1.2.3.2 Site-directed mutagenesis  
Site-directed mutagenesis was achieved using overlapping extension PCR. 25 μL of 2 x Phusion 
Master Mix was added to 2.5 μL of a 10 μM solution of each of the primers along with 0.5 μL 
of vector  and 19.5 μL of milli-Q to make a total volume of 50 μL.  An initial 30 second 
denaturation was used and then 16 cycles of; 30 sec denaturation, 1 min annealing at 68 oC, 6 
min extension at 72 oC.  The PCR mixtures were then treated with Dpn1 for 1 hr at 37 oC prior 
to transformation into E.coli. 
 
2.1.2.4 DNA ligation   
Ligations of cut insert and cut plasmid were carried out with a 3:1 molar ratio of insert:vector 
using a Quick-Stick Ligase (Bioline) according to the manufacturer’s instructions. A negative 
control was carried out by replacing the insert DNA with an equal volume of sterilised Milli-
Q.  
 
2.1.2.5 Transformation  
For DNA that had been ligated, 5 μL of the ligation mixture was transformed into 50 μL of α-
select gold efficiency competent cells (BioLine). For circular plasmids, 100 ng of DNA was 
transformed into 50 μL of α-select bronze efficiency competent cells (BioLine).  
 
Cells were incubated with the DNA on ice for 30 min, heat-shocked at 42 oC for 45 sec and 
recovered on ice for 2 min. Cells were incubated with 300 μL of media (SOC media (Bioline) 
was used for ligation mixtures, autoclaved 2xTY media for standard ligations) and grown  at 
37 oC at 550 RPM for 1 hr.  Cells were then pelleted at 3200 RPM and resuspended in 50 μL 
of  2xTY media and plated on a LB agar plate with an appropriate antibiotic for 15 hr.  
 
2.1.2.6 DNA extraction  
A single colony from a LB agar plate was added to 5 mL of 2xTY media with an appropriate 
antibiotic in a 50 mL Falcon tube and incubated at 37 oC at 220 RPM for 16 hr. Cells were 
pelleted by spinning at 4 oC at 5000 RPM for 5 min. The media was then separated from the 
pellet and the DNA extracted using a GeneJET Miniprep kit. DNA concentrations were 
measured using a NanoDrop 2000 (Thermo Fisher Scientific) and DNA sequencing was sent 





2.1.3 Protein expression and purification 
This section details the expression of proteins in this study. α-synuclein was prepared by 
Francesco Aprile (Department of Chemistry). c-Myc DARPin was prepared by Laura Mitchell 
and Albert Perez-Riba.  
 
2.1.3.1 Properties of proteins in this study  
Table 5: The molecular weight, extinction coefficient and pI of purified constructs used in this 
























2.1.3.2 Large-scale preparation 
Binding buffer/ Wash buffer/ Gel filtration buffer for:  
c-Myc DARPin W156E: 50 mM Tris-HCl, 150 mM NaCl pH 8.5 




α-synuclein CTPR2 11.6 26360 
α-synuclein CTPR6 27.7 88130 
c-Myc DARPin 26.9 12950 
Thrombin CTPR6   27.3 83660 
Human Kelch domain Keap1 (post 
TEV cleavage) 
33.6 58330 
Keap1 RTPR2 11.6 28880 
Keap1 CTPR2-1-1 11.0 28880 
Keap1 CTPR2-1-Control 11.0 28880 
Keap1 CTPR2-2-1 11.5 28880 
Keap1 CTPR2-2-2 11.2 28880 
Keap1 CTPR2-2-3 11.4 28880 
Keap1 CTPR2-3-1 11.5 28880 
Keap1 CTPR2-3-2 11.7 28880 
Keap1 CTPR2-3-3 11.5 28880 
Keap1 CTPR2-3-4 11.5 28880 




α-synuclein CTPRs: 10 mM Sodium Phosphate, 150 mM NaCl pH 7.4 
Keap1 RTPR2: 50 mM Tris-HCl, 150 mM NaCl pH 8.5 
Keap1: 50 mM Tris-HCl 150 mM NaCl 2 mM DTT pH 8  
 
Non-specific binding buffer: Binding buffer + 30 mM imidazole 
Elution buffer: Binding buffer + 300 mM imidazole.  
 
The expression plasmid was transformed into chemically competent E. coli C41 cells (derived 
from BL21 cells). An agar plate of colonies was resuspended in 10 mL of 2xTY media and used 
to transfect one 500 mL culture of 2TY media with 50 μg/mL of ampicillin. Cultures were 
grown at 37 oC and 180 RPM until the O.D. reached 0.6-0.8.  The cultures were induced using 
0.5 mM IPTG and left to grow for 16 hr at 20 oC. The cells were pelleted using centrifugation 
(5000 RPM, 4 oC, 5 min). The supernatant was resuspended in 35 mL of binding buffer (with 
one EDTA-free SIGMAFASTTM protease inhibitor cocktail tablet/ 100 ml binding buffer). 
Cells were lysed with three passages through an Emulsiflex C5 homogeniser  at 10000 psi and 
then pelleted (17000 RPM, 4 oC, 45 min). Nickel batch purification was carried out using 5 mL 
of Ni-NTA resin (Amintra Ltd.). Beads were first washed with 50 mL of binding buffer and 
subsequently incubated with the supernatant from the centrifugation step for 2 hr at 4 oC on a 
rotator. The beads were washed with wash buffer (3 x 50 mL), non-specific binding buffer (1 x 
10 mL) and elution buffer (3 x 5 mL). The resulting 15 mL eluent was injected onto a HiLoad 
26/60 Superdex 75pg G75 column using a 50 mL superloop (GE Healthcare) and the protein 
was purified by gel filtration. Fractions were analysed using SDS-PAGE and fractions with 
>95% purity were pooled and concentrated using a VIVASPIN 20 concentrator (Sartorius 
Stedim Biotech) for the appropriate molecular weight. The resultant protein was frozen on dry 
ice and stored at -80 oC.  
 
2.1.3.3 TEV cleavage of His-tag 
The N-terminal His-tag of the Keap1 construct was successfully cleaved at the TEV cleavage 
site using EZCutTM TEV Protease according to the manufacturer’s instructions.  
 
2.1.3.4 Small-scale preparations 
Binding buffer: 50 mM Tris-HCl 150 mM NaCl 
Non-specific wash buffer: 50 mM Tris-HCl 150 mM NaCl 30 mM imidazole pH 8.5 





DNA was transformed into chemically competent E. coli Lemo21(DE3) cells and a single 
colony was grown with 15 mL of 2xTY media in a 50 mL falcon tube with chloramphenicol 
and ampicillin at 37 oC for 16 hr until a OD of 0.6-0.8 was reached. Cells were pelleted (4000 
RPM, 5 min), washed with 1 mL PBS, transferred to a 1.5 mL eppendorf and repelleted (13000 
RPM, 1 min). Cells were then resuspended in 1 mL Bugbuster and left to incubate for 20 min 
on a rotator at room temperature. The cell debris was pelleted (13000 RPM, 1 min) and the 
supernatant was incubated with 150 μL of Ni-NTA beads (washed from ethanol using binding 
buffer) in a 1.5 mL eppendorf for 30 min at room temperature. The beads were pelleted (4000 
RPM, 2 min), and washed 4 times with Non-specific binding buffer (with 10% bugbuster for 
the first and third washes). The protein was eluted with Elution buffer. Protein buffer was buffer 
exchanged back to Binding buffer using a P-10 desalting column (GE Healthcare) according to 
the manufacturer’s instructions.  The resultant protein was frozen on dry ice and stored at -80 
oC. 
 
2.1.3.5 Protein analysis 
2.1.3.5.1 Matrix-assisted laser desorption/ionisation (MALDI)  
Protein identity was confirmed by Matrix-assisted laser desorption/ionisation (MALDI) mass 
spectrometry by Len Packman (Department of Biochemistry) and by Albert Perez-Riba and 
Rohan Eapen in the Department of Chemistry.    
 
2.1.3.5.2 SDS-PAGE analysis 
All protein samples were run on RunBlue SDS Gel 4-20% (12 well) in RunBlue SDS Run 
buffer unless otherwise stated.  
	
2.1.4 Peptide Synthesis 
All Keap1-binding peptides were synthesised by Cambridge Peptides Ltd and provided at a 





2.1.5 Biophysical assays 
2.1.5.1 Fluorescence Polarisation (FP) 
A Fluorescence Polarisation assay based on the assay developed by Hancock et al. was 
employed using a 384 well black opaque optiplate microplates with a total volume of 40 µl in 
order to minimise protein usage.102 For the direct fluorescence polarisation assay, 1 nM FITC-
beta-ala-DEETGEF-OH peptide in 50 mM Tris-HCl 150 mM NaCl pH 8.5 was incubated with 
a serial dilution of Keap1 protein for 30 min. The experiment was repeated three times, and the 
data were fitted in GraphPad Prism 6.0 to a one-site binding model using the following Equation 
1: 
 																	𝐴𝐹 = %[']
)*+[']
+ 𝑁𝑠[𝑃] + 𝐶 
Equation 1: A one-site binding model where AF is the polarisation fraction, B is the maximum 
specific binding, [P] is the protein concentration in µM, KD is the midpoint concentration where 
half the maximum signal is reached, Ns is the gradient of the non-specific binding, and C is the 
background polarisation fraction. 
 
For the fluorescence polarisation competition assay, 1 nM FITC-b-Ala-DEETGEF-OH tracer 
and 237.5 nM Keap1 protein in 50 mM Tris-HCl 150 mM NaCl pH 8.5 was then incubated 
with a serial dilution of CTPR protein for 30 min using a 384 well black opaque optiplate 
microplates with a total volume of 40 µl. The experiment was repeated three times, and the data 
were fitted in GraphPad Prism 6.0 and the equation reported by Wang et al.171 For the 
experiments reported in Chapter 4, the gain adjustment was set at 40 mP for the wells with the 
highest concentration of CTPR. For all experiments in Chapter 5, the gain adjustment was set 
at 200 mP and carried out on a well with 40 µl of Milli-Q.   
 
2.1.5.2 Isothermal Titration Calorimetry (ITC)  
2.1.5.2.1 Experiments with α-synuclein CTPR6 
Experiments were performed on a Microcal VP-ITC Microcalorimeter. All proteins were 
dialysed overnight into PBS at room temperature for 2 hr using Midi D-tube dialysers 
(Molecular dimensions) at the appropriate molecular weight. 55 µM α-synuclein CTPR6 was 
titrated into a solution of 10 µM α-synuclein, over 30 injections of 10 µL, with a reference 
power of 13 µcal/sec, an injection duration of 12 sec, 500 sec spacing and a stirring speed of 





2.1.5.2.2 Experiments with Keap1 CTPRs and Keap1 binding peptides 
Experiments were performed on a Microcal iTC200  Microcalorimeter. All proteins were 
dialysed overnight into 50 mM Tris-HCl 150 mM NaCl 0.5 mM TCEP pH 8.5 at 4 oC using 
Midi D-tube dialysers (Molecular Dimensions) with the appropriate molecular weight cut-off. 
166.66 µM Keap1  was used for all Keap1 CTPRs and peptides except for Keap1 CTPR2-3-2 
for which 100 µM was used. The solution was titrated into  the Keap1 CTPR or peptide solution 
at 16.66 µM, except for Keap1 CTPR2-3-2 for which 10 µM was used,   over 20 injections of 
2 µL, with an initial delay of 60 sec, a reference power of 5 µcal/sec, an injection duration of 
0.8 sec, 150 sec spacing and a stirring speed of 750 RPM. The experiment was repeated with a 
titration of Keap1 into buffer and the previous data were then subtracted from this background 
data. Keap1 was also titrated into CTPR2n at the same concentrations as a negative control. 
The data were analysed using Origin 7.0 and fitted using a one-site binding model.  
 
2.1.5.3 Bio-Layer Interferometry (BLI) 
2.1.5.3.1 Experiments with α-synuclein CTPR6 
The BLI experiments were carried out on a ForteBIO BLItz® System. For all experiments with 
α-synuclein CTPR6, the sensor was first equilibrated in PBS buffer for 10 min at room 
temperature.  
 
Assays using Pall ForteBio Ni-based biosensors (Ni-NTA, anti-Penta-HIS and HIS2). After an 
equilibration step, an initial baseline was carried out for 30 sec in PBS. The sensors were then 
loaded with 1.8 μM α-synuclein CTPR6 for 120 to 150 sec. A second baseline was then carried 
out for 30 sec in PBS. An association step was then carried out with 7 μM and/or 200 μM α-
synuclein for 120 sec. A dissociation step was then carried out for 120 sec in PBS. 
 
For the experiments with the Capture Select biotin anti-C-tag conjugate antibody, a streptavidin 
biosensor (ForteBio) was used. After an equilibration step, an initial baseline was carried out 
for 30 sec in PBS. The sensors were then loaded with 5 μg/mL of the Capture Select antibody 
for 120 to 180 sec. A second baseline was then carried out for 60 sec in PBS to allow for better 
equilibration than had been seen in previous assays. A second association step was carried out 
with 50 μg/mL α-synuclein. A third baseline was then carried out for 60 sec in PBS. An 
association step was then carried out with 112.2 μM α-synuclein CTPR6 for 120 sec.  A 





2.1.5.3.2 Experiments with Keap1 CTPRs and Keap1 RTPRs 
All Keap1 TPRs were dialysed into 50 mM Tris-HCl 150 mM NaCl 2mM DTT pH 8 using 
Midi D-tube dialysers (Molecular Dimensions) at the appropriate molecular weight prior to the 
experiment. For all experiments, the Ni-NTA sensor was first equilibrated in 50 mM Tris-HCl 
150 mM NaCl 2mM DTT pH 8 buffer for 10 min at room temperature.  
 
After an equilibration step, an initial baseline was carried out for 30 sec in 50 mM Tris-HCl 
150 mM NaCl 2mM DTT pH 8. The sensors were then loaded with 50 μg/mL of the Keap1 
TPR for 120 sec. A second baseline was then carried out for 30 sec in 50 mM Tris-HCl 150 
mM NaCl 2mM DTT pH 8. An association step was then carried out with 7 μM Keap1 for 120 
sec.  A dissociation step was then carried out for 120 sec in 50 mM Tris-HCl 150 mM NaCl 
2mM DTT pH 8. 
 
2.1.5.4 Circular Dichroism (CD) Spectroscopy 
Secondary structure content was assessed using circular dichroism (CD) Spectroscopy. The 
spectra of 10 µM CTPR proteins in 50 mM Tris-HCl 150 mM NaCl pH 8.5 was measured using 
an Applied Photophysics Chirascan CD spectrophotometer (Applied Photophysics).  with a 
1mm cuvette between wavelengths of 206 nm and 280 nm at 20 oC at 1 nm increments at a rate 
of 0.5 sec/reading with three repeats being taken. The thermal stability of the proteins was 
determined by measuring the ellipticity of the solution at 222 nm upon heating the sample to 
94 oC at a rate of 0.5 oC per minute with five repeats of the readings being taken.  The solution 
was then cooled to 20 oC, and the CD spectrum was re-measured. The data were analysed using 
GraphPad Prism 6 software and melting temperatures determined using a sigmoidal sloppy 
Boltzmann equation (Equation 1). The reported standard error is the fitting error.  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + exp((𝑉50 − 𝑥) /𝑆𝑙𝑜𝑝𝑒) 
Equation 2: Sigmoidal Sloppy Boltzmann Equation used to fit CD data. Top and Bottom 
represent the maximum and minimum in the curve. V50 is the potential at which Y is half-
maximum. SLOPE is the gradient. 
2.1.5.5 BCA assay 
The concentration of the c-Myc DARPin W156E mutant was assessed using a BCA assay was 





2.1.5.6 Seeded aggregation experiments 
α-synuclein  CTPR6 was incubated with 70 μM monomeric α-synuclein at 1:1, 1:4, 1:8 and 
1:16 molar ratios and 3.5 μM of pre-formed fibrils and 20 μM ThT at 37 °C in PBS. The ThT 
fluorescence of the samples was continuously monitored using a FLUOstar OPTIMA plate 
reader (BMG Labtech Ltd.) with excitation and emission wavelengths of 440 nm and 480 nm 
respectively (slit widths of 10 nm) for 16.7 hr. No CTPR, no α -synuclein and no THT controls 
were used. 
 
2.1.6 Tissue Culture 
2.1.6.1 Retroviral Transduction 
10 μg DNA was incubated with 60 μL of SuperFect lipophilic reagent (QIAGEN) in 300 μL of 
Dulbecco’s Modified Eagles Medium (DMEM) media and incubated for 15 min at room 
temperature to allow micelle formation. This mixture was then added to 5 mL of DMEM + 10 
%  Fetal Calf Serum (FCS) and added directly to phoenix ampho retroviral packaging cells. 
After 3 hr the media was changed for 12.5 mL of 5 mL of DMEM + 10 % FCS. After 48 hr, 
the media containing recombinant retroviral particles was harvested, filtered and stored at 4 oC. 
The relevant cells were infected with virus by adding this media with hexadimethrine bromide 
(Polybrene, 4 μg/mL) directly to cells. This was left to incubate for 3 hr and subsequently 
replaced with fresh media. 
 
2.1.6.2 Puromycin selection 
Selection of retrovirally transduced cells was achieved by culturing in media containing 0.5-2 
μg/mL puromycin. The media was changed every two days and selection was carried out until 
death of uninfected cells was observed (typically six days).  
 
2.1.7 Liposome experiments 
2.1.7.1 Rhodamine labelling of Keap1 CTPR2-2-3 
Keap1 CTPR2-2-3 protein was dialysed into 1 M NaCO3 using Midi D-tube dialysers 
(Molecular Dimensions) at the appropriate molecular weight. 100 µL of 1 mg/mL Rhodamine 
isothiocyanate  in DMSO was added to 0.73 mg/ mL of  Keap1 CTPR2-2-3 protein in 1000 µL 
of  1 M NaCO3. The mixture was stirred in a glass vial covered in tin foil overnight at 4 oC. 2.7 
mg of NH4Cl was then added to quench the reaction and the mixture was stirred for a further 2 




healthcare) to change the buffer to 10 mM HEPES pH 7.4 and in order to remove the any free 
dye. The protein was then concentrated to 1.9 mg/mL and stored at 4 oC. 
 
2.1.7.2 Liposome preparation  
The Keap1 CTPR2-2-3 (unlabelled or Rhodamine-labelled) was buffer exchanged into 10 mM 
HEPES pH 7.4 using a PD-10 desalting column (GE healthcare). This was then used to hydrate 
the lipid film prepared by Piyush Chaturbedy so that the final lipid concentration was 4 mg/mL 
and the protein concentration was 26 x that reported in the text in total volume of 31 µL. This 
dispersion was vortexed for 1-2 min and then sonicated for 20 mins at room temperature.  
 
2.1.7.3 Confocal experiments 
HCT 116 cells were seeded in a µ-slide 4-well Ph+ #1.5 polymer coverslip, tissue 
culture treated, sterilised plate (ibidi) in McCoy’s 5a medium, modified, with L-Glutamine 
(Sigma Aldrich) and a 700 µL well volume for 24 hr at the specified concentration. The 
specified amount of liposomes were added to DMEM media to make a total volume of 780 µL. 
700 µL of this mixture was then added to the cells and incubated for 15 min at 37 oC. The cells 
were then washed twice with 700 µL of PBS and 700 µL of Hank’s Balanced Salt Solution 
(HBBS) media (Life Technologies). Confocal images were taken of the live cells on a Leica 
TCS SP5 Confocal Microscope with  Lex = 633 nm, and Lem = 720-800 nm for DiR and Lex 
= 514 nm, and Lem = 530 -650 nm for Rhodamine B isothiocyanate (RITC) respectively. 
Images were captured at a single focal point, an objective of 60x and 2x zoom. The sample area 
was scanned at a resolution of 1260x1260 pixels at a scanning speed of 100Hz. Images were 
averaged over 3 frames meaning each pixel was scanned thrice and average of three scans was 
taken as the image. Images were processed using Fiji software.  
 
2.1.7.4 Probing the effect of liposome delivery on HCT 116 cells.  
1.5 x 105 HCT 116 cells were seeded in a 24-well multidish culture plate (Nunc) for 24 hr. 30 
µL of proteoliposomes were added to DMEM media to make a total volume of 519.89 µL at a 
final Keap1 CTPR2-2-3 concentration of 1.2 µM and 3.5 µM. 500 µL of this mixture was then 
added to the cells and incubated for 15 min at 37 oC. The cells were then washed twice with 
700 µL of PBS and 500 µL of fresh DMEM media was added to the cells. Cells were then 




loading dye and heated at 100 oC for 5 min and subsequently pelleted (13200 RPM, 1 minute). 
Untreated cells, cells treated with empty liposomes and cells treated with 3.5 µM CTPR2n.  
 
2.1.8 Immunoprecipitation experiments (IP) 
2.1.8.1 Cross-linking of antibodies to Protein G Sepharose Resin 
Elution Reagent: 1 M glycine pH 3 
Dilution buffer: 1 mg/mL BSA in PBS		
Wash buffer: 0.2 M triethanolamine in PBS 
Quenching buffer: 50 mM ethanolamine in PBS 
Stock Solution of Dimethyl pimelimidate (DMP): 13 mg/mL DMP 
 
30 μL of Protein G sepharose 4 fast flow (GE Healthcare) were washed from ethanol with 300 
μL of PBS.  The beads were subsequently pelleted (13200 RPM, 15 secs) and mixed with 30 
μL of PBS and rotated overnight at 4 oC. The beads were again pelleted (13200 RPM, 15 secs) 
as the PBS was aspirated off. 400 μL of dilution buffer was added to the beads and rotate for 
10 min at 4°C. The beads were then pelleted and the supernatant discarded as before. 1 μL of 
the mouse monoclonal anti-HA and anti-E1A antibodies (Sigma H9658 and abcam ab33183 
respectively) were added to beads along with 29 μL of dilution buffer. The solutions were mixed 
well and incubated rotated for 1 hr at 4 oC. The beads were pelleted and the supernatant 
discarded as before. 30 μL of dilution buffer was added to the beads and rotated for 5 mins at 4 
oC. The beads were then pelleted and the supernatant discarded as before. 1 mL of the stock 
solution of DMP was then mixed with 1 mL wash buffer and immediately vortexed. 300 μL of 
the mixture was added to the beads and rotated for 30 min at room temperature. The beads were 
washed with 500 μL of wash buffer and rotated for 5 min at room temperature.  The beads were 
pelleted and the supernatant discarded as before. This cross-linking and subsequent wash step 
using DMP was then repeated twice more. The beads were  washed with 300 μL of quench 
buffer and rotated for 5 min at room temperature. The beads were pelleted and the supernatant 
discarded as before. The beads were then washed with 300 μL of PBS and then pelleted and the 
supernatant discarded as before. The beads were then washed with 200 μL of elution buffer in 
order to remove any unlinked antibody and  rotated for 10 min at room temperature and were 
then pelleted and the supernatant discarded as before. This elution step was repeated once more. 
The beads were washed with 200 μL of PBS + 0.1 % TWEEN and rotated for 5 min at room 
temperature. This wash step was repeated twice more and the beads were stored in the final 





2.1.8.2 c-Myc DARPins 
TBS buffer: 1 x TBS pH 8, 0.5% IQEPAL, 0.5% BSA, 1 mM DTT  
RIPA buffer: 0.15 M NaCl, 1 % IQEPAL, 0.5% NaDOC, 0.1% SDS, 0.05M Tris-HCl pH 8 
 
107 HeLa cells were grown to 80% confluency and were washed with 10 mL PBS and lysed in 
1 mL TBS lysis buffer (TBS buffer + 0.5% BSA + 1 Roche c0mplete mini, EDTA free protease 
inhibitor cocktail protease tablet/ 10 mL), or RIPA lysis buffer (RIPA buffer + 1 Roche 
c0mplete mini, EDTA free protease inhibitor cocktail tablet/ 10 mL) and the DNA sheared by 
forcing through a 26G needle. Cell lysates were pelleted by centrifugation (20 000 g, 1 min, 4 
oC). 125 μL Ni-NTA resin was washed from ethanol using 3 x 500 μL washes with TBS or 
RIPA wash buffer (Buffer + 1 Roche c0mplete mini, EDTA free protease inhibitor cocktail 
tablet/10 mL). The beads were then incubated with 10 μL 70 μM DARPin for 15 min at 4 oC 
and subsequently pelleted (13200 RPM, 15 sec). The resin was again washed with  3 x 500 μL 
washes with TBS or RIPA wash buffer. The resin was then incubated with 150 μL of lysed cells 
plus 300 μL of the appropriate lysis buffer for 40 min at 4 oC and then pelleted (13200 RPM, 
15 secs) The resin was then washed with 5 x 1 mL of the appropriate wash buffer. The resin 
was then incubated with 40 μL 1 x SDS-PAGE loading buffer (3 min, 95 oC) and clarified by 
centrifugation (13200 RPM, 5 min). 
 
2.1.8.3 Keap1 CTPRs 
1 % Triton buffer: 1 % Triton-X, 10 % glycerol, 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA 
+ 1 Roche c0mplete mini, EDTA free protease inhibitor cocktail protease tablet/ 10 mL. 
 
107 HEK293T cells were grown to 80% confluency and washed with PBS and lysed in 2.5 mL 
1 % Triton buffer and scraped into an eppendorf and incubated for 30 min on ice and the DNA 
sheared by forcing through a 26G needle. Cell lysates were pelleted by centrifugation (20 000 
g, 30 min, 4 oC). 50 μL Ni-NTA resin was washed from ethanol using 3 x 500 μL washes with 
1 % Triton buffer. The resin were then incubated with 1 mL of cell lysate for 3 hr at 4 oC and 
subsequently pelleted (13200 RPM, 15 secs). The resin was then washed with 3 x 1 mL 1 % 
Triton buffer. The resin was then incubated with 20 μL 1 x SDS-PAGE loading buffer (3 min, 





2.1.8.4 Omomyc-like peptides 
TBS buffer: 1 x TBS pH 8, 0.5% IQEPAL, 0.5% BSA, 1 mM DTT  
 
107 HeLa cells were grown to 80% confluency and were washed with 10 mL PBS and lysed in 
1 mL TBS lysis buffer (TBS buffer + 0.5% BSA + 1 Roche c0mplete mini, EDTA free protease 
inhibitor cocktail tablet/ 10 mL) and the DNA sheared by forcing through a 26G needle. Cell 
lysates were pelleted by centrifugation (20 000 g, 1 min, 4 oC). 30 μL Protein G sepharose 4 
fast flow (GE Healthcare) was washed from ethanol using 3 x 500 μL washes with TBS wash 
buffer (Buffer + 1 Roche c0mplete mini, EDTA free protease inhibitor cocktail tablet/ 10 mL). 
The beads were then incubated with 1 μL mouse monoclonal anti-HA antibody (H9658, Sigma) 
or 1 μL mouse monoclonal anti-E1A (ab33183, abcam) with 1 μL 10 mM Omomyc-like peptide 
for 15 min at 4 oC and subsequently pelleted (13200 RPM, 15 secs).  The resin was then washed 
using 3 x 500 μL TBS wash buffer. The resin was then incubated with 150 μL of lysed cells 
plus 250 μL of the appropriate lysis buffer for 40 min at 4 oC and then pelleted (13200 RPM, 
15 secs) The resin was washed with 5 x 1 mL of the TBS wash buffer. The resin was incubated 
with 40 μL 1 x SDS-PAGE loading buffer (3 min, 95 oC) and clarified by centrifugation (13200 
RPM, 5 mins). 
 
2.1.9 Western Blotting 
2.1.9.1 1 mm SDS PAGE gel recipes 
Stacking gel: 2.5 mL 0.5 M Tris-HCl pH 6.8, 1.5 mL 30 % Acrylamide, 100 μL 10% SDS, 10 
μL TEMED, 200 μL 10% APS  and made up to 10 mL using Milli-Q 
12 % Separating gel: 5 mL 1.5 M Tris-HCl pH 8.8 , 8 mL 30 % Acrylamide, 200 μL 10%  SDS, 
25 μL TEMED, 75 μL 10% APS  and made up to 20 mL using Milli-Q  
 
2.1.9.2 Standard Western blotting protocol  
The following method was used as standard for the western blotting experiments. Any 
modifications are detailed in the relevant section.  
 
10 μL of each sample was loaded onto a 1mm SDS-PAGE gel and was run at 150 V for 70 min 
in running buffer and transferred to a Immobilon-P polyvinylidene difluoride (PVDF, 
Millipore), which had been placed in 100% methanol followed by transfer buffer (running 
buffer + 20% methanol). The proteins were transferred to the membrane using electroblotting  




temperature and then with a stated  dilution of the primary antibody in 5 mL incubation buffer 
for 1 hr at the specified temperature. Membranes were subsequently washed with 3 x 20 mL of 
wash buffer for 5 min. Membranes were incubated with the stated dilution of the secondary 
antibody in 5 mL incubation buffer for 1 hr at the specified temperature. Membranes were 
subsequently washed with 3 x 20 mL of wash buffer for 5 min. Proteins were then visualised 
on the membranes using a Pierce ECL Western Blotting Substrate Kit and exposing to X-ray 
films for HRP-conjugated secondary antibodies. Membranes incubated with IR conjugated 
secondary antibodies were visualised using a  LI-COR Odyssey CLx. 
 
2.1.9.2.1 c-Myc DARPins IP 
Gel running buffer: 192 mM glycine in 25 mM Tris-HCl 
Blocking buffer: 4 % Marvel +0.1% TWEEN 20 in TBS 
Incubation buffer: 2 % Marvel in TBS 
Wash buffer: TBS + 0.1% TWEEN 20 
 
1 in 500 dilution of the Rabbit anti-c-Myc primary antibody (Y69, Abcam).  
1 in 10000 dilution of the Goat anti-Rabbit IgG (whole molecule)-Peroxidase secondary 
antibody (A0545, Sigma Aldrich).  
 
Westerns were incubated with the appropriate antibodies at 4 oC. 
 
2.1.9.2.2 Keap1 CTPRs IP 
Gel running buffer: 192 mM glycine + 25 mM Tris-HCl 
Blocking buffer: Odyssey Blocking buffer (LI-COR).  
Incubation buffer: Odyssey Blocking buffer + 0.1% TWEEN 20 
Wash buffer: PBS + 0.1% TWEEN 20 
 
1 in 500 dilution of the Rabbit polyclonal anti-Keap1 primary antibody (10503-2-AP,  
Protein Technologies) 
1 in 1000 dilution of the IRDye® 800CW Rat Anti-Rabbit secondary antibody (LI-COR 
Biosciences).  
 





2.1.9.2.3 Liposome delivery of Keap1 CTPR2-2-3 into HCT 116 cells 
Gel running buffer: 192 mM glycine in 25 mM Tris-HCl 
Blocking buffer: 4 % Marvel + 0.1% TWEEN 20 in PBS 
Incubation buffer: 4 % Marvel + 0.1% TWEEN 20 in PBS  
Wash buffer: PBS + 0.1% TWEEN 20 
 
1 in 100 dilution of the primary mouse monoclonal anti-HO-1 (A-3, Santa Cruz Biotechnology) 
and mouse monoclonal anti-γ-GCS antibody (H-5, Santa Cruz Biotechnology) 
1 in 2500 dilution of the rabbit polyclonal anti-actin primary antibody (A2066, Sigma) 
1 in 2500 dilution of the goat anti-mouse HRP conjugated secondary antibody (P0447, Dako)  
1 in 10000 dilution of the swine anti-Rabbit HRP conjugated secondary antibody (P0399, Dako) 
 
Westerns were incubated with the appropriate antibodies at 4 oC.  
 
2.1.9.2.4 Omomyc-like peptides IP 
Gel running buffer: 192 mM glycine + 25 mM Tris-HCl 
Blocking buffer: Odyssey Blocking buffer (LI-COR).  
Incubation buffer: Odyssey Blocking buffer + 0.1% TWEEN 20 
Wash buffer: PBS + 0.1% TWEEN 20 
 
1 in 1000 dilution of the primary anti-c-Myc primary antibody (Y69, Abcam) 
1 in 10000 dilution of the IRDye® 800CW Rat Anti-Rabbit secondary antibody (LI-COR 
Biosciences).  
 
Westerns were incubated with the appropriate antibodies at room temperature.  
 
2.1.9.2.5 Omomyc-like CTPRs 
Gel running buffer: 192 mM glycine + 25 mM Tris-HCl 
Blocking buffer: Odyssey Blocking buffer (LI-COR).  
Incubation buffer: Odyssey Blocking buffer + 0.1% TWEEN 20 
Wash buffer: PBS + 0.1% TWEEN 20 
 
Akt-HA-ER expressed in rat vascular smooth muscle cells was used as a negative control (90 





1 in 5000 dilution of the mouse monoclonal anti-HA primary antibody (Sigma H9658) 
 
1 in 10000 dilution of the IRDye® 800CW Rat Anti-Mouse secondary antibody (LI-COR 
Biosciences).  
 






























3 Grafting computationally-designed peptides into repeat-
protein loops 
3.1.1 Introduction  
Pietro Sormanni designed the complementary peptides used in this study. Francesco Aprile 
offered  support with the experimental design of the seeded aggregation experiments. Albert 
Perez-Riba also provided useful discussions and advised that the DPNN sequence should be 
used both before and after the grafted peptide in order to maintain protein stability. He also 
cloned the α-synuclein CTPRs as well as cloned  and purified the c-Myc DARPin in 
collaboration with Laura Mitchell.   
 
3.1.1.1 Intrinsically-disordered proteins 
Intrinsically disordered proteins (IDPs) are proteins that do not adopt a well-defined tertiary 
structure and are implicated in many diseases such as cancer and Parkinson’s disease, making 
them attractive drug targets. However, IDPs present a major challenge to conventional drug 
discovery because their lack of a clearly defined tertiary structure means that structure-based 
approaches to drug design, such as the use of co-crystal structures, can rarely be used.172, 173 
 
3.1.1.2 Rational design of complementary peptides  
Sormanni et al. developed a method with the potential to target any epitope, including those 
found in intrinsically disordered proteins.108 They used sequence-based, rather than structure-
based, targeting so the lack of a clearly defined tertiary structure no longer posed a hurdle to 
inhibitor design. The method relies on the development of a complementary peptide designed 
to bind the target epitope in a β-strand conformation via backbone hydrogen bonds using 
structures published in the Protein Data Bank. This complementary peptide is then grafted on 
to a single domain antibody (sdAb) scaffold at solvent-exposed complementarity-determining 
regions (CDRs, Figure 13). 
 
Using this method, Sormanni et al. were able to design sdAbs to successively target Aβ peptide, 






3.1.2 Using grafted complementary peptides to rationally design a 
CTPR to target α-synuclein 
 
3.1.2.1.1 α-synuclein 
After Alzheimer’s disease, Parkinson’s Disease is the second most common neurological 
disease. It is characterised by slowness of movement, the presence of a tremor along with 
rigidity.174 Sufferers have neural cell loss and the presence lewy bodies in the substantia nigra.  
 
These lewy bodies have been shown to be composed of α-synuclein protein (Figure 14 and 
15).175 The accumulation and aggregation of α-synuclein to form amyloid fibrils, which in turn 
forms Lewy bodies, is characteristic of Parkinson’s disease (Figure 15).175-177 The exact 
mechanism of α-synuclein aggregation is not yet known. Work has suggested that at a neutral 




Figure 14: The different regions of α-synuclein along with the primary sequence of each region 
.8 The non-amyloid-β component makes up the hydrophobic core of the protein.  
Figure 13. The design of the single domain antibody (sdAb). Complementary peptide design 
(Green) through grafting together peptides from different Protein Data Bank structures to target 





Figure 15: A basic outline of the formation of α-synuclein fibrils.179 
The non-amyloid-β component (NAC) is a highly hydrophobic region of α-Synuclein (residues 
61-96, Figure 15) has been shown to be involved in inducing this aggregation, making it an 
attractive drug target.180 
   
3.1.2.2 Design 
Although Sormanni et al. were able to design sdAbs to target intrinsically disordered proteins 
related to protein misfolding diseases, these designed sdAbs were found to have problems with 
solubility and stability (Pietro Sormanni, Personal Communication). The work described in this 
Chapter sought to investigate whether this method of design could also be applied to a CTPR 
scaffold. CTPRs have a much higher stability than the sdAbs and have previously been shown 
to be amenable to protein engineering projects so using them in place of the sdAbs may results 
Figure 16: Design of α-synuclein CTPR6 and α-synuclein CTPR2. A: A complementary 
peptide, shown in pink, is grafted into the central loop of the CTPR. B:  The 
complementary peptide (pink) is designed so as to form an anti-parallel β-sheet with the 




in proteins with higher stability and solubility.150 In addition, TPRs function as molecular 
scaffolds in nature, and loop extensions of 10 or more residues are common.181 This observation 
along with the fact that the inter-repeat loops of CTPRs have been previously shown to be 
amenable to extensions of up to 25 amino acids, suggests the inter-repeat loops of CTPRs may 
also be amenable to the grafting of binding peptides into the inter-repeat loops in order to impart 
functionality.182 
 
a-synuclein was targeted rather than another intrinsically disordered protein, because the 
binding of the sdAb designed to target a-synuclein was much stronger compared to those 
designed to bind to the two other intrinsically disordered proteins reported by Sormanni et al.108 
This sdAb is designed to bind the NAC of a-synuclein and has the advantage that it has been 
shown to reduce the rate of a-synuclein aggregation in vitro.108  
 
A similar complementary peptide to that used for the sdAb was used, but it was increased in 
length from seven to eleven residues and so now targeted 68-78 (GAVVTGVTAVA) of the 
NAC region of α-synuclein as opposed to residues 70-77, because Pietro Sormanni felt the 
higher thermal stability of the CTPR might mean that it is able to tolerate grafting of longer 
peptide sequences and consequently have higher affinity and specificity for the target. Two 
CTPRs were designed to target a-synuclein, one with six protein repeats (α-synuclein CTPR6) 
and one with two protein repeats (α-synuclein CTPR2). Both were designed using the consensus 
sequence reported by Main et al. and had the peptide grafted in the inter-repeat loop between 
the central two repeats, i.e., between repeats 1 and 2 in α-synuclein CTPR2 and between repeats 
3 and 4 in α-synuclein CTPR6 (Figure 16).134  The peptide was grafted in the centre of the 
CTPR6 construct,  as it was thought this may overcome the potentially destabilising nature of 
the complementary peptide insertion into the loop due to the fact that the CTPR3 either side of 
the grafted peptide can fold independently. A 2- repeat CTPR (CTPR2) and 6-repeat CTPR 
(CTPR6) were used to investigate the effect of increasing number of repeats on protein  
structure and stability. The inter-repeat loop of the CTPR has the DPNN sequence (residues 31-
34 of the repeat). The P32 induces the turn and is stabilised by backbone hydrogen bonding to 
W4 of the next repeat.134, 183 N34 of the CTPR repeat also has previously been shown to form 
an amide-pi bond with the Y5 residue. In order to maintain these interactions, and hence 
hopefully retain protein stability, a DPNN peptide was added to both the start and the end of 






3.1.2.3.1 Expression and Purification of α-synuclein CTPR2, α-synuclein CTPR6 and 
Thrombin CTPR6 
 
The proteins were isolated using expression in chemically competent E.coli C41(DE3) followed 
by Ni-affinity and gel filtration chromatography (Figure 17).  The elution profile from both the 
purification of α-synuclein CTPR2 and α-synuclein CTPR6 showed multiple peaks, which were 
all shown to be of the correct mass by MALDI analysis. The presence of these multiple peaks 




Figure 17: Elution profile for the gel filtration purification of α-synuclein CTPR2. The  
elution profile shows that the α-synuclein CTPR2 forms different oligomeric states. The peak 
at 200 mL presents as possible dimer on SDS PAGE. Purification with a HiLoad 26/60 




Figure 18: A: Gel filtration purification of α-synuclein CTPR6 SDS PAGE reveals the potential 
presence of several oligomeric species in addition to the potential monomer at ~25 KDa. B: Gel 
filtration purification of α-synuclein CTPR6 (Black) and Thrombin CTPR6 (Green). 
Purification with a HiLoad 26/60 Superdex 75pg G75 column in 10 mM Sodium Phosphate, 
150 mM NaCl pH 7.4. 
An additional CTPR6 was purified to act as a negative control for my experiments. This 
CTPR6, known as ‘Thrombin CTPR6’, has a sequence that includes the thrombin cleavage site 
in the loop rather than a complementary peptide although it is the same number of amino acid 
residues. Again, several peaks in the elution profile of Thrombin CTPR6 were also observed, 
but these were shown to be very pure using SDS-PAGE (Figure 18). Therefore, oligomerisation 
may be induced mostly by the process of inserting the peptide into the protein loop, rather than 
being dependent on peptide sequence. This is because both the Thrombin CTPR6 and the α-
synuclein CTPRs show oligomerisation and have a peptide insert of the same length in all 
constructs despite having a different sequence. 
 
The fact that the peaks in the elution profile for both Thrombin CTPR6 and α-synuclein CTPR6 
are at similar volumes suggest that the two proteins are adopting similar oligomerisation states. 
One explanation for this observation is that this oligomerisation is due to domain swapping, 
which is the process by which proteins swap part of their structures to form dimers or higher 







3.1.2.3.2 Circular Dichroism (CD) 
Following protein purification, CD was used to determine whether the proteins were correctly 
folded and in order to determine their thermal stabilities. α-synuclein CTPR2, α-synuclein 
CTPR6 and Thrombin were all shown to be correctly folded, refold after thermal denaturation 
and to have high melting temperatures (Table 6, Figure 20). Interestingly, it was not possible 
to unfold α-synuclein CTPR6 using thermal denaturation up to temperatures of 94 oC, helping 
to emphasise the high stability of the protein.  
 
 
Figure 19: Hypothetical process of domain swapping for CTPRs with elongated inter-repeat 
loops to produce A: monomers, B: dimers and C: trimers. Each box represents a CTPR repeat. 




   
Table 6: Melting temperatures of CTPRs using CD. The reported melting temperature in the 






3.1.2.3.3 Probing binding of the CTPRs to α-synuclein 
Following the CD studies, which suggest that the α-synuclein CTPR6 is much more 
thermostable than α-synuclein CTPR2, I decided to focus on investigating the binding of α-
CTPR Melting temperature ± SE (oC) 
α-synuclein CTPR2 81.1 ± 1.2 
α-synuclein CTPR6 n.d. 
Thrombin CTPR6 60.3 ± 1.2 
Figure 20: CD experiments carried out with 10 μM protein to investigate protein structure and 
stability. CD spectra of i) CTPRs both before (black) and after (coloured) thermal denaturation 
and ii) their thermal denaturation at 222 nm monitored using CD for A: α-synuclein CTPR2 
(green), B: α-synuclein CTPR6 (red) and C) Thrombin CTPR6 (blue). Error bars shown on 




synuclein CTPR6 to α-synuclein and whether the α-synuclein CTPR6 could reduce the 
aggregation of α-synuclein.  
 
3.1.2.4 Seeded aggregation assay 
α-synuclein is prone to aggregation, with this process eventually leads to the formation of fibrils 
and is implicated in Parkinson’s disease.175-177 The NAC region is thought to be important in 
regulating this process. In order to investigate the specificity of  the α-synuclein CTPR6 for the 
target NAC sequence and to probe the function of the α-synuclein CTPR6, experiments were 
carried out to investigate the ability of the CTPR6 to inhibit α-synuclein aggregation. This was 
carried out using a seeded aggregation assay as reported by Sormanni et al. for the sdAbs 
designed to bind α-synuclein (Figure 21).8 Here preformed fibrils are added to α-synuclein 
monomer to initiate aggregation and this is measured by observing ThT fluorescence, which 
increases and experiences a red shift upon binding to protein aggregates. If α-synuclein CTPR6 
is able to bind to α-synuclein this iwould be demonstrated by a reduction in the rate of 
aggregation. 
 
A seeded aggregation assay was used since it was hypothesised that the designed α-synuclein 
CTPR6 may preferentially bind to oligomers rather than monomers. This was hypothesised 
Figure 21: Seeded aggregation assay. Data points shown from assays with α-synuclein CTPR6 
(red), CTPR6 (black) and in the absence of CTPR (blue). The molar ratio of α-synuclein:CTPR 




since oligomeric α-synuclein may already have a β-sheet conformation, so will be in the correct 
conformation to bind the α-synuclein CTPR6 (and therefore have a low entropic cost of 
binding) and allow the grafted sequence to form an additional  β-strand.  
 
No reduction in the rate of aggregation was observed in the presence of α-synuclein CTPR6. 
These results suggest the α-synuclein CTPRs are unlikely to specifically bind the target epitope 
because, if they did, a significant rate of reduction in aggregation would be expected as binding 
would block the NAC region necessary to initiate aggregation. A reduction in aggregation 
should definitely be observed for a protein that binds to the α-synuclein monomer with such a 
low KD of 370 nM. For instance, Sormanni et al. saw a significant reduction in aggregation rate 
when a related complementary peptide grafted into a sdAb was used at as low a molar ratio as 
1:0.05 of α-synuclein: sdAb and here the binding affinity was only 18 μM.8  
 
3.1.2.4.1 Native gels 
 
Figure 22: 8-16 % TRIS-Glycine Native gels of α-synuclein CTPR6. A: Analysing the 
oligomeric state of α-synuclein CTPR6 B: Probing binding of α-synuclein to α-synuclein 
CTPR6. GelA has  α-synuclein CTPR6  from two different purifications loaded in lane 1 and 
lane 2.  
After observing multiple peaks in the gel filtration elution for α-synuclein CTPR6 and 
Thrombin CTPR, I wanted to investigate whether the final peak solely consisted of monomeric 
protein, or whether it was also prone to oligomerisation. Therefore, native gels were used to 




binding between α-synuclein and α-synuclein CTPR6 (Figure 22). If the two bind, the complex 
should be observed as a higher mass band on the gel.  
 
No complex was observed on the native gel. In addition, although α-synuclein CTPR6 ran at a 
higher molecular weight than expected, so did a consensus CTPR6, indicating it was likely that 
the protein was running as a monomer rather than in an oligomeric state. 
 
3.1.2.5 Analytical gel filtration  
 
The analytical gel filtration experiment was carried out with wild-type human α-synuclein and 
α-synuclein CTPR6 in order to further probe binding between the two proteins (Figure 23). A 
small shift to a smaller elution volume is visible in the trace of ‘α-synuclein CTPR6 + α-
synuclein’ compared to ‘α-synuclein CTPR6’. In addition the  ‘α-synuclein CTPR6 + α-
synuclein’ trace is greater than the sum of the ‘α-synuclein CTPR6’ and ‘α-synuclein’ traces. 
This may be due to α-synuclein  inducing α-synuclein CTPR6 to interact. The assay should be 
repeated to verify the result.   
 
Upon reflection this experimental set-up was not ideal, as α-synuclein has no tryptophan 
residues and so has a very weak absorption at 280 nm. Future experiments could be repeated at 
215 nm. 
 
Figure 23: Analytical gel filtration experiment to investigate the interaction between α-
synuclein (red) and α-synuclein CTPR6 (black), with the 1:1 molar ratio of α-synuclein + α-
synuclein CTPR6 shown in blue.  





















3.1.2.5.1 Bio-Layer Interferometry (BLI) 
Figure 24: Bio-layer interferometry uses a biosensor (blue) and can be used to bind a tagged-
protein (yellow) such as a His-tag and then used to measure binding of the tagged protein to the 
analyte (purple).  
Bio-layer interferometry (BLI) is a high-throughput and label-free technique that can be used 
to probe protein-protein interactions. It also has the advantage of requiring very little sample.185 
In BLI, the biosensor sits at the end of optical fibre and has a biomolecular bait immobilised on 
the tip, such as Ni-NTA (Figure 24). The immobilised ligand (e.g., a protein with a His-tag) 
then binds to this tip as seen in the loading step. The binding partner of the bait protein then 
binds to the immobilised ligand. Each binding event increases the thickness of the biosensor tip 
and increases the path length of the light and results in a wavelength shift proportional to 







Figure 25: Bio-layer interferometry experiments with α-synuclein CTPR6 and α-synuclein. A: 
Using Ni-NTA biosensors. The green and pink graphs are with 7 μM and 200 μM  α-synuclein, 
respectively.  B: Using PENTA-His biosensors. C: Using HIS2 biosensors.  
BLI experiments were carried out in order to further probe the binding of α-synuclein CTPR6 
with α-synuclein without the need for large quantities of sample. An anti-His tag biosensor was 
used to first bind the His-tagged CTPR to the biosensor, with α-synuclein then added as the 
potential binding partner. No binding of α-synuclein was detected with the Ni-NTA resin, so 
the assay was repeated with two different biosensors; PENTA-His and HIS2 (Figure 25). Again, 
no binding of α-synuclein was detected. It is possible that binding may be inhibited by the 
negatively charged biosensor repelling the negatively charged C-terminus of α-synuclein. It 
would have been good to verify this assay set-up with a His-tagged protein that is known to 
bind α-synuclein as a positive control. However, this was not readily available and so a new 




In order to overcome any potential electrostatic repulsion, the assay was turned around so that 
the α-synuclein was now bound to the biosensor as opposed to the CTPR. This was achieved 
by using a biotinylated antibody raised against ‘EPEA’, the last four residues at the C-terminus 
of α-synuclein, known as a CaptureSelectTM Biotin Anti-C-tag Conjugate and commercially 
available from Thermo Fischer Scientific. This antibody was bound to streptavidin biosensor, 
which in turn bound α-synuclein and then the potential binding partner, α-synuclein CTPR6. 
After optimisation of the loading time for the antibody, binding of α-synuclein CTPR6 was 
observed (Figure 26D).  
 
The assay was then repeated without the α-synuclein (Figure 26E), and subsequently in the 
absence of both the antibody and α-synuclein (Figure 26F). This was done as a negative control 
in order to probe whether there was non-specific binding of α-synuclein CTPR6 to the resin or 
antibody. The binding observed in Figure 26F shows that α-synuclein CTPR6 binds to the 
streptavidin biosensor. In order to try and counteract this non-specific binding, the assay was 
repeated in 1 x PBS, 1% BSA and 0.05% TWEEN as a non-specific binding buffer. A reduction 
in non-specific binding of α-synuclein CTPR6 was observed. However, when the assay was 
repeated in order to measure the strength of binding of α-synuclein to the biosensor alone in the 
Figure 26: BLI experiments with α-synuclein CTPR6 and α-synuclein using a streptavidin 
biosensor and the biotinylated anti-‘EPEA’ antibody. D: Initial assay E:  Assay conducted in 
the absence of α-synuclein F: Assay conducted in the absence of α-synuclein and the 





non-specific binding buffer, considerable binding was observed. In order to counteract this 
effect, the assay was repeated (Figure 26G). However, this time using super-streptavidin 
biosensors. These biosensors have a higher selectivity for biotin, so it was hoped they would 
lead to a reduction in non-specific binding. However, non-specific binding was nevertheless 
observed.  
In summary, these results suggest that Streptavidin biosensors are not an appropriate method 
for measuring α-synuclein and α-synuclein CTPR6 binding due to the stickiness of the proteins. 
The absence of α-synuclein binding when using His-tag sensors also suggest that the α-
synuclein CTPR6 does not bind α-synuclein. 
 
3.1.2.5.2 Isothermal Titration Calorimetry (ITC) 
  
Guilliams et al. published a related study in which ITC was used to characterise the binding of 
two nanobodies to α-synuclein, and so this assay was repeated here in order to determine 
whether there was any binding between the CTPR to α-synuclein.186  Even though Guilliams et 
al. recorded nanomolar equilibrium dissociation constants, they used a high concentration of 
150 μM of each of the nanobodies with 10 μM α-synuclein.  
 
Therefore the assay was carried out with 10 μM α-synuclein and the higher α-synuclein CTPR6 
concentration of 55 μM α-synuclein CTPR6 in order to better mimic the assay conditions but 
conserve protein (Figure 27). However, no binding was observed. The ITC could be repeated 








with higher concentrations of α-synuclein CTPR6, but these data in combination with the 
seeded aggregation data, native gel analysis, analytical gel filtration, and BLI data all indicate 
that α-synuclein CTPR6 does not bind α-synuclein. 
 
3.1.3 Using grafting of complementary peptides to rationally-
design a DARPin to target c-Myc 
3.1.3.1 c-Myc 
c-Myc is a transcription factor that plays an important role in regulating cell growth, death, 
differentiation and metabolism.57 c-Myc is overtly dysregulated in many human cancers.9, 58, 59 
This, and the fact that many tumour types have been shown to be c-Myc dependent, makes c-
Myc an attractive drug target.60-62 c-Myc has been described as ‘undruggable’, in part due to its 
status as an IDP, but it is also difficult to target specifically due to its high sequence similarity 
to other Myc network proteins.  
 
3.1.3.2 c-Myc Structure 
c-Myc is composed of an N-terminal transactivation domain and a C-terminal basic helix-loop-
helix leucine zipper (bHLH-LZ) domain (Figure 28).58 Monomeric c-Myc is unstructured and 
is only active once bound to Myc-associated factor X (Max), forming a coiled-coil structure. 
Heterodimerisation initiates binding of residues in the basic region of both c-Myc and Max with 
the E-box sequence (5’- CACGTG-3’) in DNA.9  
 
Figure 28: The structure of c-Myc. A: A schematic showing the different regions of c-Myc B: 






3.1.3.3 Designed Anrkyrin Repeat Proteins (DARPins) 
DARPins were first developed using the consensus design of natural ankyrin repeat proteins.187 
These proteins consist of a β-turn, followed by two anti-parallel helices, followed by a loop 
region. They have been shown to express well and are an extremely stable scaffold. DARPins 
have been used for various purposes such as crystallisation chaperones, protein conformation 
sensors and as biotherapeutics.142 
 
DARPins have major potential as biotherapeutics due to their high stabilities, making them 
well-suited to protein engineering projects. DARPins, however, were initially limited in this 
application by their concave and rigid structure. Therefore Schilling et al. designed 
LoopDARPins to overcome these limitations, in which the central loop of the DARPin was 
extended by 19 residues without detriment to the stability of the scaffold.123 Ribosome display 
was then used to induce binding to extracellular signal-related kinase 2 (ERK2) and members 
of the BCL-2 family with nanomolar to picomolar affinity. In addition, Zahnd et al. evolved a 
DARPin with picomolar affinity against human epidermal growth factor receptor 2 (Her2) using 
ribosomal display.154 
 
3.1.3.4 Design of c-Myc DARPin 
Here we looked to engineer a DARPin that could bind c-Myc using two grafted complementary 
peptides rather than one. Sormanni et al. previously explored whether it was possible to graft 
an additional complementary peptide into the complementarity determining region (CDR) 2 in 
addition to the grafted peptide in the CDR3 of the sdAb protein to create a protein with a higher 
affinity for a-synuclein, which bound either side of the target a-synuclein forming a b-sheet. 
Figure 29: Loop 3 and loop 4 of the c-Myc DARPin form an antiparallel β-sheet with the 
c-Myc epitope. The blue lines represent backbone-backbone hydrogen bonds. The 




This protein was found to have a higher affinity for the target protein of 5 µM, but had very low 
stability and was found to precipitate at pH 6. 
 
The geometry of the protein loops of DARPins is such that, like sdAbs , binding either side of 
the epitope is possible. However, unlike the sdAbs, DARPins have a very high protein stability 
and have previously been shown to tolerate loop extension without detriment to their 
stability.123 Therefore, we predicted that the DARPins may be tolerant of peptide grafting, 
especially as we only planned to extend the loop by two residues compared to the consensus 
sequence. However, this was the first case where two peptides were being extended at once and 
it was difficult to predict whether this would be as well tolerated. 
 
Two complementary peptides to c-Myc were grafted onto the middle two inter-repeat loops 
(loop 3 and loop 4) of a seven repeat DARPin (Figure 29). The DARPins used in this study are 
derived from the consensus sequence designed by Mittl et al. 139 The complementary peptides 
target the KVVILKKAT (residues 392-401) c-Myc epitope and were designed in collaboration 
with Pietro Sormanni. This particular epitope was chosen because it is predicted to be 
completely disordered using S2D software and it also results in DARPins with low aggregation 
propensity using Zyggregator.188, 189 The flanking GADVNA sequence residues preceding the 
complementary peptide and the DGYT sequence following it were retained from the consensus 






When considering the experimental design I would use to probe binding of c-Myc DARPin to 
c-Myc,  I noted that c-Myc protein is known to be notoriously difficult to purify despite the 
published method by Metallo et al.190 Therefore, I decided not to use assays requiring purified 
c-Myc protein. Instead, binding was probed by using HeLa cell lysate as a source of c-Myc for 
immunoprecipitation experiments. 
 
3.1.3.5.1 Investigating the propensity of c-Myc DARPin to form oligomers 
In order to investigate the propensity of c-Myc DARPin to form oligomers, the protein was run 
on a native gel (Figure 30). Significant protein oligomerisation was observed.  
CamSol predictions carried by Pietro Sormanni suggested that mutating the tryptophan to 
glutamic acid in the second grafted peptide in the fourth loop of the seven-repeat DARPin 
(Figure 29) would increase the solubility, and hence prevent oligomerisation of the DARPin.191 
This would work by increasing repulsion between the loops. The resultant protein is referred to 
as c-Myc DARPin W156E. The mutation was introduced using Overlap Extension PCR and 
then expressed in chemically competent E.coli C41(DE3) cells and purified using a batch Ni-
affinity step and gel filtration chromatography (See Methods). The initial purification gave low 
yields, but when repeated from a 1L culture (rather than a 6L) greater protein purity and yield 
Figure 30: 8-16 % TRIS-Glycine native gel of c-Myc DARPin and c-Myc DARPin W156E. 
The DARPins have a molecular weight of 27 KDa so the lowest band most likely represents the 
protein in a monomeric state, with the band of the second lowest molecular weight most likely 




was achieved. Potential oligomerisation of the protein was observed by gel filtration 
chromatography (Figure 31). 
3.1.3.5.2 Optimisation of c-Myc DARPin W156E purification 
 
Figure 31: Gel filtration elution profile for the purification of c-Myc DARPin W156E using a 
HiLoad 26/60 Superdex 75pg G75 column in 50 mM Tris-HCl, 150 mM NaCl pH 8.5 
c-Myc DARPin W156E and c-Myc DARPin were run on a native gel in order to probe whether 
the point mutation has reduced the propensity of the protein to form oligomers (Figure 30). This 
showed the c-Myc DARPin W156E to undergo significantly less oligomerisation compared to 
c-Myc DARPin, and instead consisted predominantly of dimer molecules.  
3.1.3.5.3 Immunoprecipitation experiments with HeLa lysate 
 
Figure 32: Immunoprecipitation assay where His-tagged c-Myc DARPin constructs were bound 
to Ni-NTA and HeLa lysate as a c-Myc source. Samples were run on a 12% gel prior to western 
blotting.   



















Despite the protein oligomerisation of c-Myc DARPin, it may still be able to bind c-Myc. In 
order to test this, binding of both DARPins to c-Myc was investigated using an 
immunoprecipitation assay with HeLa cells as a source of c-Myc (Figure 32). The pull-down 
was carried out in two types of buffer: RIPA and TBS. In TBS, the c-Myc-Max interaction is 
maintained, whereas in RIPA it is destroyed (Dr Trevor Littlewood, personal communication). 
By using the two buffers, we are able to observe whether the DARPin can bind c-Myc both in 
the presence and absence of Max. 
 
The results revealed that in TBS, c-Myc was binding the resin in both the presence and absence 
of c-Myc DARPin. In RIPA buffer the control DARPin (a 6-repeat DARPin with no grafted 
binding peptides) was shown to bind c-Myc more tightly than either of the designed DARPins. 
This suggests that c-Myc DARPin may not bind c-Myc but additional experiments should be 
carried out in order to probe this further. The assay shows that Ni-NTA resin should not be used 
for c-Myc immunoprecipitation assays and future immunoprecipitation assays could be carried 
out by using a different tag, e.g., HA tag.  CD should be used to determine whether the protein 
is correctly folded and used to guide future protein design.  
 
3.1.3.6 Discussion 
In work described in this chapter aimed to graft computationally designed peptides to target α-
synuclein and c-Myc into CTPR and DARPin scaffolds respectively. The CTPRs with peptides 
grafted into the inter-repeat loop were shown to be fully folded and have high thermal stabilities. 
Gel filtration purification resulted in a spectrum with many peaks due to protein 
oligomerisation, but the isolated monomer was shown to not be prone to oligomerisation using 
native gel analysis.  
 
The interaction between α-synuclein and α-synuclein CTPR6 was probed using native gel 
analysis, analytical gel filtration, Bio-layer interferometry, Isothermal Titration Calorimetry 
and indirectly through an α-synuclein seeded aggregation assay. No binding was observed via 
BLI, ITC and native gel analysis. No effect was seen in the seeded aggregation assay, 
suggesting that the CTPR is not specifically binding to α-synuclein. I hypothesise that we 
ultimately do not see binding of the α-synuclein CTPR6 to α-synuclein because the isolated 
grafted complementary peptide is unable to bind α-synuclein. This is because the peptide has 
only been reported to have a weak affinity for α-synuclein (18 μM) when grafted into a sdAbs, 




are that the geometry of the CTPR inter-repeat loop is not favourable for the grafting of a 
peptide that needs to adopt an extended conformation in order to bind its target. This is because 
the CTPR loop is a tight turn where the α-carbons of D31 and N34 residues separated by only 
6.1 Å, meaning the grafted peptide is unable to adopt an extended conformation. In sdAbs, the 
CDR3 loops are much more extended and so it is much more able to adopt a linear geometry 
and for the sdAb this issue does not arise. The low affinity of the complementary peptide for 
the target (18 μM when grafted into the sdAb) also exacerbates the effect because this along 
with the unfavourable conformation will leave the complementary peptide with a very low 
affinity for α-synuclein.108 If instead future work focused on grafting known binding peptides 
with known high affinity for their targets along with peptides which had geometries that were 
more suited towards to the CTPR loop then binding to the target may be observed (Chapter 4 
and 5).   
 
Although Pietro Sormanni felt that DARPins and not CTPRs have the propensity to bind a 
target with more than one grafted binding peptide due to structural constraints, I  hypothesise 
that the structure of CTPRs does also allow for the grafting of more than one functional peptide. 
This is because although inter-repeat loops are offset by 45°, these can be designed to bind the 
target at different epitopes such as in Figure 33. This idea also demonstrates the potential of 
CTPRs to be able to bind multiple partners through grafting of multiple functional peptides.  
 
 
Figure 33: Potential grafting strategy for grafting multiple binding peptides into a CTPR for a 
particular protein target e.g. α-synuclein (Purple) with the CTPR scaffold shown in Blue and 




It is possible that domain swapping was observed in the α-synuclein CTPRs causing protein 
oligomerisation. Future work could focus on understanding the concentration dependance of 
this oligomerisation. Future work could focus on reducing the propensity of the CTPR with 
loop grafted peptides to undergo domain swapping. This could be achieved by reducing the 
effect of the grafted peptide on destabilising the inter-repeat loop.184 For example, by choosing 
to graft peptides into the inter-repeat loop that have a similar bioactive conformation to that of 
the inter-repeat loop, it may be possible to minimise the destabilising effect of peptide grafting 
(See Chapter 4 and 5).   
 
My investigations with c-Myc DARPin and c-Myc DARPin W156E did not establish whether 
these DARPins were able to bind c-Myc. Future work could focus on recloning these DARPins 
with a HA-tag so that the pull-down assay shown in Figure 32 could be repeated with anti-HA 
agarose, which will hopefully mean c-Myc will no longer non-specifically bind to the beads. 
However, this study does demonstrate how a point mutation can drastically reduce the 
propensity of a protein to undergo oligomerisation. This can be seen in the native gel 
comparisons of c-Myc DARPin and c-Myc DARPin W156E. This method could therefore be 
used in my future protein designs to help reduce oligomerisation.   
 
An extra point for consideration was that Pietro Sormanni chose the target epitope based on 
solubility consideration with regards to both the epitope and complementary peptides.191 
However, this did not take into consideration the region of c-Myc that might be best to target 
from a biological perspective. The MAX network of proteins have a high sequence similarity 
but can have very different functions so it is important that we are able to specifically target c-
Myc. Therefore, an alignment of c-Myc with Max and other related proteins, demonstrated that 
of the nine residue epitope that c-Myc DARPin and c-Myc DARPin W156E are designed to 
target, five residues were conserved in Max (Figure 34).  
 
If future pull-down assays reveal the DARPins to bind both c-Myc and Max we may need to 
choose a new epitope in c-Myc that is less conserved in Max. The DARPin is also designed to 






Figure 34: Alignment of a selection of  Myc network proteins in Clustal Omega software. The 

























4 Exploring the grafting of Keap1-binding peptides into 
the inter-repeat loops of CTPRs 
4.1.1 Introduction  
In Chapter 3, the project sought to graft a designed peptide of unknown affinity for its target 
even though this was the first known attempt to graft a functional peptide into the inter-repeat 
loop of the CTPR. The work described in this Chapter seeks to take a step back by focusing on 
the grafting of a known functional peptides of high affinity for its target.   
 
In this chapter there was also evidence for domain swapping in α-synuclein CTPRs. Therefore, 
in this chapter functional peptides that better matched the conformation of the CTPR loop were 
used so as to not destabilise the CTPR inter-repeat interface and therefore potentially reduce 
the propensity of the CTPR to form oligomers. Crystal structures suggest that Nrf2 peptides 
have a β-turn structure which is structurally similar to the inter-repeat CTPR loop.23, 132 
Therefore, in this chapter we propose that grafting Nrf2 and other Keap1-binding peptides into 
the loop of the CTPRs.  
 
In Chapter 3, it was hypothesised that CTPRs could be designed with two grafted functional 
peptides to bind a specific target. Further work hypothesised that CTPRs could also be designed 
to be bifunctional, i.e. have two grafted peptides with each designed to bind a different target. 
Furthermore, it was suggested that this potential bifunctional capacity could be manipulated to 
turn CTPRs into PROTACs. It was hoped that the work described in this chapter could be later 
used to aid the design of a PROTAC CTPR that binds to both Keap1 and a target protein, 
targeting this protein for ubiquitination and subsequent degradation via the 26S proteasome. 
 
In this Chapter, we explore the effect of grafting Keap1-binding peptides of differing amino 
acid compositions and lengths on the stability of the CTPR and its affinity for Keap1. Work 
started with a Keap1-targeting Arginine Tetratricopeptide Repeat protein (Keap1 RTPR) to 
investigate whether the lysines could be mutated to arginine residues to make the protein 
resistant to protein degradation as whether the protein is able to bind Keap1. Work then moved 
to the design on the first generation Keap1-targeting consensus-designed Tetratricopeptide 
Repeat proteins (Keap1 CTPRs), which explore the effect of the removal of the arginine 
mutation on protein stability and solubility as well as the effect of the introduction of 




the second generation Keap1 CTPRs, which explores the effect of grafting different Keap1-
binding peptides into the inter-repeat loop of the CTPR on the protein stability and binding 
affinity for Keap1. This chapter also investigates the relationship between the binding affinity 
of the free peptides compared to the binding affinity of the grafted peptides for Keap1. Keap1 
RTPR2 was designed and cloned by Albert Perez-Riba.  
 
4.1.2 An Arginine mutant consensus-designed TetratricoPeptide 
Repeat proteins (RTPR) to target Keap1 
4.1.2.1 Protein design  
In order to determine the amenability of the CTPRs for use as PROTACs, it was important to 
demonstrate not only that they could be designed to bind a specific target through peptide 
grafting into the inter-repeat loop, but also that these designs can be made resistant to 
ubiquitination by the E3 ubiquitin ligase complex and potential subsequent degradation by the 
26S proteasome. In order to achieve this, it was essential to mutate out all lysines as these are 
potential sites of ubiquitination. The three lysines in the CTPR repeat were replaced with 
arginines due to them both having a +1 charge at physiologiocal pH. This was not expected to 
disrupt the structure as the lysines are solvent-exposed. These new CTPRs with the lysines 
replaced with arginines are referred to as Arginine mutant consensus-designed 
TetratricoPeptide Repeat proteins (RTPRs) in the text. Removing the lysines may also have 
extra importance in the case of CTPRs to solely target Keap1, because the grafted Nrf2 or other 
Keap1-binding peptides CTPR is designed to bind Keap1 near a ubiquitination site of the 
Keap1-Cul3 ligase, increasing the likelihood of ubiquitination and perhaps subsequent 
degradation of the CTPR.  
 
The lysines were replaced in the CTPR construct reported by Grove et al.136 This CTPR 
construct was used because of its high stability and solubility despite the absence of a capping 
repeat.137, 182 A two-repeat CTPR (CTPR2) was chosen rather than a larger CTPR with more 
repeats because the small size of this protein of around 11.5 KDa is similar to the molecular 
weight of a single-domain antibody (12-15 KDa) and may make it more amenable for use as a 
biotherapeutic. For example, its smaller size may facilitate its cell-penetrating capabilities. 
Work by Perez-Riba et al. also suggests that the effect of loop extension on CTPR stability is 
proportionally smaller for CTPR2 proteins than for larger arrays.182 The CTPR2 construct 
developed by Grove et al. and without a grafted peptide, was used as a negative control for the 




   
Table 7: TPRs designed to target Keap1 described in this Chapter. Green residues represent the 
grafted peptide, black are consensus residues and blue residues indicate additional mutations to 
flanking region.  
Group name TPR Loop Sequence Peptide insertion Description 
Keap1 RTPR 
1st  generation Keap1 CTPRs 
 

























Initially a Nrf2 peptide was grafted into the RTPR to create the Keap1 RTPR2 construct (Table 
7). The peptide was chosen because in isolation it is known to have high affinity (355 nM) for 
Keap1.101, 102 In this Chapter, the sequences flanking the grafted Keap1-binding peptide, 
referred to as the flanking region, were mutated from the consensus sequence 
DPNNXXXXXXXXXDPNN (DPNS consensus) to DPNNXXXXXXXXXDPNS (DPNS 
mutant), where X represents a residue in a grafted Keap1-binding peptide (peptides of different 
lengths were also tested). This mutation was made by Albert Perez-Riba because he 
hypothesised that this may improve the loop solubility based on his simulations carried out in 
CIDER software.193  
 
As the effect of a Keap1-binding peptide insertion on protein stability and solubility was not 
known, the number of repeats may have been required  to be increased in order to improve the 
protein stability through cooperativity.182 Therefore, all TPR constructs described in this 
chapter end in RS versus at the C-terminus rather than the the NN found in the consensus 
sequence. This design was used because the RS design has been shown to not significantly 
affect protein stability as well as providing a BglII restriction site which could allow for the 







4.1.2.2.1 Expression and Purification  
Purification of Keap1 RTPR2 was first attempted using a large scale purification. However, no 
protein was detected on the gel after the Ni-NTA batch purification step, potentially suggesting 
the protein had low solubility. Small-scale bugbuster purification as described by Perez-Riba 
was then used as this had been shown to work well for other proteins with low solubilty.194 
Proteins were eluted into 50 mM Tris-HCl 150 mM NaCl pH 8.5 because this buffer had a pH 
which was at least 2 units from the pI of all proteins described in this study. This protocol was 
used to express Keap1 RTPR2, with expression levels being probed in the following  chemically 
competent E.coli strains: C41(DE3), MDS42 and Lemo21(DE3). The E.coli Lemo21(DE3) 
cells showed the highest expression levels (Figure 35).   
 
CTPRs generally do not run at the expected molecular weight on SDS-PAGE gels (Albert 
Perez-Riba, Personal Communication). The monomeric Keap1 RTPR2, which was later 
verified using mass spectrometry, is circled in Red. Keap1 RTPR2  showed significant levels 
of protein expression in the insoluble fraction, suggesting these proteins may have poor 
solubility. A band at around 15 KDa was observed in many of the fractions, which is circled in 
Blue in Figure 35. This band may be a dimer of Keap1 RTPR2. This potential dimer is observed 
in large amounts when expressing in E.coli C41(DE3) and in E.coli MDS42 but in much smaller 
amount is observed when expressing in  E.coli Lemo21(DE3) cells.   
 
Figure 35: Optimisation of the purification of Keap1 RTPR2 shown on 4-20% gel A  and gel 
B. U,B,I,W1,W2 and E indicate Unbound fraction, Ni-NTA beads after elution, Insoluble 
fraction, Ni-NTA bead wash 1, Ni-NTA bead wash 2 and Elution respectively. L, C and M 
indicate expression in E coli Lemo21(DE3), C41(DE3) and MDS42 cells respectively. Keap1 




4.1.2.2.2 Circular Dichroism  
 
Figure 36: CD data of Keap1 TPRs. i) CD Spectrum to determine protein folding. ii) thermal 
denaturation monitored by CD at 222 nM. A: Keap1 RTPR2 both before (red) and after (blue) 
thermal denaturation; and CTPR2n (black)  B: Keap1 CTPR2-1-1 (red), Keap1 CTPR2-1-
Control (blue) and CTPR2n (black) and C: Keap1 CTPR2-2-1 (red), Keap1 CTPR2-2-2 












Table 8: Keap1 CTPRs designed to target Keap1 described in this Chapter. Green residues 
represent the grafted peptide, black are consensus residues and blue residues indicate additional 
mutations to the flanking region. Melting temperatures are given for each construct. These were 
determined using thermal folding monitored by CD. 5 data points were taken at each 







The structure and thermal stability of the proteins were probed using CD (Figure 36A, Table 
8). Keap1 RTPR2 was found to have a high degree of α-helicity, to refold after thermal 
denaturation and to have a high melting temperature. 
 
4.1.2.2.3 Bio-layer interferometry (BLI) 
 
A bio-layer interferometry screening assay was developed as a method to quickly probe whether 
the Keap1 RTPR was able to bind Keap1 and to give an estimate of their binding affinity to 
Keap1. The method was similar to that described in Chapter 3, with the Keap1 RTPR2 bound 
Group name for Keap1 TPRs TPR Loop Sequence Tm ± SE (°C) 
Keap1 RTPR 
1st  generation Keap1 CTPRs 
 


















73.8 ± 1.7 
~61.4 
67.2 ± 0.7 
75.2 ± 1.1 
73.0 ± 1.0 
72.7 ± 1.9 
>80 
Figure 37: Bio-layer interferometry experiments of Keap1 with the Keap1 RTPR2 and  1st 
generation Keap1 CTPRs. Probing the binding of Keap1 to A: Keap1 RTPR2, B: Keap1 




to the Ni-NTA biosensor via its His-tag and then the binding to Keap1 monitored. In order to 
prevent binding of the His-tag from the Keap1 construct binding to the biosensor, the His-tag 
was cleaved via the TEV cleavage site.  
 
The results suggest that Keap1 RTPR2 binds Keap1 with no binding of Keap1 observed in the 
absence of Keap1 RTPR2 protein (Figure 37A and Figure 37E). Future work should focus on 
optimising this BLI screening assay since there is some variation in the loading of the TPR and 
the first baseline does not reach equilibrium in all experiments.  
 
4.1.2.2.4 Fluorescence Polarisation  
The work described in this chapter uses a Fluorescence Polarisation competition assay to probe 
the binding between the CTPRs and their target. The technique works by exciting the 
fluorescent ligand with polarised light (Figure 38).195 An unbound fluorescent ligand tumbles 
rapidly in solution, causing the emission of depolarised light. However, when fluorescent 
ligands bind to larger molecules, their effective volume increases causing them to tumble more 
slowly and allowing emission of polarised light. This therefore allows ligand binding to its 
target to be detected.   
 
Figure 38: The effect of fluorescent ligand binding on Fluorescence Polarisation. A: An 
unbound fluorescent ligand tumbles rapidly in solution leading to the emission of depolarised 










Figure 39: A: FP binding assay of Keap1 with FITC- β-Ala-DEETGEF-OH in PBS (black) 
and 50 mM Tris-HCl 150 mM NaCl pH 8.5 (red) and Fluorescence Polarisation competition 
assay with B: Ac-DEETGEF-OH, C:CTPR2n, D: Keap1 RTPR2, E: Keap1 CTPR2-2-1, F: 













A FP competition assay was developed by Hancock et al. to measure the binding affinities of 
various peptides to Keap1.102 This assay was used to probe the binding of Keap1 TPRs (Keap1 
RTPRs, 1st generation Keap1 CTPRs and 2nd generation Keap1 CTPRs) to Keap1. First, the 
binding assay of Keap1 to the fluorescent ligand, FITC- β-Ala-DEETGEF-OH, was repeated 
as reported in the literature. The only exception was that  OptiPlate 384-well black opaque 
microplates were used for all fluorescence polarisation plates instead of Corning 96-well Black 
plates. These plates were chosen because they have a smaller well volume so required smaller 
amount of TPR to carry out the assay. The assay gave a very similar KD to that reported in the 
literature (119 ± 3.3 nM vs. 95.7 ± 2.9 nM reported by Hancock et al, Figure 39A). Therefore, 
the assay was repeated, but this time the buffer was changed from PBS to 50 mM Tris-HCl 150 
mM NaCl pH 8.5. This was done because the pH of the Tris buffer was at least 2 units away 
from the pI of all TPRs used in this study, so would help promote good protein stability. A KD 
of 183 ± 29 nM was measured and this value was used to work out the Ki of Keap1 RTPR2 
using a fluorescence competition assay. The assay revealed that Keap1 RTPR2 had a Ki of 860 
± 260 nM for Keap1 (Figure 39D, Table 9). The assay was also validated by measuring the Ki 
of Ac-DEETGEF-OH which was similar the value reported in the literature and converted from 
IC50 to Ki using the method developed by Cer et al. (2.73 ± 0.5 versus 5.24 ± 0.5 μM reported 
by Hancock et al., Figure 39B, Table 9).196 The assay was also repeated with CTPR2n (Figure 
39C, Table 9). No binding was detected, but the Fluorescence Polarisation was found to 
increase linearly with increasing protein concentration. This result may instead be due to the 
non-specific binding of the tracer to CTPR2n. In order to investigate this further, the assay 
could be repeated in the absence of Keap1 to see whether a similar trend was observed.  
 
4.1.3 First generation CTPRs to target Keap1 
Following the studies with Keap1 RTPR2, further work instead focused on Keap1 CTPRs (1st 
generation Keap1 CTPRs and 2nd generation Keap1 CTPRs). This was because although Keap1 







860 ± 260 
544 ± 83 
261 ± 49 
90.4 ± 26 





RTPR2 had been shown to bind Keap1 and have good thermal stability, it had relatively low 
solubility as a considerable amount of the protein expressed in the insoluble fraction. This 
meant that Keap1 RTPR2 was difficult to purify in high yields. It was hoped that Keap1 CTPRs 
would have higher solubilities.  
 
When reverting back to the consensus sequence of the CTPR, consideration was given to what 
consequences this may have for the protein. Studies suggest that the rate of degradation by the  
proteasome is dependent on a range of factors, such as the ubiquitin chain length and shape, the 
presence of a disordered region and the sequence of the initiation sequence.197 Due to these 
many factors, the differences in the degradation of RTPRs vs. CTPRs by the 26S proteasome 
may be negligible. The main concern would instead be the effect of potential ubiquitination on 
CTPR structure, which may affect protein structure and cause steric clashing between Keap1 
and the ubiquitinated CTPR. However, as no crystal structure of the Keap1 Cullin-RING E3 
ubiquitin ligase complex, it difficult to gauge the exact proximity of the Keap1-Nrf2 binding 
site to the ubiquitination site. Furthermore, the work described in this Chapter is looking to 
understand the effect of the grafting of binding peptides on CTPR stability, binding affinity and 
solubility and is not looking to probe the activity of the CTPRs in vivo. Therefore, it makes 
sense to use a CTPR scaffold instead of RTPR scaffold if they are shown to have much higher 
solubilities, express in higher yields and are therefore easier to work with.  
 
4.1.3.1 Protein design  
The design of the first Keap1 CTPR construct, referred to as Keap1 CTPR2-1-1 sought to 
investigate some new approaches to protein design (Table 7). The binding peptide of Keap1 
RTPR2 was replaced with ‘DEETGEF’ since it was hypothesised that the flanking leucines of  
the Nrf2 peptide may not be well-tolerated due to their hydrophobicity.  
 
Another design  feature was explored where the flanking residues were 
DPGGXXXXXXXGGPN, where X represents a grafted Keap1-binding peptide. It was hoped 
that maintaining both prolines would help to act a break in the alpha-helix structure, and help 
to maintain the CTPR structure as the P32 residue has been shown to form a backbone hydrogen 
bond to W4 of the next repeat.134 The glycines were used because the prolines are a strong 
structural statement and may act to constrain the Nrf2 peptide in an unfavourable conformation 




stems of the extended protein loop, but the grafted peptide of Keap1 CTPR2-1-1 was scrambled 
to form Keap1 CTPR2-1-Control (Table 7).  
 
4.1.3.2 Results 
4.1.3.2.1 Expression and Purification  
 
Figure 40: Purification of Keap1 CTPR2-1-1 Truncated (K) and Keap1 CTPR2-1-Control (C) 
and shown on A: gel 1 and B: gel 2. I,W1,W2 and E indicate Insoluble fraction, Bead wash 1, 
Bead wash 2 and Elution respectively. L indicates expression in E.coli. Lemo21(DE3) cells. 
The proteins were again expressed in E.coli  Lemo21(DE3) cells and purified using the small-
scale bugbuster protocol used for Keap1 RTPR2. Although the constructs have different grafted 
peptides and flanking residues so are not immediately comparable, the Keap1 CTPRs did show 
much higher levels of expression and proportion of the protein in the soluble fraction compared 
to Keap1 RTPR2 (Figure 40).  
 
4.1.3.2.2 Circular Dichroism  
The structure and thermal stability of the 1st generation Keap1 CTPRs were probed using CD 
(Figure 36B i) and ii)). The assay was carried out in 50 mM Tris-HCl 150 mM NaCl  pH 8.5 
rather than 10 mM Sodium Phosphate 150 mM NaCl pH 7.4 buffer used for the CD experiments 
for Keap1 RTPR2. This was because although sodium phosphate buffer is thought to be a good 
buffer for CD experiments due to its low absorption at the wavelengths of light used in the 
experiment, the experiment to probe binding described in this study are carried out in 50 mM 
Tris-HCl 150 mM NaCl  pH 8.5 so it makes sense to investigate the protein structure and 
thermal stability under these conditions.  
 
Both 1st generation Keap1 CTPRs were found to have a high degree of α-helicity, to refold after 




was lower than that observed for the CTPR2n construct, suggesting that peptide grafting and/or 
changing the flanking regions can both affect protein structure and the thermal stability of the 
CTPR. However, the very high stability of CTPR2n meant that despite the presence of this 
stability loss, the resultant 1st generation CTPRs still had good thermal stabilities.  Interestingly, 
the melting temperatures of these 1st generation Keap1 CTPRs was lower than that observed 
for Keap1 RTPR2. This may be due to the mutation of the flanking residues, which are known 
to be important for stability.183  
 
It is interesting that both Keap1 CTPR2-1-1 and Keap1 CTPR2-1-Control have similar 
structures and Keap1 CTPR2-1-Control has a slightly higher thermal stability than Keap1 
CTPR2-1-1. This is because although the peptides have the same amino acid composition, the 
scrambled peptide is unlikely to have a β-turn conformation. This suggests that the grafting of 
a peptide with a β-turn conformation is not necessary to ensure high degrees of protein α-
helicity and high thermal stabilities.   
 
4.1.3.2.3 Bio-Layer Interferometry (BLI) 
The BLI screening assay developed for the Keap1 RTPR2 was repeated to investigate whether  
Keap1 CTPR2-1-1 and Keap1 CTPR2-1-Control were able to bind Keap1. Binding of Keap1 
CTPR2-1-1 to Keap1 was observed but no binding of Keap1 CTPR2-1-Control was detected 
(Figure 37B and 37C).  This finding suggests that binding of the Keap1 CTPR2-1-1 to Keap1 
is specific. 
 
The BLI screening also gave an estimate of the binding affinities for Keap1 with a KD of 2.25 
μM obtained for Keap1 RTPR2 and 8.50 μM for Keap1 CTPR2-1-1. This may suggest that the 
binding affinities of the Keap1 TPRs for Keap1 may correlate with the affinities of the free 
peptide. However, the difference in binding affinities may be, at least in part, due to the different 
flanking sequences.    
 
4.1.4 Second generation CTPRs to target Keap1 
4.1.4.1 Protein design  
The previous studies with Keap1 TPRs have varied too many factors at once: (i) the effect of 
mutating lysines to arginines, (ii) the effect of changing the flanking residues for polyglycine 
groups and (iii) using grafted peptides of different lengths. However, these studies have 




CTPRs, that the polyglycine design reduces the protein thermal stability and that the  binding 
affinity of the Keap1 CTPR may correlate with the binding affinity of the grafted peptide.  
 
In order to reduce the number of variables and taking these factors into account, three 2nd 
generation Keap1 CTPRs were designed to probe the effect of grafting peptides of different 
sequences and lengths on the stability and binding affinities for Keap1: Keap1 CTPR2-2-1, 
Keap1 CTPR2-2-2 and Keap1 CTPR2-2-3 (Table 7). The grafted peptides in these CTPRs are 
a 9mer Nrf2 peptide (LDEETGEFL), a Phage peptide (DPETGEL) and a modified phage 
peptide (LGETGELL). The Nrf2 and Phage peptide also have different binding affinities, so it 
will be interesting to observe the correlation between the binding affinities of these peptides 
and the binding affinities of the 2nd generation Keap1 CTPRs for Keap1.102 The modified phage 
peptide is unique to this thesis, and was inspired by the sequences of the Nrf2 peptide and the 
phage peptide. The Keap1 CTPR2-2-3 construct with the grafted modified phage peptide was 
also designed because in the Nrf2 peptide (LDEETGEFL), the flanking leucines  are important 
for the intramolecular structure of the Nrf2 peptide and induce an improvement in the binding 
affinity of the peptide. Therefore, the addition of these flanking leucine residues may also be 
able to improve the peptide affinity in the case of the Phage-derived peptide.102 For all designs, 
the flanking regions were kept constant  and the poylglycine design was not used. 
 
4.1.4.2 Results          
4.1.4.2.1 Expression and Purification 
 
Figure 41: A: the purification of Keap1 RTPR2 and B: the purification of Keap1 CTPR2-2-1. 
UL,BL,IL,W1L,W2L and EL indicate Unbound fraction, Beads after elution, Insoluble fraction, 
Bead wash 1, Bead wash 2 and Elution respectively. L indicates expression in  E.coli 





The proteins were expressed in E.coli Lemo21(DE3) cells and purified using the small-scale 
bugbuster protocol as previously described.  The Keap1 RTPR2 and Keap1 CTPR2-2-1 
constructs only differ in that the lysines present in Keap1 CTPR2-2-1 are mutated to arginines 
in Keap1 RTPR2. Despite the weaker staining of gel B compared to gel A, the gels in Figure 
41 show that Keap1 CTPR2-2-1 expresses exclusively in the soluble fraction, whereas Keap1 
RTPR2 expresses in both. This demonstrates the higher solubility of  Keap1 CTPR2-2-1 
compared to Keap1 RTPR2 and suggests that  Keap1 RTPRs may be less soluble than Keap1 
CTPRs.  
 
4.1.4.2.2 Circular Dichroism Spectroscopy 
The structure and thermal stability of the 2nd generation Keap1 CTPRs were probed using CD 
(Figure 36C i) and ii)). The 2nd generation Keap1 CTPRs were found to have a high degree of 
α-helicity, to refold after thermal denaturation and to have a high melting temperature (Table 
8). The 2nd generation Keap1 CTPRs also had a significantly lower melting temperature than 
CTPR2n, but had a higher melting temperature than Keap1 CTPR2-1-1 and Keap1 CTPR2-1-
Control, suggesting that conservation of the flanking residues is important in conserving the 
thermal stability of the TPR.  
 
The CD spectra for Keap1 CTPR2-2-1 and Keap1 RTPR2 were carried out in 50 mM Tris-HCl 
150 mM NaCl  pH 8.5 buffer and 10 mM Sodium Phosphate 150 mM NaCl pH 7.4 buffer 
respectively. Therefore, the results are not comparable.  
 
4.1.4.2.3 Fluorescence Polarisation  
The binding affinity of Keap1 CTPR2-2-1, Keap1 CTPR2-2-2 and Keap1 CTPR2-2-3 to Keap1 
was probed using the fluorescence polarisation competition assay described for Keap1 RTPR2 
(Figure 39, Table 9). The binding affinity of Keap1 CTPR2-2-3 was very tight at 90.4 nM. 
Keap1 RTPR2 and Keap1 CTPR2-2-1 had Ki values that were within error of each other, 





4.1.4.2.4 Isothermal Titration Calorimetry 
Table 10: ITC data for the binding of Keap1 to the 2nd generation Keap1 CTPRs and free Keap1-
binding peptides. *indicates data reported in literature measured using surface plasmon 




Free Peptide Peptide grafted into CTPR 
KD ± SE 
(nM) 




KD ± SE 
( nM) 




LDEETGEFL 355* - - 763 ± 270 
 
-11.6 ± 0.6 -10.9 
DPETGEL 341 ± 45 -11.4 ± 0.2 -8.56 143 ±11 -12.5 ± 0.2 -10.6 
       
LDPETGELL 4.65 ± 3.8 -13.5 ± 0.2 -7.27 22.0 ± 4.4 
 
-11.3 ± 0.1 -2.86 
Figure 42: ITC experiments to determine the binding of the 2nd generation Keap1 CTPRs for 
Keap1 to A: Keap1 CTPR2-2-1, B: Keap1 CTPR2-2-2, C: Keap1 CTPR2-2-3, D: CTPR2n, E: 
Ac-DPETGEL-NH2 (Phage) and F: A-L DPETGELL-NH2 (Modified Phage). 166.66 µM 
Keap1 was used for all experiments except for the assay with Keap1 CTPR2-3-2 for which 
100 µM was used. The solution was titrated into  the Keap1 CTPR or peptide solution at 16.66 
µM. All experiments were carried out once under the final optimised assay conditions except 




An ITC assay was used, as it would not only allow the binding affinities of 2nd generation Keap1 
CTPRs to be determined, but also the enthalpy and entropy of binding (Figure 42, Table 10). 
These values would help to determine the entropic and enthalpic difference between Keap1 
CTPRs with different Keap1-binding peptides grafted into the inter-repeat loop.  The measured 
affinities were found to be of the same order of magnitude as those derived from the FP 
Competition assay, helping to support the validity of both assays.  
 
The results also show that the binding affinity of the grafted peptide is of the same order of 
magnitude as the free peptide. In order to make the two comparable, the peptides were 
acetylated at the N-terminus and had a C-terminal amide so as to mimic peptide bonds. This is 
an interesting observation that suggests that the structural match of the Keap1-binding peptides 
and the CTPR inter-repeat loop allows the grafted peptide to maintain a conformation which is 
similar to its bioactive conformation. It is also interesting that the binding affinity of Ac-
LDPETGELL-NH2 is tighter for Keap1 than any other natural amino acid peptide previously 
reported.2, 101, 102 
 
The results show a significantly smaller entropic cost of binding for Keap1 CTPR2-2-3 
compared to Keap1 CTPR2-2-2. This suggests the introduction of the two extra leucines may 
induce preorganisation of the grafted peptide. It is interesting that a similar reduction is not seen 
in the case of the Ac-DPETGEL-NH2 and Ac-LDPETGELL-NH2 free peptides and may 
suggest that the grafted DPETGEL is unable to adopt its bioactive conformation. The 
introduction of the flanking leucines in Keap1 CTPR2-2-3 may enhance intramolecular 
interactions in the grafted peptide, as has been shown for the Nrf2 peptide, inducing the peptide 





4.1.4.2.5 Pull-down assay with HEK293T cell lysate.  
Following the observed tight binding of the 2nd generation Keap1 CTPRs to Keap1, a 
preliminary assay was carried out to determine whether these CTPRs could bind endogenous 
Keap1. In order to investigate this a pull-down assay was carried out as reported by Guntas et 
al.126 Here HEK293T lysate was used as a source of Keap1and the CTPRs were bound to the 
Ni-NTA via their His-tag.  
 
The western was probed with an anti-Keap1 antibody and a band at the appropriate molecular 
weight was observed (Figure 43). This suggests that Keap1 CTPR2-2, Keap1 CTPR2-2-2 and 
Keap1 CTPR2-2-3 are all able to bind endogenous Keap1. In addition, no binding was observed 
for the two-repeat consensus-designed tetratricopeptide repeat protein (CTPR2) which did not 
have a peptide grafted into its inter-repeat loop. This suggests that binding of Keap1 to the 2nd 
Figure 43: Pull-down assay of immobilised His-tagged Keap1 CTPRs with HEK293T cell 
lysate as a source of Keap1 and probed using an anti-Keap1 antibody. The band of interest is 




generation Keap1 CTPRs is due to binding to the grafted peptide and not due to non-specific 
binding of the CTPR scaffold. The western blot was also probed with an anti-His antibody to 
demonstrate even loading of the CTPRs but no clear bands were detected. This may be due to 
the poor specificity of many anti-His antibodies and/or may be because the gel percentage 
(12%) was too low to resolve bands of low molecular weight.  
 
The smearing on the gel is likely to be because too much protein was loaded. The whole pull-
down was used because there was concern that only weak bands would be detected in this 
preliminary assay.  
 
4.1.5 Discussion 
All the findings for this chapter are within the context of the tested Keap1-binding peptides that 
have been grafted into CTPR loops. However, these findings would likely apply, at least in part, 
to the grafting of other peptides into the inter-repeat loop. The results presented help to show 
that CTPRs can be designed to bind Keap1 through the grafting of Keap1-binding peptide into 
the inter-repeat loop. It also shows this can achieve low nanomolar affinities (22 nM in the case 
of Keap1 Nrf2 Modified Phage).  
 
The 1st generation  Keap1 CTPRs have similar α-helicities and thermal stabilities to each other. 
This observation and the fact that the the 2nd generation Keap1 CTPRs also have similar 
structures and thermal stabilities to each other suggests that the thermal stability of Keap1 
CTPRs is relatively insensitive to the length, sequence and structure of the grafted Keap1-
binding or scrambled peptide. This is an exciting trend and suggests that CTPRs are amenable 
to the grafting of a range of different binding peptides. Future work should focus on the grafting 
of different binding peptides so that a better understanding of the importance of peptide 
structure, sequence and length and can be developed.  
 
In contrast, although the grafted peptide was slightly shorter in the case of the 1st generation 
Keap1 CTPRs compared to the 2nd generation Keap1 CTPRs, this work does suggest that 
changing the consensus flanking residues for polyglycine groups may reduce the thermal 
stabilities of the CTPR. N34 of the CTPR repeat has been shown previously to form an amide-
pi bond with the Y5.183 This along with the observations of this study suggest that this residue 





The ITC data suggest that grafted peptides have similar Keap1-binding affinities compared to 
the tested free peptides (Table 10). This is an interesting observation and may mean that the 
Keap1-binding peptides have a high propensity to form a b-turn structure as well as good 
structural match to the CTPR inter-repeat loop. This in turn may mean that the grafted peptide 
is able to adopt its bioactive conformation. This observation may mean that the structure of the 
grafted peptide is important in determining the affinity of the grafted peptide and future work 
should focus on grafting functional peptides of different geometries so as to better understand 
the effect of  peptide structure on the affinity of the functionalised CTPR for its target.  
 
The absence of Keap1 CTPR2-2-1 in the insoluble fraction compared to a sizeable fraction of 
total protein being in the insoluble fraction for Keap1 RTPR2 suggests that Keap1 CTPR2-2-1 
has a much higher solubility than Keap1 RTPR2. This is an interesting observation and may 
suggest that the mutations causes hydrophobic regions of the CTPR to become solvent exposed. 
If future work required the use of the arginine mutations, each of the three point lysine to 
arginine mutations could be assessed individually to better understand their effect on protein 
solubility. 
 
The preliminary pull-down assay suggests that the 2nd generation Keap1 CTPRs are able to bind 
endogenous Keap1. This assay should be repeated but this time 2nd generation Keap1 CTPRs 
should be expressed with a GST-tag. This tag was used for the experiment as described by 
Guntas et al.126 This would mean that we would easily be able to blot for a GST-tag as this can 
be recognised much better by an antibody in order to show that loading of the protein was even. 
In order to avoid the smearing observed on the western blot in Figure 43, future pull-down will 
measure the total protein concentration using a BCA assay and then carry out a titration of the 
loaded protein. This will enable the optimisation of the assay conditions so that clear Keap1 
bands can be detected. The pull-down could also be run both on a 12% and a 20%, with the 
20% gel ensuring the band for the CTPR can be resolved.  
 
In this chapter, the free modified phage peptide, Ac-LDPETGELL-NH2 has low nanomolar 
affinity for Keap1. This is a higher affinity for Keap1 than any other natural amino acid peptide 
we are aware of.2, 101-103, 166, 198 The discovery of this peptide suggests that the CTPRs could be 
developed to screen new binding peptides. This peptide has a C-terminal amide to mimic a 
peptide bind so that the peptide affinities can be compared to the grafted peptides. However, 
the DPETGEL (Phage) peptide with a C-terminal acid group has tighter binding affinity for 




should focus on characterising the binding of the LDPETGELL with a C-terminal acid group 
to Keap1 as this may allow even tighter binding of the peptide to Keap1.  
 
The binding of Keap1 CTPRs and the lack of binding of α-synuclein CTPRs to their respective 
targets may be due to a range of factors. It may be because the better structural match of the 
grafted peptide in the Keap1 CTPRs than in the α-synuclein CTPRs make improve binding 
affinities and/or reduce the propensity to form oligomers. However, it is likely that the main 
reason for the difference in binding abilities between the Keap1 CTPRs and α-synuclein CTPRs 
is due to the difference in the affinities of the grafted peptides for their targets. The tested 
Keap1-binding peptides have been shown to bind Keap1 with high affinity, whereas the binding 
of the α-synuclein targeting peptide is likely to be very weak, and rmore work is required to 



























5 Exploring new strategies for peptide grafting using 
CTPRs to target the Keap1-Nrf2 interaction 
5.1.1 Introduction 
The work in Chapter 4 showed that the tested Keap1-binding peptides can be grafted into 
CTPRs to create stable, soluble proteins that have nanomolar affinity for Keap1.  
In this chapter, work builds on this finding in order to explore the effect of mutating the flanking 
residues of the grafted peptide on protein stability and affinity for Keap1. Generating a stable 
protein with high affinity for its target can be achieved using surface display by directed 
evolution, computational design and combinations of both these methods.109, 120, 121, 125 
However, work has also shown that grafting of known binding peptides into protein loops using 
more of a ‘cut-and-paste’ approach is a viable strategy.115, 116 Grafting into protein loops can 
also be especially challenging compared with grafting into α-helices because it is difficult to 
predict loop conformations as well as predict the entropic cost of binding.114 The work 
described in this Chapter looks to develop strategies to overcome these challenges.  
 
5.1.1.1 Protein design  
Table 11: Third generation Keap1 CTPRs designed to target Keap1 described in this Chapter. 
Green residues represent the grafted peptide, black are consensus residues and blue residues 







In Chapter 4, the CTPR scaffold reported by Grove et. al was shown to be amenable to the 
grafting of Keap1-binding peptides of various sequences and lengths.136  Therefore, the same 
scaffold was again used in this Chapter. Using the same scaffold as used in Chapter 4 is also 
useful as comparison between the results may allow new trends to be identified. In this Chapter, 
the sequences flanking the grafted Keap1-binding peptide, referred to as the flanking region, 
were returned back to the consensus sequence. This means the flanking region was changed 
from DPNNXXXXXXXXXDPNS (DPNS mutant) to DPNNXXXXXXXXXDPNN (DPNN 
consensus), where X represents a residue in a grafted Keap1-binding peptide (peptides of 
different lengths were also tested in Chapter 4). This mutation was made to investigate the effect 














of the DPNS mutant vs the DPNN consensus design on the thermal stability, α-helicity and 
solubility of CTPRs with grafted Nrf2 peptides. In a CTPR2 with no grafted peptide, the DPNN 
consensus sequence has been shown to be 1 Kcal mol-1 more stable that the DPR’ mutant in 
CTPR2 protein both in the absence and presence of a loop extension.182, 183 Furthermore, the 
work described in Chapter 4 demonstrated that varying the flanking residues could adversely 
affect the thermal stability of the protein. A CTPR2 scaffold was again used as it had previously 
been shown to be amenable to peptide grafting of Keap1-binding peptides in Chapter 4. 
The Nrf2 peptide, LDEETGEFL, was used for grafting into the CTPR in this Chapter, as 
opposed to the DPETGEL (referred to as the Phage) or LDPETGELL (referred to as the 
Modified Phage) peptides used in Chapter 4. Although the Phage and Modified Phage peptides 
have been shown to have a higher affinity for Keap1, no crystal structure of these Keap1-
binding peptides in complex with Keap1 exists.102 Therefore, the conformation that these 
peptides adopt when in complex with Keap1 is not known. However, a crystal structure of the 
AFFAQLQLDEETGEFL Nrf2 peptide in complex with Keap1 has been published, so we have 
an indication of the bioactive conformation of the LDEETGEFL Nrf2 peptide. (Figure 44 ).7 
This Chapter focuses on manipulating the flanking residues to change the structure of the 
grafted peptide and allow it to adopt its bioactive conformation, it was important that we were 
aware of the structure of the free peptide.  This 9-mer Nrf2 peptide was chosen because Hancock 
et al. reported that it was approximately 14 x more potent that the shorter DEETGEF peptide, 
Figure 44: Crystal structure of the Keap1(Blue) -Nrf2 (Green) interaction adapted from PDB 




and longer Nrf2 peptides have been shown to not have considerable  improvements in binding 
affinity.102 This peptide has also been shown to be amenable to grafting into the CTPR scaffold 
and have a high affinity for keap1 once grafted in Chapter 4.  
 
A series of four 3rd generation Keap1 CTPRs were designed to probe the effect of changing the 
flanking residues on the stability and binding affinities for Keap1: Keap1 CTPR2-3-1, Keap1 
CTPR2-3-2, Keap1 CTPR2-3-3 and Keap1 CTPR2-3-4 (Table 11). The Keap1 CTPR2-3-1 
construct was designed to act as a point of reference for which the stabilities and binding 
affinities of the other designs could be compared to. It also would allow the effect of the DPNS 
to DPNN mutation to be explored since the Keap1 CTPR2-2-1 has an identical sequence aside 
from this mutation. The CTPR2 construct developed by Grove et al. and without a grafted 
peptide, was used as a negative control for the experiments.136 It is referred to as CTPR2n in 
the text.   
 
The Keap1 CTPR2-3-2 construct was designed to explore the effect of the addition of flexible 
polyglycines, with two glycines residues being placed both before and after the grafted Nrf2 
peptide (Table 11). Although the structural match between the CTPR inter-repeat loop and the 
Nrf2 peptide is similar as described in Chapter 4, the introduction of polyglycine groups to 
increase the flexibility of the system may reduce unfavourable conformational constraint on the 
grafted peptide and may allow the grafted peptide to adopt its bioactive conformation. This may 
in turn improve the binding affinity for Keap1 and was explored since flexible groups should 
improve the flexibility of the system. This design was inspired by the fact that flexible residues 
are often seen to modulate binding in nature.199 The introduction of polyglycine flexible 
sequences was previously explored in Chapter 4 with the Keap1 CTPR2-2-1 design, which was 
shown to have low thermal stability. However, in this study both the C-terminal and N-terminal 
DPNN flanking sequences of the grafted peptide were conserved and the polyglycine sequences 
were added in addition to the consensus flanking regions. This was done to both improve 
stability but also to ensure that the flexibility of the system will be increased relative to the 
Keap1 CTPR2-3-1 design.  
 
Brownian dynamics studies have shown electrostatic interactions to increase the amount of  
time two binding partners spend in close proximity to each other, increasing the time available 
for each to adopt their appropriate binding conformation.200 Electrostatic forces have also been 
shown to increase the basal association rate by five-fold in the case of the Barstar:Barnase 




improve the affinity of the Keap1 CTPRs for Keap1. Keap1-Nrf2 interaction is an 
electrostatically-driven interaction. The binding site of Keap1 consisting of mainly positively 
charged residues (D77, E78, E79, E82), whereas the Nrf2 includes mainly negatively charged 
residues in the binding site (R380, R415, R483) so increasing the negative charge of the 
flanking residues of the grafted peptide through a DPNN to DPDN mutation both before and 
after the grafted peptide may potentially increase the electrostatic interaction between Keap1 
CTPR2-3-3 and Keap1, which may in turn improve the rate of association, and hence improve 
the binding affinity for Keap1.   
 
The Keap1 CTPR2-3-4 construct aimed to constrain the peptide in its bioactive conformation 
through making mutations to the flanking regions, which were guided by the CIDER 
programme.193 CIDER is a programme developed by Pappu et al. that models the structure of 
intrinsically disordered proteins, with several possible broad conformations available. If we 
make the assumption that loop regions are disordered regions, we can use CIDER to suggest 
how certain mutations may move the peptide between different conformations. Changing the 
loop sequence from DPNNLDEETGEFLDPNN to DPNNLDEETGEFLDPRN induced a shift 
from region 1 (swollen coils) to region 3 (coils, hairpins and chimeras), and may allow the 
grafted peptide to adopt its native b-turn conformation and thus lead to a higher affinity of 
binding (Figure 45).  
 
Figure 45: A: CIDER plot for ‘DPNNLDEETGEFLDPNN’ input vs.  B: CIDER plot for 






5.1.2.1 Expression and Purification  
All proteins were purified using the method described for the 1st and 2nd Keap1 CTPRs 
described in Chapter 4. All proteins, like the  2nd generation Keap1 CTPRs, were found to 
express exclusively in the soluble fraction. 
 
5.1.2.2 Circular Dichroism Spectroscopy  
Figure 46: CD data for the 3rd generation Keap1 CTPRs to probe the structure and thermal 
stability of the proteins. i) CD spectra to probe protein folding both before (Black) and after 
thermal denaturation (Red) for Keap1 CTPR2-3-1. CD data to ii) probe protein folding and iii) 
the thermal unfolding at 222 nM for Keap1 CTPR2-3-1 (Red), Keap1 CTPR2-3-2 (Orange), 
Keap1 CTPR2-3-3 (Blue), Keap1 CTPR2-3-4 (Green) and CTPR2n (Black). Error bars 
represent SEM. 
Table 12: CTPRs designed to target Keap1 described in this Chapter. Green residues represent 
the grafted peptide, black are consensus residues and blue residues indicate additional mutations 
to the flanking region. Melting temperatures are given for each design measured using Circular 
Dichroism and binding affinities were measured using a Fluorescence Polarisation Competition 
assay. The fluorescence polarisation competition assay was repeated three times. Five readings 








All proteins have high levels of α-helicity similar to the CTPR2n protein, suggesting that they 
were folded (Figure 46). All of the 3rd generation Keap1 CTPRs were found to refold after 
thermal denaturation. All constructs have high melting temperatures, but a reduction in the 
melting temperature compared to CTPR2n was again observed (Table 12). All constructs have 
similar melting temperatures except for Keap1 CTPR2-3-3 which has a slightly lower melting 
TPR Loop Sequence Tm ± SE 
(°C) 










DPNNLDEETGEFLDPRN   
DPNN 
70.0 ± 1.3 
68 ± 1.0 
65.6 ± 0.9 
70.6 ±1.5 
>80 
282 ± 64 
109 ± 18 
817 ± 75 





temperature. It is interesting that the melting temperature of Keap1 CTPR2-3-2 is very similar 
to Keap1 CTPR2-3-1 and helps to support the previous hypothesis described in Chapter 4 that 
the thermal stability of the CTPRs with grafted peptides may be near independent of the nature 
of the grafted sequence. It is also interesting that the melting temperature of Keap1 CTPR2-3-
1 is lower than Keap1 CTPR2-2-1 since the only difference between the two sequences is the 
DPNN to DPNS mutantion, and you would expect the consensus sequence (DPNN) of Keap1 
CTPR-3-1 to have a higher thermal stability. 
 
5.1.2.3 Fluorescence Polarisation 
 
Table 13: Measured Ki values for the 3rd generation Keap1 CTPRs for Keap1 using a 











282 ± 64 
109 ± 18 
817 ± 75 
103 ± 15 
269 ± 60 
101 ± 23 
1113 ± 320 
107 ± 32 
Figure 47: Fluorescence Polarisation competition assay with a serial dilution from a top 
concentration of 10 μM of A: Keap1 CTPR2-3-1, B: Keap1 CTPR2-3-2, C: Keap1 CTPR2-3-




The binding affinity of Keap1 CTPR2-2-1, Keap1 CTPR2-2-2 and Keap1 CTPR2-2-3 to Keap1 
was probed using a FP competition assay (Figure 47, Table 13). The results showed that 
mutating the flanking residues improved the binding by more than 2-fold in the case of Keap1 
CTPR2-3-2 and Keap1 CTPR2-3-4, but Keap1 CTPR2-3-3 had an almost three-fold tighter 
affinity for Keap1 compared to Keap1 CTPR2-3-1. This is an interesting observation and may 
mean that our previous hypotheses for  Keap1 CTPR2-3-2 and Keap1 CTPR2-3-4 were correct. 
The lower binding affinity of Keap1 CTPR2-3-3 for Keap1 may be due to unfavourable 
conformational changes in the grafted peptide, causing a decrease in the binding affinity.  
 
Figure 48: Fluorescence Polarisation competition assay with 0.5 mM TCEP and a serial dilution 
from a top concentration of 10 μM of  A: Keap1 CTPR2-3-1, B: Keap1 CTPR2-3-2, C: Keap1 
CTPR2-3-3 and D: Keap1 CTPR2-3-4. Each experiment was carried out once with each CTPR 
concentration being carried out in triplicate.  
In the assay reported by Hancock et al., the fluorescence polarisation assay was carried out in 
buffer with no reducing agent for Keap1 despite the Keap1 protein having free cysteines. This 
could be an issue because the dimerisation process may affect the binding of Keap1 for the 
Keap1 CTPRs. However, the assay uses a very low concentration of Keap1 of 237.5 nM so this 
may mean that dimerisation of the protein is negligible. In order to ensure the Keap1 protein 




this time 0.5 mM TCEP was used and the Ki values were determined (Figure 48, Table 13).  
The measured affinities were very similar to those obtained in the absence of TCEP, 
demonstrating that the potential dimerisation of Keap1 through disulphide bonds between 
cysteines was not affecting the measured binding affinities.  
 
5.1.2.4 Isothermal Titration Calorimetry  
Table 14: Isothermal Titration Calorimetry data for the binding of Keap1 to the Keap1 CTPR2-
3-1, Keap1 CTPR2-3-2 and CTPR2n. Each experiment was carried out once. The given error 
is the fitting error.  
 
One of the major findings of this work is that the introduction of flexible groups into protein 
loops can help improve the binding affinity of the grafted peptide in the case of Keap1 CTPR2-
3-1 compared to Keap1 CTPR2-3-2. In order to explore this further, the binding of Keap1 
CTPR2-3-1 and Keap1 CTPR2-3-2 to Keap1 was probed using Isothermal Titration 
Calorimetry. This assay was chosen but it would also allow the binding affinities measure using 
CTPR Loop Sequence KD ± SE 
( nM) 










200 ± 78 
74.6 ± 17 
N.d. 






Figure 49: Isothermal Titration Calorimetry data for the binding of Keap1 to A: Keap1 
CTPR2-3-1, B: Keap1 CTPR2-3-2 and C: CTPR2n. 166.66 µM Keap1 was used for all 
experiments except for the assay with Keap1 CTPR2-3-2 for which 100 µM was used. The 
solution was titrated into  the Keap1 CTPR or peptide solution at 16.66 µM, except for Keap1 
CTPR2-3-2 for which 10 µM was used All experiments were carried out once under the final 




the fluorescence polarisation assay to be validated, but would also allow to explore the effect 
of the introduction of flexible residues on the enthalpy and entropy of binding (Figure 49, Table 
14). This would allow us to further our understanding of the mechanism by which the 
introduction of flexible sequences could improve the binding affinity for Keap1. 
 
The binding affinities for Keap1 CTPR2-3-1 and Keap1 CTPR2-3-2 were within error of those 
measured using the fluorescence polarisation competition assay, helping to validate both assays. 
The entropic cost of binding is higher for Keap1 CTPR2-3-2 than for Keap1 CTPR2-3-1 and is 
in fact the highest entropic cost of binding observed for any of the Keap1 CTPRs in this thesis. 
This suggests that the introduction of the polyglycine linkers increasing the disorder of the 
system by making it more flexible. A more negative enthalpy of binding is observed for Keap1 
CTPR2-3-2 than for Keap1 CTPR2-3-1, and again is the most negative binding enthalpy 
observed for the Keap1 CTPRs. Here, the large entropic cost of introducing the flexible 
polyglycine groups is overcome by the improvement in the enthalpy of binding, and therefore 
increasing the binding affinity for Keap1.  
 
5.1.3 Discussion 
The work described in this Chapter shows that the flanking groups of a grafted peptide can be 
altered to change the binding affinity of the grafted peptide for its target without the need for 
extensive computational modelling and/or screening approaches.  
 
It is especially interesting that the introduction of flexible groups induces an improvement in 
the binding affinity. With binding loops the entropic cost of binding is believed to be a big 
hurdle to overcome.114 Therefore, adding flexible flanking regions to potentially increase the 
entropy of the system may seem counterintuitive. However, in the case of grafting binding 
peptides, we know the peptide has a high binding affinity, and most likely a high enthalpy of 
binding. By adding the flexible groups to allow the peptide to adopt its bioactive conformation, 
we may maximise the enthalpy of binding and, in most senarios, we hypothesise that will 
overcome the entropic cost of introducing flexible groups. The polyglycine sequences also have 
the added benefit of reducing steric clashes between the CTPR and the target. It may be that for 
some binding peptides the entropic penalty for the introduction of flexible groups will not 
always be overcome by increased enthalpy of binding. This method could also be explored for 




especially important consideration where the structural match of the peptide with the inter-
repeat loop conformation is poor.  
 
Future work should focus on using polyglycine linkers with the Keap1 CTPR2-2-3 construct 
from Chapter 4 to see whether this combination could produce a CTPR protein with an even 
tighter binding affinity for Keap1. However, a mix-and-match approach for the strategies 
described in Chapter 4 and 5 may not necessarily improve the binding affinity because Keap1 
CTPR2-2-3 has the smallest loss of entropy of binding out of any of the Keap1 CTPRs 
investigated in this thesis. This may suggest that the peptide is already in its bioactive 
conformation.  
 
The fact that the melting temperature of Keap1 CTPR2-3-2 is so similar to that of Keap1 
CTPR2-3-1 supports the hypothesis discussed in Chapter 4 in that providing the flanking 
sequences are conserved, the tested CTPRs with Keap1-binding peptides grafted in their loops 
all have similar thermal stabilities. This is particularly stark in the case of this example, where 
the peptide is four amino acids longer.   
 
Mutations in the flanking region can affect protein stability. The melting temperature of Keap1 
CTPR2-3-1 is slightly lower than Keap1 CTPR2-2-1 described in Chapter 4. This result 
suggests the DPNS mutant in the flanking sequence imparts a higher thermal stability compared 
to the DPNN consensus sequence. This is interesting since the DPNN consensus sequence has 
been shown to be 1 Kcal mol-1 more stable that the DPRS mutant in CTPR2 protein both in the 
absence and presence of a loop extension.182, 183. Future studies should investigate the relative 
thermal stability of the DPNS mutant versus the DPNN consensus sequence in the absence of 
a grafted peptide. It is also interesting that the binding affinity of Keap1 CTPR2-2-1 for Keap1 
is weaker than Keap1 CTPR2-3-1. Therefore, future work could focus on changing the flanking 
region in Keap1 CTPR2-2-3 back to the DPNN consensus sequence to investigate whether this 











6 Probing the activity of Keap1 CTPRs in cells 
6.1.1 Introduction 
Dr Piyush Chaturbedy optimised the lipid composition and prepared the dried lipid cake from 
which the liposomes were made. He also assisted with the confocal imaging of Rhodamine-
labelled Keap1 CTPR2-2-3 in HCT 116 cells and provided useful discussions regarding the 
delivery of Rhodamine-labelled Keap1 CTPR2-2-3 into cells. 
 
Following from the biophysical work described in this thesis, and the pull-down results in 
Chapter 4 that suggest that Keap1 CTPR2-2-3 is able to bind endogenous Keap1 in HEK 293T 
cell lysate, work was carried out to explore whether such tight binding affinities translated to 
an observable biological effect in cellulo. 
 
Delivery of protein therapeutics into cells has presented a major challenge to drug discovery. 
Many studies have focused on the conjugation of the molecule to a protein transactivation 
domain or a cell-penetrating peptide to take advantage of cell uptake processes, as well as the 
use of nanocarriers.202, 203 However, endosomal escape using strategies such as these has often 
been difficult to overcome. The cytotoxicity of these methods also has to be considered. In this 
chapter, work sought to investigate whether the use of fusogenic liposomes could be used for 
the delivery of Keap1 CTPR2-2-3 into HCT 166 cells.   
 
6.1.1.1 Liposomes for cellular delivery of therapeutics  
Liposomes are a type of nanocarrier. They are spherical particles consisting of at least one 
phospholipid bilayer surrounding an aqueous centre. Liposomes have been shown to be able to 
accommodate proteins for cell delivery through the formation of proteoliposomes.204 
Liposomes are particularly suitable for delivery of therapeutics into cells because they have low 
toxicity due to their natural components, can ensure targeted delivery to diseased tissue, can 
prevent protein cargo from premature proteolysis and can minimise the immune response to the 






Figure 50: Liposome composition and the process of cargo delivery into cells using fusogenic 
liposomes. The cationic liposomes (Blue) fuse with the anionic cytoplasmic lipids (Purple) 
promoting the delivery of the liposome cargo into the cell. Figure adapted from Kube et al.170   
 
A major disadvantage of liposomes is that their uptake is mainly through endocytosis. This can 
lead to the cargo build-up in lysosomes, where it is subsequently degraded. Therefore, recent 
work has been carried out to develop a fusogenic liposome that can escape this fate.207, 208 
Fusogenic liposomes are positively charged and could easily fuse with the negative cell 
membrane, thereby delivering their payload directly into the cytoplasm (Figure 50).  Kube et 
al. were able to use these fusogenic liposomes for the delivery of proteins inside cells.170 They 
report that the attractive interaction between the negatively charged proteins and positively 
charged lipids allowed the proteoliposomes to correctly form. This included the delivery of 
streptavidin-AlexaFluor488 protein where an even distribution of the protein in the CHO cell 
cytoplasm was observed and membrane staining from the liposome DiR lipid was also observed  
due to successful liposome fusion with the cell membrane. Proteoliposome formation with 
positively charged proteins was not successful.  
 
6.1.2 Results  
6.1.2.1 Optimisation of liposome composition 
Dr Piyush Chaturbedy optimised the liposomes for use with the low isoelectric point (pI) of 
Keap1 CTPR2-2-3 of 5.58. 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),  1,2-




tetramethylindotricarbocyanine iodide (DiR) were used and the ratio of these lipids was 
optimised to a DOPE:DOTAP:DiR  ratio of 1:1:0.1 (w/w, Figure 51).170 DiR was used not only 
due to its ability to help liposomes fuse with the cell membrane, but also because it is a near IR 
dye that can be used to track this fusion process.  
 
Figure 51: Lipids used for liposome formation in this study.  
 
6.1.2.2 Optimisation of the delivery of Keap1 CTPR2-2-3 into cells 
Keap1 CTPR2-2-3 is negatively charged (pI= 5.58) at physiological pH so may be suitable for 
delivery into cells using fusogenic liposomes. In order to investigate this and to visualise the 
protein in cells, the lysines of Keap1 CTPR2-2-3 were successfully labelled using Rhodamine 
isothiocyanate with  a ratio of dye to Keap1 CTPR2-2-3 of 30:1 (See Materials and Methods). 
An initial assay was carried out to probe the ability of the liposomes to deliver Rhodamine-
labelled Keap1 CTPR2-2-3 into the HCT 116 cells (Figure 52). HCT 116 cells were chosen 
because inhibitors of the Keap1-Nrf2 interaction have previously been shown to induce changes 
in the concentrations of the downstream proteins Heme oxygenase-1 (HO-1) and γ-glutamyl- 
cysteine synthetase (γ-GCS) in this cell line.86, 209 If the Keap1 CTPR2-2-3 is successfully 
delivered into the cell, we would expect to see a clear signal (seen in green) from the rhodamine 
dye in the cell cytoplasm as reported by Kube et al. for the delivery of their streptavidin-
AlexaFluor488. If this delivery is able to occur through fusion of the liposome with the cell 
membrane and subsequent release of the Rhodamine-labelled Keap1 CTPR2-2-3 cargo, we 
would expect to see staining (seen in red) of the cell membrane with the liposome dye DiR 





Figure 52: Preliminary assay to probe the delivery of Rhodamine-labelled Keap1 CTPR2-2-3 
into HCT 116 cells using fusogenic liposomes. A: Bright field image of Cells only, B: Cells 
treated with empty liposomes, C: Cells treated with 0.8 μM Rhodamine-labelled Keap1 CTPR2-
2-3, D: Cells treated with 2.3 μM Rhodamine-labelled Keap1 CTPR2-2-3. DiR is shown in Red 
and Rhodamine-labelled Keap1 CTPR2-2-3 is shown in green. Images are a single slice. 
The proteoliposomes formed a transparent suspension, suggesting that they had formed 
correctly before they were subsequently added to the HCT 166 cells. This assay showed that 
the Rhodamine-labelled Keap1 CTPR2-2-3 had entered the cells. The staining of the cell 
membranes with the DiR was observed to be low. The confluency of the cells was also found 
to be less than 80%, which may have affected the observed results. Some colocalization of the 
DiR and rhodamine dyes was observed, indicating that release of the Keap1 CTPR2-5 from the 
liposome may not be occurring in all instances and a small number of the liposomes may be 
entering the cells  through endocytosis rather than fusing will the cell membrane as designed. 
To improve the confluency, the number of cells seeded per well was increased from 1 x 105 
cells to 2 x 105 cells. Using the new cell seeding number, the assay was repeated (Figure 53). 




increased from 0.8 μM and 2.3 μM to 2.3 μM and 3.9 μM in order to probe whether this gave 
greater staining of the cells.    
 
Figure 53: The delivery of Rhodamine-labelled Keap1 CTPR2-2-3 into HCT 116 cells using 
fusogenic liposomes with an optimised cell number and Keap1 CTPR2-2-3 concentration. A: 
Bright field image of  cells only, B: Cells treated with empty liposomes, C: Cells treated with 
2.3 μM Rhodamine-labelled Keap1 CTPR2-2-3, D: Cells treated with 3.9 μM Rhodamine 
labelled Keap1 CTPR2-2-3. DiR is shown in Red and Rhodamine-labelled Keap CTPR2-2-3 is 
shown in green. Images are a single slice. There is a slight green signal in the Lipid Tracer 
image due to background noise.  
The proteoliposomes again appeared as a transparent suspension, indicating correct formation. 
The cells incubated with 3.9 μM of Rhodamine-labelled Keap1 CTPR2-2-3 had greater staining 
compared to cells incubated with 2.3 μM, indicating a greater amount of Rhodamine-labelled 
Keap1 CTPR2-2-3 had been delivered into the cells. DiR staining of the cell membrane was 





In order to optimise the staining of the cell membrane, a titration of empty liposomes was used 
to estimate the optimal liposome concentration for good levels of staining of the HCT 116 cell 
membranes. In the previous experiments, 30 μL of the proteoliposome mixture with a 4mg/mL 
lipid concentration was added to DMEM media to make a total volume of 780 μL, with 700 μL 
being added to the cells. In order to optimise this amount, the 780 μL liposome mixture in 
DMEM media was instead prepared with 15 μL, 30 μL, 45 μL and 60 μL of  empty liposomes  
with a 4mg/mL lipid concentration. The optimal liposome concentration found to be 45 μL of 
the 4 mg/mL liposome mixture (Figure 54) because at this concentration all cell membranes 
were stained red, indicating that the DiR-containing liposomes had fused with the membrane. 
It is possible that the empty liposomes may not behave in an identical manner to the 
proteoliposomes but the approach was used as an estimate and enabled Keap1 CTPR2-2-3 to 
be conserved.  
The experiment shown in Figure 53 was then repeated with 45 μL of the 4 mg/ml liposome 
mixture. This increase in the volume of liposomes added to the cells also meant that the protein 
concentration also proportionally increased from 2.3 μM and 3.9 μM to 3.5 μM and 5.8 μM 
respectively.  This was done because this protein:lipid ratio had previously been shown to form 
liposomes well and deliver Keap1 CTPR2-2-3 into the cell. The assay demonstrated good 
staining of the cell membranes with the DiR and good visualisation of the CTPR inside the cells 
was observed (Figure 55). Some colocalization of the DiR and rhodamine dyes was observed, 
indicating that release of the Keap1 CTPR2-5 from the liposome may not be occurring in all 
instances and that the liposomes may be entering the cells  through endocytosis rather than 
fusing will the cell membrane as designed. 
Figure 54: Incubation of cells with A:15 μL(77 μg/mL), B: 30 μL (154 μg/mL),, C: 45 μL 
(230 μg/mL),  and D: 60 μL (308 μg/mL),  of empty liposomes. DiR is shown in Red. Final 
concentration of liposomes are given in brackets. Images a single slice and greater staining 





Figure 55: The delivery of Rhodamine-labelled Keap1 CTPR2-2-3 into HCT 116 cells using 
fusogenic liposomes with an optimised liposome concentration. A: Bright field image of cells 
only, B: Cells treated with empty liposomes, C: Cells treated 3.5 μM Rhodamine-labelled 
Keap1 CTPR2-2-3 and D: Cells treated with 5.8 μM Rhodamine-labelled Keap1 CTPR2-2-
3. DiR is shown in Red and Rhodamine-labelled Keap CTPR2-2-3 is shown in green. Images 




6.1.2.3 Western blot to probe the downstream effects of Keap1 CTPR2-2-3 
Following the optimisation of the delivery of Rhodamine-labelled Keap1 CTPR2-2-3 into HCT 
166, we sought to probe the biological effect of the CTPR in cellulo. Nrf2 is a transcription 
factor that allows the body to respond to oxidative and/or electrophilic stress.42 It achieves this 
through binding to ARE elements in DNA, activating the transcription of a range of 
cytoprotective enzymes (Figure 56).  
 
Characterising the changes in transcription and/or in protein expression levels of these 
cytoprotective enzymes is a good strategy to investigate the biological effect of Keap1-Nrf2 
inhibition in cellulo. This is because in the literature it appears that changes in Nrf2 levels due 
to Keap1-Nrf2 inhibition can be difficult to detect using western blot.105, 209  
 
Inhibition of the Keap1-Nrf2 interaction has previously been shown to induce significant 
changes in the transcription as well as the protein expression levels of the following downstream 
products of Nrf2: Heme oxygenase-1 (HO-1), γ-glutamyl- cysteine synthetase (γ-GCS) and 
NAD(P)H/quinone oxidoreductase (NQO1).86, 105, 126, 209 In 2015, Jiang et al. were able to probe 
the binding of a small-molecule inhibitor to Keap1 using a Fluorescence Polarisation assay.209 
The molecule had an IC50 of 14.4 nM equivalent to a Ki of 12.8 nM using the IC50-to-Ki online 
calculator.196, 209 Using a western blot assay, they probed both the effect of changing the 
concentration of the inhibitor on the effect of HO-1 and γ-GCS levels as well as how these 
levels changed over time after an initial treatment. They observed that at a concentration of 20 
μM, significant changes in HO-1 and γ-GCS levels were detected after 2 and 8 hours 
respectively. They also investigated the dose response of Nrf2-regulated proteins with an 
incubation time of 6 hours. They reported significant increases in HO-1 levels with 10 μM of 
inhibitor and a significant increase in γ-GCS levels with 20 μM of inhibitor. The assay also 
Figure 56: Nrf2 is a transcription factor that binds to ARE elements and acts as a transcriptional 
activator for a range of cytoprotective enzymes such as Heme Oxygenase 1, γ-glutamyl-




blotted for changes in NAD(P)H/quinone oxidoreductase (NQO1) which is a protein also 
regulated by Nrf2. However, Jiang et al. observed no significant	changes in the expression of 
the Nrf2-regulated NQO1. 
 
Given the results reported by Jiang et al., the same assay was adopted to test the effects of  
liposome delivery of Keap1 CTPR2-2-3.209 The liposome delivery protocol optimised 
previously for the delivery of the CTPRs into HCT 116 cells was used. The inhibitor, 18e, 
reported by Jiang et al. has a similar binding affinity to Keap1 CTPR2-2-3 (13 nM vs. 22 nM), 
suggesting the two inhibitors may show similar effects in cellulo.209 However, the in-cell 
stability of the Keap1 CTPR2-2-3 protein is likely to be lower than the small-molecule, 18e, 
with similar KD values. Therefore, the preliminary assay was carried out at the lower end of the 
incubation times where results were seen, with incubation times of 2 and 4 hours. Protein stocks 
were limited, so the initial assay was carried out with the protein:lipid ratios used in the 
experiments shown in Figure 52. Although these concentrations are lower than those reported 
by Jiang et al., these protein:lipid ratios have been optimised for liposome delivery into HCT 
166 cells, and higher concentrations of Keap1 CTPR2-2-3 may not be able to form 
proteoliposome.209  
 
The cells were lysed and the cell extracts were run on a western blot. HO-1, γ-GCS and actin 
protein levels were determined using specific antibodies. Determining the actin levels served 




Figure 57: Western blot of HCT 116 cells lysates after liposome treatment after a period 




6.1.3 Discussion  
There could be several reasons why no change in HO-1 and γ-GCS levels were observed in the 
western blot. The assay may have not been carried out under the optimal incubation times and 
with the optimal inhibitor concentrations. This is because using assays that have been developed 
for use with small-molecule inhibitors to guide the experimental design for the same assay with 
a protein inhibitor is difficult as small-molecule and protein inhibitors have different cell 
permeabilities and stabilities in the cell. 
 
Figure 58: Model of Nrf2 binding to Keap1. The DLG and ETGE motifs bind to two different 
Kelch domains of the Keap1 dimer (yellow).18, 33, 87 Keap1 recruits Cul3 and Rbx. This induces 
ubiquitination and targets Nrf2 for degradation by the 26S proteasome.  
It is possible that no reduction in HO-1 and γ-GCS levels is observed due to the CTPRs having 
very low proteolytic stability in cells. The second generation Keap1 CTPRs described in 
Chapter 4, including Keap1 CTPR2-2-3, were shown to bind Human Keap1 in HEK293T lysate 
so it is likely that the Keap1 CTPR2-2-3 is also able to bind Human Keap1 in HCT 116 cells, 
perhaps suggesting that the absence of a change in HO-1 and γ-GCS levels may be due to Keap1 
CTPR2-2-3 stability. This could be especially significant in the case of CTPRs to target the 
Kelch domain of Keap1 due to the binding side being close in proximity to the ubiquitination 
site of the E3 ubiquitin ligase complex (Figure 58). This could mean binding of the Keap1 
CTPR2-2-3 to the Kelch domain may induce ubiquitination of the protein, targeting it for 
degradation by the proteasome. 
 
In order to probe whether the CTPRs do indeed have low proteolytic stability in cells, the 
experiment could be repeated with a HA-tagged version of Keap1 CTPR2-2-3, and the western 
blot probed with an anti-HA antibody to investigate the change in Keap1 CTPR2-2-3 levels 




recognition of the antibody for the His-tagged epitope as shown in the western blot in Chapter 
4.   
 
If the stability of the CTPR in cellulo was found to be low, the assay could be repeated with 
higher concentration of Keap1 CTPR2-2-3. This would be reliant on the development of 
liposomes which could accommodate higher concentrations of protein, which may not be 
possible. If the proteolytic stability was shown to be especially low, one strategy to improve 
this could be to use a RTPR rather an CTPR to stop protein ubiquitination as described in 
Chapter 4. However, this is unlikely to be practicable because the Keap1 RTPRs have low 
solubility and express poorly. Increasing the number of repeats in the Keap1 CTPR2-2-3 would 
increase the thermal stability of the protein, which may in turn increase the proteolytic stability.  
 
Another explanation for the lack of change in HO-1 and γ-GCS levels is because there is poor 
delivery of Keap1 CTPR2-2-3 into the cells. The confocal image of rhodamine-labelled protein 
delivered into the cell is qualitative rather than quantitative result, and future work could use a 
protein concentration calibration curve as described by Kube et al. to estimate the CTPR 
concentration in the cell.170 If the concentration of Keap1 CTPR2-2-3 was found to be 
especially low, future work could focus on using transient transfection of cDNA encoding the 
CTPR into HCT 116 cells. This would allow us to determine whether the delivery method is 
the reason for the assay not working.   
 
If we are unable to overcome the proteolytic stability limitation using the approaches described 
above,  changes in HO-1 and γ-GCS mRNA levels with a qRT-PCR assay or determining the 
effects using a Nrf2 luciferase reporter assay could instead be trialed. 86, 105, 126  These 
approaches may prove be more sensitive techniques that show the Keap1 CTPR2-2-3 to induce 
a biological effect.. It is also possible that Keap1 CTPR-2-3 is able to induce some effects on 
regulating mRNA levels but that the translation is disrupted and so no change in protein 
expression levels are observed. Using qRT-PCR would be able to investigate this possibility.  
 
One limitation of this work is that the dye-labelled CTPR does not have the same size or charge 
as the unlabelled CTPR, so it is possible that the unlabelled protein is unable to enter cells 
through fusogenic liposomes. Using HA-labelled CTPRs would help us to verify this using 
western blot or fluorescent imaging respectively. We were also unable to acquire a positive 





We also need to further understand the effect of the liposomes on the cells. Here we are using 
a stock lipid concentration of 4mg/mL producing a high well concentration of up to 231 μg/mL. 
This may cause cytotoxic effects and could in turn induce changes in protein levels in the cell.  
The cytotoxicity of the liposome should be investigated using LDH and MTT assays. The 
experiment should be carried out with liposomes in both the presence and absence of Keap1 
CTPR2-2-3.  
 
A major hurdle in the development of these CTPRs could be their immunogenicity in vivo. 
Individual CTPRs could be directly tested for their immunogenicity. However, as the CTPRs 
are amenable to protein engineering an interesting approach would be to take proven functional 
CTPRs and align them with endogenous human tetratricopeptide repeat proteins. CTPR 
residues could then be mutated to mimic the endogenous TPRs to reduce CTPR 
immunogenicity.   
 
An additional issue with the liposome work was that some colocalization of the DiR and 
rhodamine dyes was observed, suggesting that the the liposomes may be entering the cells  
through endocytosis  rather than fusing will the cell membrane as designed and not realising 
the Keap1 CTPR2-2-3 cargo, leading to the colocalization of the signals. This colocalization 
was also observed for the liposomes carrying streptavidin-AlexaFluor488 into CHO cells 



















7 Targeting c-Myc using Omomyc-like stapled peptides 
and repeat proteins 
 
7.1.1 Introduction 
Dr Trevor Littlewood (Department of Biochemistry, University of Cambridge) participated in 
useful discussions that helped me with protein and peptide design, the experimental design of 
the pull-down and the retroviral transduction experiments. Dr Yaw Sing Tan grafted the 
Omomyc-like peptides into the CTPR protein and carried out the molecular dynamics 
experiments described in this study. The Omomyc peptide was synthesised by Dr Fernando 
Ferrer. 
 
7.1.1.1.1 Myc network of proteins 
The Myc network is made up of c-Myc, Max, Mad proteins. Max is able to homodimerise as 
well as heterodimerise with c-Myc and Mad  proteins (Figure 59). Whilst the c-Myc-Max 
interaction induces cell proliferation, predominantly through transcriptional activation of genes 
involved in cell cycle control, metabolism and ribogenesis, Max-Mad heterodimers act as a 
transcriptional repressors.210-212 In addition, the Mad proteins dimerise with Mlx protein 
partners that also associate with Mondo family proteins that are intimately involved in the 
regulation of metabolism. Whether this collection of interacting proteins forms a regulatory 
network or whether Max is simply a common binding partner of c-Myc and Mad remains 
unclear.  
  
Figure 59: A: The c-Myc/Max/Mad network.6 Max binds to both c-Myc and Mad family proteins. 
Figure adapted from Zhou et al.10 B: Crystal structure of the c-Myc-Max complex bound to E-




7.1.1.2 Omomyc  
Soucek et al. employed molecular modelling and mutagenesis studies to identify a 90 residue 
bHLH-LZ region of c-Myc containing four point mutations (referred to as Omomyc), which 
was able to homodimerise in the same manner seen for Max protein.128 Three of the four 
mutations are taken from the corresponding residue in the Max protein.  
 
Expression of Omomyc induced rapid and extensive regression of tumours driven by different 
oncogenes in different mouse models, suggesting that c-Myc is a common conduit of upstream 
oncogenic signaling.60-62, 129, 130, 213 Experimental reduction of c-Myc in human lung cancer cells 
recapitulates the biological effects observed for Omomyc, suggesting that Omomyc acts as a c-
Myc inhibitor.214 However, the exact molecular mechanism by which Omomyc inhibits c-Myc 
function is unclear. Omomyc is able to homodimerise in vitro and heterodimerise 
predominantly with Max but also to some extent with the wild type c-Myc protein. It is unclear 
whether Omomyc sequesters Max (or c-Myc itself) in solution or whether the transcriptionally 
inactive Omomyc-Max heterodimers or Omomyc homodimers block E-box binding sites.215, 216  
 
Interestingly, Omomyc has been shown to enhance c-Myc-induced apoptosis in myoblasts and 
glioma cells, but only in cells with elevated levels of c-Myc.62, 215, 217 The mechanism by which 
Omomyc is able to achieve this is not known but may be because the c-Myc-Omomyc complex 
is able to retain binding to other transcription factors such as Miz-1 as hypothesised by Soucek 
et al.   
 
The Omomyc protein has itself been proposed as a potential therapeutic by Soucek and others 
due to its dramatic therapeutic effect on a wide range of tumour types without any significant 
toxicity, and unlike many other targeted cancer therapies, without the emergence of 
resistance.60, 129, 130, 218 This hypothesis has been supported by the work of Wang et al., where 
Omomyc protein was conjugated to a cell-penetrating peptide and reported to enhance c-Myc 
induced cell apoptosis, reduce cell viability and reduce cell proliferation.218 However, the 
intrinsically disordered nature of  Omomyc monomer is likely to exhibit low proteolytic 
stability in vivo hindering its therapeutic potential. Moreover, like c-Myc, Omomyc has poor 





7.1.2 Design of Omomyc-like c-Myc inhibitors 
The work described in this chapter sought to encapsulate the activity of Omomyc in two forms: 
a stapled peptide and a repeat protein. Both approaches have the potential to increase the 
proteolytic stability, constrain the Omomyc-like sequences in a bioactive conformation and 
increase the solubility compared to the full-length protein, making  large-scale manufacture 
viable. 
 
When considering which region of Omomyc to use for the Omomyc-like peptide and CTPR the 
following points were taken into consideration: 
 
1) In Chapter 3, c-Myc DARPin was designed to bind to Helix2 of the bHLH-LZ region 
of c-Myc (Figure 4). However, this region also mediates association with Mix-1 whose 
transcriptional activity is squelched by c-Myc.192, 219 In addition, Soucek and colleagues 
have suggested that retention of Miz-1 binding may be important for Omomyc’s 
therapeutic activity. 192, 216 Hence, targeting of this region of c-Myc was specifically 
avoided in work described in this chapter.  
2) Given the large number of proteins sharing related dimerisation interfaces, it is essential 
to retain Omomyc’s specificity for the Myc network in the Omomyc-like stapled peptide 
and the Omomyc-like CTPRs. The specificity of Omomyc is likely to be determined by 
the leucine zipper region, because this is the region that offers the highest sequence 
variation amongst the Myc network members and is responsible for dimerisation.  
3) The design of the Omomyc-like inhibitors was optimised using molecular dynamic 
















7.1.2.1.1 Molecular Dynamics (MD) simulations and further peptide design  
Table 15: Molecular dynamics determined thermodynamic values for the binding of Max, 
Omomyc, Omomyc-like peptide 1 and Omomyc-like peptide 2 to c-Myc protein to aid 
Omomyc-like peptide design. The peptides were made with Fmoc-(S)-2-(4-pentenyl)Ala-OH 
as X for hydrocarbon stapling. 
 
Bearing these requirements in mind,  Dr Yaw Sing Tan took sections of the leucine zipper 
region of Omomyc and carried out MD simulations to determine the optimal sequence a double 
stapled peptide for maximising the strength of binding to c-Myc.  
 
Two Omomyc-like peptides were shown to bind c-Myc with high affinity using MD 
simulations, referred to as Omomyc-like peptide 1 and Omomyc-like peptide 2 (Table 15, 
Figure 60). These simulations were for peptides that were double-stapled. Hydrocarbon stapling 
was chosen as the stapling method as this has been optimised for i,i+4 stapling, and the double-
stapling should allow us to induce a high level of alpha-helicity over the full length of the 29mer 
peptide as well as lead to increased proteolytic stability.4, 100 Omomyc-like peptide 1 was 
synthesised first out of the two Omomyc-like peptides because it is predicted to have a lower 
Gibbs Free energy for its interaction with c-Myc. In addition, this design has the two staples 
further away from each other than in Omomyc-like peptide 2 and hence cross-reactivity 
between staples is less likely during the stapling process. Omomyc-like peptide 1 is 
subsequently referred to as Omomyc-like peptide.  
 
The Omomyc-like peptide was also designed to have a HA-tag at the N-terminus in order to aid 
immunoprecipitation experiments, meaning the final peptide sequence, referred to as HA-
labelled Omomyc-like peptide, was designed to be 






Max Ac-DKR......RAL-NH2 -119.0 ± 0.9 -72.7 ± 0 -46.3 ± 0.8 
Omomyc Ac-NVK......EQL-NH2 -119.0 ± 3.2 -69.1 ± 1.6 -49.9 ± 4.7 
Omomyc-like 
peptide 1 
Ac-LXSEIXLLRKQNEXLKHXL-NH2 -58.2 ± 4.9 -38.8± 2.5 -19.5 ± 2.4 
Omomyc-like 
peptide 2 




YPYDVPDYA(Ahx)LXSEIXLLRKQNEXLKHXL. The peptides were made with Fmoc-(S)-
2-(4-pentenyl)Ala-OH as X for hydrocarbon stapling. A HA-tag was chosen rather than a His-
tag so that the pull-down experiments would not require Ni-NTA resin, which can bind c-Myc 
(Chapter 3). The Omomyc-like peptide was also designed to contain an aminocaproic acid 
(Ahx) linker between the HA-tag and the peptide designed to bind c-Myc. This design allows 
the HA-tag to have free rotation, so as to allow it to point away from the binding interface and 
not interfere with binding to c-Myc. The peptide was subsequently synthesised by Dr Fernando 
Ferrer from A*STAR, Singapore. 
 
7.1.2.1.2 Western blots to probe the binding of the Omomyc-like peptide to c-Myc and 
Max 
c-Myc is difficult to purify in E.coli due to its insolubility and propensity to aggregate (Dr 
Trevor Littlewood, Personal Communication). Omomyc is likely to also be difficult to purify 
due to its high sequence similarity to c-Myc. The absence of purified c-Myc and Omomyc 
protein posed restrictions on the assays that could be used in this study. Therefore the same 
approach was used as previously described in Chapter 3, where HeLa cell lysates were used as 
sources of c-Myc protein .  
 
The experiments sought to determine whether the HA-labelled Omomyc-like peptide behaved 
like Omomyc full-length protein as well as ultimately act as a c-Myc inhibitor. Omomyc protein 
has been previously shown to bind to c-Myc.128 A pull-down assay was used to probe whether 
the Omomyc-peptide was also able to bind c-Myc.  
 
Figure 60: Further molecular dynamics simulations. A: The binding of Omomyc to c-Myc 
protein B: The predicted α-helicity of Omomyc-like peptide 1 (red), Omomyc-like peptide 2 
(blue) and Omomyc protein. C: Representation of the binding of Omomyc-like peptide 1 to c-




For the assay, a mouse monoclonal anti-HA antibody was bound to Protein G sepharose 4 fast 
flow (GE Healthcare). The HA-labelled Omomyc-like peptide was captured by the anti-HA 
antibody on the beads and then incubated with HeLa cell lysate known to contain c-Myc. 
Following washing of the beads, co-immunoprecipitated c-Myc was detected by western blot 
using an antibody that recognises the amino terminal of c-Myc  (an epitope absent from the 
Omomyc-like peptide) (Figure 61). Control immunoprecipitations were carried out with a 
matched isotype monoclonal antibody recognising the adenovirus Early region 1A (E1A) 
protein.  
The westerns showed a band at the correct molecular weight, suggestive of binding of the HA-
labelled Omomyc-like peptide to c-Myc. It was difficult to see the band due to the similar 
molecular weights of the c-Myc protein and the heavy chain of the anti-HA mouse antibody 
that cross-reacted with the HRP-conjugated secondary anti-mouse Ig antibody. In order to limit 
this cross-reaction, the experiment was repeated following cross-linking of the anti-HA 
antibody to the Protein G sepharose using Dimethyl pimelimidate (DMP) (Figure 62).  
Figure 61: Western blot of the pull-down of the Omomyc-like peptide blotted with an anti-c-
Myc antibody. Total Hela cell lysate is used as a positive control and an anti-E1A antibody is 






Consistent with previous results, the experiments shown in Figure 62 indicates that the HA-
labelled Omomyc-like peptide bound c-Myc. However, a weak band was also observed for the 
anti-E1A antibody, which may suggest some degree of non-specific binding of c-Myc to the 
anti-E1A antibody or the Protein G Sepharose.  
 
Figure 62: Western blot of the pull-down to probe binding of the Omomyc-like peptide 
to c-Myc from HeLa cell lysate. Here the anti-HA antibody has been cross-linked to the 
resin. Westerns are blotted with an anti-c-Myc antibody. Total Hela cell lysate is used as 
a positive control and an anti-E1A antibody is used as a negative control. The band of 




7.1.3 Targeting c-Myc using an Omomyc-like CTPR 
The design of the Omomyc-like stapled peptide was used as inspiration for the creation of an 
Omomyc-like tetratricopeptide repeat protein. Here instead of chemical stapling the Omomyc-
like peptide, the Omomyc sequence was instead constrained into its bioactive conformation by 
grafting into an outer α-helical region of the CTPR, in a manner previously described by Chin 
et al.111 The CTPR reported by D’Andrea et al. was used for this grafting process.132 The design 
ensured wild-type CTPR residues pointed towards the hydrophobic core of the CTPR remaining 
conserved in order to maintain protein stability.132  Unlike the CTPRs designed with loop 
insertions, little is known about the effect of peptide grafting onto the outer α-helix of the CTPR 
on the protein stability. Cortajarena et al. have previously grafted sequences across multiple 
CTPR helices and observed that the resultant protein had a very similar structure to the 
consensus sequence using crystallography, but no protein stability studies were carried out.149 
Therefore, it was hoped that grafting the c-Myc binding helix into a CTPR with a large number 
of repeats such as the five-repeat CTPR (CTPR5) would help retain the protein structure and 
ensure high protein stability.   
 
The Omomyc-like CTPRs were then probed for their enthalpy of binding to c-Myc protein 
using MD simulations. The three top scoring designs were c-Myc CTPR5-1, c-Myc CTPR5-2 
and c-Myc CTPR5-3 (Figure 63, Table 16).  c-Myc CTPR5-1, c-Myc CTPR5-2 had the 
Omomyc peptide grafted into the N-terminal helix of the CTPR5. In c-Myc CTPR5-2, an extra 
three Omomyc residues were extended out from the CTPR helix scaffold in order to maximise 
Figure 63: Simulations of the Omomyc-like c-Myc CTPRs (orange) binding to c-Myc (green). 
Simulations show: A: c-Myc CTPR5-1, B: c-Myc CTPR5-2 and C: c-Myc CTPR5-3 binding 
to c-Myc. The unstructured N-terminus of c-Myc CTPR5-2 is shown prior to capping with 
asparagine for c-Myc CTPR2-5 (circled in black). The location of the grafted Omomyc 
sequence is circled in blue. The C-terminus and N-terminus are labelled with C and N 




binding. This is highlighted by the black circle in Figure 63. c-Myc CTPR5-3 has the Omomyc 
sequence grafted into the C-terminal solvating helix of the CTPR5.  
 
The Omomyc-like CTPR proteins were designed with a HA-tag to facilitate pull-down 
experiments. This tag was chosen in preference to a His-tag because c-Myc can bind non-
specifically to Ni-NTA resin (Chapter 3). The HA tag was added on the C-terminus of c-Myc 
CTPR5-1and c-Myc CTPR5-2 and the N-terminus of c-Myc CTPR5-3 so as to not disrupt c-
Myc binding.  The tag was linked to the CTPR protein scaffold via a poly-GS linker so as to 
not disrupt CTPR folding. 
 
The proteins were expressed within a mammalian system as opposed to being expressed 
recombinantly as this would allow us to also easily investigate the effect of the proteins on cell 
proliferation. The genes were purchased and cloned into a mammalian retroviral vector, pBabe 
Puro, using restriction digestion cloning, so that the Omomyc-like CTPRs could be expressed 
directly within the target cell. This vector was chosen as it has previously been used for the 
successful retroviral transduction of Omomyc into cells.215 It was hoped this approach would 
allow us to quickly test whether the CTPRs were able to bind c-Myc, and not be concerned with 














Human MRC-5 fibroblasts and HEK293T kidney cells were transduced with each of the 
Omomyc-like CTPR-expressing retroviruses. MRC-5 cells were chosen due to their relative 
Protein Predicted enthalpy (∆H) of 
binding to c-Myc (kcal/mol) 
Max -119.0 ± 0.9 
Omomyc -119.0 ± 3.2 
c-Myc CTPR5-1 -73.3 ± 2.2 
c-Myc CTPR5-2 -55.0 ± 1.4 
c-Myc CTPR5-3 -57.0 ± 0.4 
Table 16: Predicted enthalpies of binding of Max, Omomyc and the Omomyc-like CTPRs 




sensitivity to c-Myc levels for proliferation. Therefore, it was hypothesised that a decrease in 
cell proliferation would be observed when the Omomyc-like CTPRs were expressed within the 
cells providing the Omomyc-like CTPRs were able to act as c-Myc inhibitors (Trevor 
Littlewood, personal communication). In contrast, HEK293T cells exhibit elevated levels of c-
Myc and were therefore chosen for the co-immunoprecipitation assays, in order to observe c-
Myc binding to the Omomyc-like CTPRs using western blot. Cells were also infected with 
retrovirus expressing the 5-repeat consensus-designed CTPR (CTPR5) to be used as a negative 
control for these experiments.  
 
After puromycin selection, expression of the CTPRs was determined by western blot using an 
antibody specific for the HA tag (Figure 64). However, no expression of any of the CTPRs was 
observed.  In contrast, the antibody readily detected expression of the Akt1-HA-ER protein 
(Trevor Littlewood). It was decided that the experiment would be repeated with new cell-lines 
HeLa and Rat1 cells as these are known to be readily infected with amphotropic and ecotropic 
retroviruses respectively. MRC-5 cells are especially hard to infect as they proliferate slowly, 
and insertion of retroviral sequences into the host DNA is dependent on host cell DNA synthesis 
(Trevor Littlewood, personal communication).  HeLa cells express high levels of c-Myc and 
were chosen as a source of c-Myc for pull-down assays (Trevor Littlewood, personal 
communication). Human HeLa cells and Rat1 fibroblasts were transduced with each of the 
Omomyc-like CTPR-expressing retroviruses. After puromycin selection, expression of the 





Figure 64: Western blot of HEK293T and MRC-5 cell lysate after infection with Omomyc-like 
CTPRs and subsequent selection. The positive control is a HA-labelled protein, Akt1-HA-ER, 
which sits at the correct molecular weight of 90 KDa, and is circled in black. The negative 
control is non-infected HEK293T cell lysate.  
Figure 65: Western blot of Hela and Rat1 cells after infection with Omomyc-like CTPRs and 
subsequent selection The positive control is a HA-tagged protein, Akt1-HA-ER at the correct 





However, again no expression of the CTPRs was observed in these cells. Although retroviral 
transfection was successful in that the cells were puromycin resistant, it is possible that the 
separate promoter that drives Omomyc-like CTPR expression was repressed (possibly by 
methylation) in the host cells. If true, this suggests that Omomyc-like CTPR expression is 
selected against in culture.  
 
7.1.4 Discussion 
This chapter sought to investigate whether Omomyc-like peptides and Omomyc-like CTPRs 
were able to replicate the effect of  full-length Omomyc in vitro and in cellulo. The work with 
the HA-labelled Omomyc-like peptide suggested that the peptide could bind c-Myc in cell 
lysates because a band at the correct molecular weight of c-Myc was detected with a c-Myc 
specific antibody by western blot. Further work is required to confirm these results. First, the 
pull-down experiments should be again repeated with cross-linked antibodies, but this time the 
following negative controls should be used: a pull-down in the absence of the HA-labelled 
Omomyc-like peptide, a pull-down in the absence of the anti-HA antibody and a pull-down 
where the anti-HA antibody has been substituted for the anti-E1a antibody. These controls will 
detect any non-specific binding of c-Myc to Protein G sepharose or the anti-HA antibody. The 
presence of a possible faint band in Figure 62 for the anti-E1A antibody negative control may 
indicate non-specific binding of c-Myc to the control antibody. Future experiments should be 
carried out with an additional washing step to reduce any non-specific binding. Providing 
positive results are seen, a further pull-down assay should be carried out in order to probe 
whether the Omomyc-like peptide is able to inhibit the c-Myc-Max interaction as this has been 
seen for full-length Omomyc.128 Here, c-Myc protein could be bound to the resin using an anti-
c-Myc antibody and a titration of Omomyc-like peptide used.  The presence of Max protein 
could then be determined by western blots of  immunoprecipitated proteins.  
 
Following the validation of the pull-down assay results, the biological effect of the Omomyc-
like peptides should be compared to full-length Omomyc protein. To this end, the effect of the 
peptide on the rate of apoptosis of myoblast cells should be investigated, as described by Soucek 
et al.215 An unmodified Omomyc-like peptide could first be introduced into the cells using 
electroporation in order to carry out this assay. Following this, the effect of the peptide on cell 
viability and cell proliferation should be determined as described by Wang et al.218 Methods to 
promote delivery of successful peptides into cells will be investigated. For example, 




studies have found conjugation of this peptide to full-length Omomyc protein was able to induce 
cell apoptosis.  
 
It was not possible to determine the biological effect of Omomyc-like CTPRs as we were unable 
to detect expression of the Omomyc-like CTPRs in HEK293T, MT MRC-5, Rat1 or HeLa cells. 
The fact that the CTPRs could not be expressed in any of these cell lines may suggest that CTPR 
is cytotoxic, especially since the host cells retained resistance to puromycin. However, since 
expression of CTPR and puromycin resistance is driven by separate promoters it is possible that 
the promoter responsible for CTPR expression is repressed.  This has been described before 
(Trevor Littlewood, personal communication). It would be possible to use a different vector 
containing an IRES sequence such that CTPR and puromycin resistance are expressed form a 
single promoter – thus, retention of resistance to puromycin will correlate with CTPR 
expression. Alternatively, the HA-tagged CTPRs could be expressed in E.coli using the method 
described in Chapters 4 and 5. The purified protein could then be used for pull-down 
experiments with HeLa cell lysate as a source of c-Myc protein using a similar protocol to that 
used for the HA-labelled Omomyc-like peptide. If these experiments are successful, the DNA 
coding for these proteins could be transiently transfected into cells in order to measure their 
effect on cell viability and apoptosis, as described above for the Omomyc-like peptide.218 The 



















8 Final discussion and future work 
Repeat proteins are inherently amenable to protein engineering using rational design  due to 
their modularity, the predominance of short-range interactions between residues leading to a 
very simple topology, and their high thermal stabilities. Their modularity also highlights 
possibilities for the development of bifunctional proteins.120 Previous approaches to protein 
engineering to impart binding capacity have generally focused on screening and/or 
computational design.107  Approaches to engineer CTPRs in particular have also failed to 
achieve high binding affinities.149-152 In this work, I sought to demonstrate that the amenability 
of CTPRs to rational design could (i) be manipulated to allow the grafting of binding peptides 
into the loops of CTPRs and (ii) this could be used to impart high affinity for a specific target 
without the need for complex approaches. Such an approach could potentially be used for drug 
discovery to develop binders at a much faster rate and a lower overall cost than for other 
scaffolds.  
 
The work in Chapter 4 and Chapter 5 shows CTPRs to be amenable to the grafting of Keap1-
binding peptides into the inter-repeat protein loops. My CD experiments demonstrated that the 
length and sequence of the tested Keap1-binding peptides does not significantly impact protein 
structure. Although losses in protein stability are seen, the high stability of the CTPR2 protein 
means that CTPR2s with functional peptides grafted into the inter-repeat loops still have high 
melting temperature of around 70 °C. The work does, however, highlight the importance of the 
flanking regions in these CTPRs, with changes to the flanking regions leading to a reduction in 
the thermal stability.  
 
The biophysical binding assays in Chapter 4 indicates that the binding affinity of the tested 
Keap1 CTPRs correlates with, and is of the same order of magnitude as, the binding affinity of 
the corresponding free peptide for Keap1, reaching binding affinities as low as 22 nM for Keap1 
CTPR2-2-3. This correlation supports my hypothesis that it is important to graft peptides with 
known high binding affinity for their targets to achieve CTPRs with measurable binding 
affinities for their targets. This hypothesis is further supported by my work in Chapter 3 when 
grafting a low affinity peptide (a KD of 18 µM when grafted in a single domain antibody 
scaffold) and where no binding was detected between the alpha-synuclein CTPRs and alpha-
synuclein.108 The tight binding affinity of 22 nM is also significant since, to date, CTPRs have 
only been designed to have up to micromolar affinities for a target.153 The binding affinity of  




to be in the nanomolar to picomolar range, with binding scaffolds optimised using 
computational and/or screening approaches often reaching picomolar affinities.126, 154 This 
suggests this binding affinity could be relevant in a therapeutic context and could be further 
improved using screening-based methods.  
 
I hypothesise that the grafted Keap1-binding peptides had a similar affinity to the free peptides 
due to the conformational match of the inter-repeat loop with the Nrf2 peptide structure. In 
Chapter 5, I built upon this hypothesis, and explored new strategies for improving the 
conformation of the grafted peptide so that it was closer to that of its bioactive conformation. 
In order to achieve this aim, I explored how changing the loop flanking residues could be a 
useful strategy. This included the introduction of polyglycine residues, where I hypothesised 
that the increased flexibility of the system would reduce the conformational strain on the grafted 
peptide. This would in turn allow its conformation to be determined by the peptide’s intrinsic 
structure to a greater extent. The fluorescence polarisation experiments show that a two-fold 
improvement in binding affinity could be seen upon introduction of a polyglycine linker.  
 
Exploring whether functionality could be imparted to a repeat protein through peptide grafting 
into inter-repeat loop of the CTPR also led to a curiosity as to whether the same was true for 
the α-helices. Previous work where several residues had been mutated to impart binding affinity 
to Hop, supported the hypothesis that this might be possible.149, 150 This along with a curiosity 
with regards to how to best target c-Myc led to the identification of a new approach for how to 
potentially manipulate the activity of Omomyc for c-Myc inhibition. To this end, Omomyc 
residues were grafted into the CTPR helices in Chapter 7. It is possible that the imperfect 
conformational match between the α-helix of the CTPR and the α-helical form of Omomyc may 
disrupt binding as well as work to remove the entropic cost of binding. This Omomyc segment 
was also made into a stapled Omomyc-like peptide. A band at the correct molecular weight for 
c-Myc was detected during the pull-down experiment, indicating potential binding of c-Myc to 
the Omomyc-like peptide.  Future work should focus on further exploring the functionality of 
Omomyc-like peptides and CTPRs as a route to c-Myc inhibition. 
 
The work described in Chapter 4 and 6 explored the potential of the CTPRs to be used as 
therapeutics. Specifically in Chapter 4, we investigated whether the lysine residues could be 
replaced with arginine residues in order to make sure the proteins were resistant to 
ubiquitination, which would be especially important if they were to be used as PROTACs. 




unable to be expressed and purified in high yields. The CTPR equivalents, however, expressed 
in the soluble fraction, giving much higher protein yields. This suggests that, at least with 
regards to Keap1 CTPRs, the use of RTPRs is unlikely to be a useful strategy moving forward. 
The work described in Chapter 6 highlights that the Keap1 CTPRs could be introduced into 
HCT 116 cells through the formation of proteoliposomes. However, no observation of the 
activity of the CTPR was observed despite Keap1 CTPR2-2-3 previously being shown to bind 
Keap1 using a pull down assay in Chapter 4. This suggests the CTPR was not present in the 
HCT 116 cells at the necessary concentrations to induce a biological effect, perhaps due to poor 
delivery or protein degradation.  
 
The work described in Chapter 4 led to the identification of a new Keap1-binding peptide with 
low nanomolar affinity for Keap1. Future work should further optimise the new Keap1-binding 
(Modified Phage) peptide through modification of the C-terminus as this may improve the 
binding affinity. Work should also focus on further characterising the binding of this peptide 
Keap1, perhaps through crystallographic studies, so as to aid future Keap1-binding peptide 
development and to aid the further optimisation of this peptide.  
 
The identification of this new Keap1-binding peptide in Chapter 4 highlights the potential of 
CTPRs to quickly and cheaply screen for new binding peptides for a specific target. The 
potential for CTPRs to include multiple binding loops first discussed in Chapter 3 could also 
be expanded as strategy for peptide screening that would allow the display of many potential 
binding peptides on a single CTPR. Perhaps the same binding peptide could be displayed on 
the CTPR many times through many loops. This approach could mean the CTPR would have a 
higher binding affinity for the target compared to the free peptide. It would therefore allow for 
more stringent screening conditions, allowing false binders to be more quickly removed and 
saving precious time and money. This would approach would be particularly appropriate for 
peptides that, like Nrf2 peptides, are likely to have a bioactive conformation which structurally 
similar to the inter-repeat loop.  
 
The pull-down assay of the Keap1 CTPRs with HEK293T cell lysate in Chapter 4 highlights 
an additional application in which the CTPRs with loop-grafted peptides could also have good 
scope as antibody alternatives, especially where high affinity binding peptides have already 
been designed to bind to the target. They would have an advantage over antibodies in the market 
as they are very soluble, can be easily and cheaply expressed in high yields and unlike many 




customer. Knowing that it binds specifically at the Keap1-Nrf2 interface means it could be 
useful antibody-like protein for investigating the other binding interfaces of Keap1, such as the 
dimerisation interface. This is in keeping with other non-immunoglobin scaffolds that have 
been used as antibody equivalents in ELISA, western blot, microscopy, microarrays and flow 
cytometry assays.120, 220-224 For example, the CTPR with a loop-grafted peptide could be 
expressed with a HA or GFP tag for easy detection.  
 
Creating a new protein therapeutic is not without its challenges. Cell permeability,  metabolic 
stability and immunogenicity all present major hurdles to the use of protein therapeutics. Many 
strategies have been developed to overcome these challenges, such as the use of and the 
liposome delivery of proteins described in Chapter 6 for cell delivery. Even if this approach 
isn’t shown to be viable in a clinical context, many non-immunoglobin proteins in clinical trials 
have been used to successfully target extracellular targets.120 PEGylation has proved effective 
for many other non-immunoglobin scaffolds top reduce protein immunogenicity.225  However, 
in the case where these challenges cannot be overcome, the use of CTPRs for peptide screening 
and as antibody alternatives are just a couple of the other possible applications.  
 
Assuming these challenges can be overcome and work focuses on using the technology for 
therapeutic purposes, future work could  build on the ideas discussed in Chapter 3 and focus on 
grafting multiple binding peptides into the CTPR scaffold to create bispecific and biparatopic 
proteins, which has already been shown to be viable for other non-immunoglobin scaffolds.226-
228 This could include their use as PROTACs, where the sequences I have described here could 
be used to recruit Keap1 for selective degradation of a protein of interest. In this study, I have 
been able to design CTPRs with differing affinities for Keap1. This could prove could to be 
helpful in optimising the activity of the PROTAC because in order to achieve optimal 
degradation of the protein of interest it will be useful to test a range of Keap1 CTPRs with a 
range a binding affinities and on and off rates. However, the Keap1-binding peptide component 
of the peptide PROTAC reported by Lu et al. has a binding affinity of 18 nM, which is very 
similar to the binding affinity of 22 nM reported for Keap1 CTPR2-2-3.166 Therefore, the first 
CTPR PROTAC design should therefore incorporate this loop design.  
 
However, the relative rigidity of TPR proteins, compared to the polyglycine and PEG linkers 
used for peptide and small-molecule PROTACs, may present a challenge when it comes the 
optimisation of these proteins.229 Other PROTACs generally rely on the use of flexible linkers 




of the PROTAC binding to both the protein of interest and the E3 ubiquitin ligase.166, 230-232 In 
order to overcome this challenge, flexible polyglycine linkers could be used as described in 
Chapters 4 and 5 to help to increase the flexibility of the system and increase the probability of 
binding to both targets.  
 
Future work should focus on exploring the use of these polyglycine sequences when grafting 
peptides that have active conformations that have a poor structural match with the inter-repeat 
loop of the CTPR scaffold as this may improve the binding affinity. The approach could also 
be used for grafting long binding peptides which would otherwise be constrained into 
unfavourable conformations upon CTPR grafting. The length of the polyglycine linkages could 
even be optimised for each grafted peptide, with peptides with a poor structural match to the 
CTPR loop perhaps benefiting from the use the use of longer polyglycine linker sequences.  
 
Peptide grafting as a route to functionalisation can often be seen as an approach that is unable 
to compete with more lengthy computational or directed evolution approaches. This work 
ultimately highlights that the amenability of the CTPRs to rational design means that they can 
be easily designed to have up to nanomolar affinity for a target through the simple approach of 
peptide grafting. It also shows that CTPRs are amenable to the grafting of Keap1-binding 
peptides of various lengths and sequences, and future work may demonstrate that the CTPRs 
are amenable to the grafting of various different functional peptides. Moreover, the work offers 
new insights into how to graft functional peptides into CTPR scaffolds, which could impact the 
grafting of functional peptides into other scaffolds. This work ultimately argues for the 
importance of a conformation-focused approach to peptide grafting in order to instil high 

















Table 17: Sequences of all constructs in this study 
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